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ABSTRACT 
A commonality among cancer types is the high frequency of mutations that inhibit or alter 
signaling of the p53 and pRb (Retinoblastoma) tumor suppressors.  These genes regulate 
processes vital for cancer suppression such as apoptosis, senescence, and cell cycle arrest among 
others.  Loss of both p53 and pRb promotes processes that support cancer progression and is 
associated with decreased patient survival and increased rates of tumor reoccurrence.  Although 
data points to the ability of p53 and pRb to collaborate and to inhibit tumorigenesis, it remains 
unclear how p53 and pRb cooperate toward this task.  Using RNA expression profiling, 179 p53 
and pRb cross-talk candidates were identified in normal lung fibroblasts (WI38) cells 
exogenously coexpressing p53 and pRb.  Regulator of G protein signaling 16 (RGS16) was 
among the p53 and pRb cross-talk candidates and reports suggest it inhibits the activation of 
several oncogenic pathways associated with proliferation, migration, and invasion of cancer 
cells.   
RGS16 is downregulated in pancreatic cancer patients with metastases compared to patients 
without metastasized pancreatic cancer.  The role of RGS16 in cancer cell metastasis is 
unknown; therefore I tested the hypothesis that RGS16 inhibits pancreatic cancer cell migration 
and invasion in vitro. Expression of RGS16 was decreased in the pancreatic cancer cell lines 
tested compared to control. Expression of RGS16 inhibited fetal bovine serum (FBS) and 
epidermal growth factor (EGF) induced migration of the BxPC-3 and AsPC-1 but not PANC-1 
pancreatic cancer cells. It also inhibited EGF induced invasion of BxPC-3 and AsPC-1 cells with 
no impact on cell viability. Although RGS16 inhibited cell migration and invasion of BxPC-3 
and AsPC-1 cells, there was no change in F-actin polymerization or the amounts of p-AKT, p-
ERK and the epithelial mesenchymal transition (EMT) marker vimentin proteins, but there was a 
slight increase in E-cadherin protein expression in BxPC-3 cells.  Our data suggests the 
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inhibitory effect of RGS16 on EGF induced pancreatic cancer cell migration is independent of 
the PI3K and MAPK pathways.  To our knowledge, for the first time, we performed analyses to 
identify p53 and pRb cross-talk candidates and demonstrated a role for RGS16 in suppressing 
EGF and FBS induced pancreatic cancer migration and invasion.  
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CHAPTER 1.  
INTRODUCTION 
SECTION 1.1: p53 AND pRb COLLABORATORS IN THE FIGHT 
AGAINST CANCER 
Background 
The two most commonly mutated signaling pathways in cancer are those associated with 
tumor protein 53 (p53) and retinoblastoma protein (pRb).  p53 and pRb are the first two tumor 
suppressors identified, however, years after identifying and cloning p53 (1979) and pRb (1986) 
we are still working to understand their function [1].  p53 and pRb regulate the same processes 
(such as; cell arrest, apoptosis, senescence, etc.) using different mechanisms and studies suggests 
these two tumor suppressors cooperate to inhibit cancer progression [2-5].  The ability of p53 
and pRb to communicate in regulating cellular functions and determining cellular fate could be a 
reason mutations in these pathways often occur in cancer.  The focus of this section is to give an 
overview of p53 and pRb functions and their regulation while presenting evidence and examples 
of the p53 and pRb cross-talk.   
Brief overview of p53 function and regulation 
The function of p53 has been extensively studied; this section will provide a brief 
overview of the function and regulation of p53.  Originally thought to function as an oncogene, 
p53 is now known to induce a variety of processes in cells that inhibit tumorigenesis such as: cell 
cycle arrest, apoptosis, DNA repair, and senescence (reviewed in [6-10]).  These processes aid in 
protecting the integrity of DNA supporting the use of p53’s nickname as “Guardian of the 
Genome”[11].  The ability of p53 to regulate a wide variety of processes is due in part to its 
functions as either a transcriptional activator or a repressor.  p53 forms a tetramer, binds to DNA, 
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and recruits co-activators inducing transcription of genes that are involved in DNA repair 
(p53R2, MLH1, XPC, PCNA, and DDB2), apoptosis (Bax, Noxa, Bid, APAF-1, DR4, DR5 and 
PUMA), senescence (plasminogen activator inhibitor 1: pai-1, p21), G1 (G1: BTG2, p21), and 
G2 cell cycle arrest (GADD45, 14-3-3 sigma, and MCG10) [12-15].  The p53 tumor suppressor 
promotes differentiation by repressing transcription of factors that promote pluripotency such as 
oct4 and nanog and inducing transcription of pRb to initiate myogenesis [16, 17].  In addition to 
its transcription regulatory activity,  p53 translocates to the mitochondria and interacts with the 
outer membrane leading to mitochondria permeabilization by activating the pro-apoptotic Bax 
and Bak proteins and inhibiting the pro-survival Bcl-2 and Bcl-xl proteins [13].  These actions 
initiate mitochondria membrane permeabilization, the release of cytochrome c, and activation of 
caspases that trigger apoptosis (Figure 1.1).     
In order to prevent the random induction of apoptosis and other p53-regulated processes, 
expression of p53 is normally sustained at low basal levels by the E3 ubiquitin ligase HDM2.  
HDM2 a transcriptional target of p53, binds and translocates p53 to the cytoplasm preventing 
p53 from binding to DNA and initiating transcription [12, 14].  HDM2 also poly-ubiquitinates 
p53 marking it for degradation by the proteasome. Stabilization of p53 occurs due to post-
translational modifications by factors activated when the cell is under stress such as: DNA 
damage, hypoxia, loss of normal cell contacts, and activity of oncogenes [12, 14].  Post-
translational modifications such as phosphorylation and acetylation stabilize p53 by preventing 
its poly-ubiquitination and degradation [12, 14]. The binding of p14ARF to HDM2 also leads to 
the stabilization of p53 preventing its polyubiquitination by HDM2.  Figure 1.1 contains a 
summary of the function and regulation of p53 demonstrating the complexity of p53 signaling.  
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Brief overview of pRb function and regulation 
Known for its ability to induce cell cycle arrest at the G1/S checkpoint, pRb also 
regulates apoptosis, DNA repair, senescence, and differentiation.  pRb is a transcription regulator 
that binds to co-factors and either functions as a co-repressor or co-activator of transcription.  
Classically, pRb is acknowledged for its role in binding to the cell cycle stimulatory E2F 
transcription factors and recruiting histone deacetylases and other transcription repressors and 
thereby inhibiting transcription of E2F target genes and initiating cell cycle arrest [18-20]. 
Figure 1.1: Schematic depicting regulation of p53 and downstream transcription 
targets.  p53 initiates a variety of responses through its ability to regulate transcription of 
targets that are involved in DNA repair, apoptosis, cell cycle arrest, senescence, and 
differentiation.  p53 expression is regulated by its own downstream transcriptional target, 
HDM2 which polyubiquitinates p53 marking it for degradation in the proteasomes.  p53 
expression is stabilized by signals initiated by DNA damaging, hypoxia, or overexpression 
of oncogenes.  p53 also initiates apoptosis by binding and interacting with mitochondria 
outer membrane and proteins located there. Pathway was constructed using Qiagen’s 
Ingenuity pathway Analysis (IPA®, QIAGEN Redwood City, 
www.qiagen.com/ingenuity) Pathway Designer tools.  Adapted from Levine, A. J. et al. 
2006 
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Cyclin-dependent kinases-4 and -6 phosphorylate pRb inhibiting binding of pRb with E2F 
resulting in the release of E2F to bind to DNA and its dimerization partner (DP2) resulting in the 
initiation of transcription of cell cycle stimulatory proteins [19, 21].  Activation of E2F 
transcription results in the expression of cyclin E, which binds to cyclin-dependent kinase 2 and 
functions in a negative feedback loop to promote phosphorylation and inactivation of pRb.  
Phosphorylation of pRb is inhibited by cyclin-dependent kinase inhibitors among which are the 
proteins p27, p16, and p21.  Figure 1.2 summarizes the regulation and function of pRb to inhibit 
activation of E2F target genes.   
The best known or studied function of pRb is its ability to act as a transcriptional 
repressor of E2F targets genes.  However, pRb can regulate cellular processes or suppress cancer 
progression irrespective of its ability to bind to E2F family members.   Studies using pRb 
mutants found E2F binding deficient pRb activated transcription and initiated differentiation and 
suppressed tumor progression in vitro and in vivo [22, 23].  pRb has been found to bind and 
enhance transcription of several transcription factors and nuclear receptors listed in Table 1.1.  
Enhanced transcriptional activity by pRb promotes differentiation and regulates hormone 
signaling (Table 1.1).  However, there is still not much known regarding pRb’s ability to 
function as a transcriptional co-activator indicating the need for more research to understand the 
full mechanisms of pRb suppression of cancer progression and promotion of differentiation 
processes.  
Studies have implicated pRb in having a divergent role in either promoting or inhibiting 
apoptosis.  pRb, like p53, can interact directly with the mitochondria mediating the induction of 
apoptosis triggered by tumor necrosis factor-α [24].  Ianari et al. found that pRb potentiates the 
induction of apoptosis triggered by genotoxic or oncogenic stress in proliferating cells [25].  The 
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ability of pRb to initiate apoptosis is context dependent, for example; in Ianari’s study, pRb 
bound to E2F, enhanced the induction of apoptosis initiated by stress in proliferating cells [25].  
However, in another study conducted using breast cancer cells, loss of pRb enhanced the 
activation of apoptosis mediated by E2F1 [26].  Furthermore, pRb inhibits induction of apoptosis 
by p53 in HeLa overexpressing exogenous p53 and pRb [27].   
Table 1.1: Transcription factors that are regulated by pRb 
Transcription Factor Effect Source 
MyoD Regulates muscle differentiation [28] 
C/EBP (CAAT/enhancer-binding protein) 
family 
Regulates adipocyte and 
monocyte differentiation 
[29, 30] 
c-Jun 
Regulates keratinocyte 
differentiation 
[31] 
AP-2 
Binds and initiates activation of 
E-cadherin bcl-2 promoter 
[32] [33] 
CBFA1 (Runx2) 
Regulates Osteogenic 
differentiation 
[34, 35] 
SP-1 Regulates differentiation [36, 37] 
Nuclear receptors (Glucocorticoid receptor;  
Androgen receptor; ERα & ERβ (Estrogen 
receptor α & β); HNF4 (hepatocyte nuclear 
factor-4); SF-1 (steroidogenic factor-1); 
and NGF1-B orphan nuclear receptor 
family members NGF1-B/Nurr 77/NR4A1, 
NOR1, & Nurr1) 
Initiates transcription of genes 
that regulate hormone signaling 
and differentiation 
 
[38-44] 
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p53 and pRb cross-talk 
Evidence of p53 and pRb Cross-talk 
The existence of a p53 and pRb cross-talk pathway is supported by evidence collected 
from tumor analyses and in vitro and in vivo experiments. Most tumors, including osteosarcomas 
and cancers of the breast, lung (small cell), cervix, and bladder [1, 4, 45, 46], have deficiencies in 
either the p53 or pRb pathway. Both p53 and pRb have a high frequency of mutations in 
osteosarcomas, lung (non-small cell), breast, and cervical carcinomas [1, 4, 46]. Approximately 
60% of osteosarcomas have loss of both functional p53 and pRb, which is vital for osteosarcoma 
Figure 1.2: Schematic depicting pRb regulation and function as a transcriptional 
repressor.  Pathway was constructed using Qiagen’s Ingenuity pathway Analysis (IPA®, 
QIAGEN Redwood City, www.qiagen.com/ingenuity) Pathway Designer tools.  
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(OS) development [1, 46].  Patients who have mutations in both TP53 and RB1 have increased 
tumor recurrence and decreased survival compared to patients with only one inactive tumor 
suppressor genes [45, 47].  Deletions or mutations in the p16 locus, and overexpression of 
HDM2 or cyclin-D can also interfere with p53 and pRb activity.  Table 1.2 describes examples 
(small representative) of mutations and alterations that prevent p53 and pRb activation.  
Table 1.2: Examples of alterations that can occur in cancers that alter p53 and pRb 
signaling 
 
Alteration Cancer Sources 
p16 deletions/mutations 
Pancreatic cancer, Head & Neck 
Squamous Cell Carcinomas 
(HNSCC), Non-Small Cell Lung 
Cancers (NSCLC), 
Glioblastomas (GBMs)- 
[48-51] 
Overexpression of HDM2 
Sarcomas (soft tissue and 
osteosarcoma), retinoblastoma, & 
esophageal carcinomas 
[52, 53] 
Overexpression of cyclin-D 
HNSCC, breast cancers, 
pancreatic cancers, and prostate 
cancers 
[54-57] 
Loss of both p53 and pRb promotes cancer by initiating tumorigenesis and increasing 
chromosome instability, and chemoresistance.  Binding of DNA tumor virus proteins associated 
with adenovirus, certain strains of human papilloma virus (HPV), and simian virus 40 (SV-40) to 
p53 and pRb with resultant loss of activity is vital for viral induced transformation [4, 58].   
Chromosome instability is associated with cancer initiation, promotion of tumor growth, and 
chemoresistance [59, 60].  In cell lines from two different cancer types, loss of both p53 and pRb 
synergizes to promote chromosome instability due to chromosome gains and losses during 
mitosis [60].  Loss of pRb leads to increased genetic alterations (gains or losses) and the loss of 
p53 cooperates to allow the continued proliferation of these cells [60].     
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A study examining p53 mediated responses to chemotherapy found a reduction in cellular 
response if there was a loss of pRb signaling [61].  Interestingly, inactivation of both p53 and 
pRb (through the use of a p53 dominant negative fragment and pRb siRNA) increased sensitivity 
of the cancer cells to chemotherapy compared to inactivation in p53 alone [61].  However, this 
was not seen in cells where p16 levels were decreased via siRNA, suggesting that p16 and p53 
mutations are more advantageous for cancer progression [61].  Another study found loss of both 
p53 and pRb can induce multidrug resistance prior to transformation [62].  Accordingly, patients 
diagnosed with breast cancer and treated with adjuvant chemotherapy had a better response if 
they had functional p53 and pRb [61].  
Several mouse models utilize inactivation of p53 and pRb to initiate tumor development 
that mimics the human disease.  For example, inactivation of both TP53 and RB1 genes in bone 
marrow mesenchymal stem cells or dermal connective tissue cells resulted in the development of 
osteosarcomas or soft tissue sarcomas respectively [63, 64].  Mutations in both tumor suppressor 
genes work synergistically to promote cancer progression.  Conditional inactivation of the RB1 
and TP53 genes in lung epithelial cells of mice, led to the development of aggressive small cell 
lung tumors [65].  Also p53
-/-
 mice  that were also  RB1
+/-
 developed more tumors than mice with 
single mutations; i.e. heterozygous TP53
+/-
 RB1
-/-
 or TP53 null mice [4].  Furthermore, 
inactivation of TP53 and RB1 genes in the prostate epithelium of mice led to the development of 
aggressive prostate cancers that were highly metastatic resulting in decreased survival compared 
to mice with only one in activated gene [5].  Likewise, inactivation of pRb by a fragment of the 
SV40 T-Antigen in mammary epithelium results in formation of adenocarcinomas that appear 
earlier in mice that are also TP53
+/- 
[66].   
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Loss of functional p53 and pRb signaling happens with a high frequency in cancers and 
promotes processes involved in tumor progression.  Loss of p53 or pRb promotes metastasis and 
both tumor suppressors inhibit processes such as migration and invasion needed for the spread of 
cancer [67-69, 70{Feakins, 2003 #7786]}.  However, there is a lack of studies investigating 
whether the concomitant loss of p53 and pRb promotes migration and invasion more than 
inactivation of just one pathway.  Although p53 and pRb are two of the most studied genes in 
cancer, there is a lack of understanding how they synergistically function to inhibit cancer 
formation and/or progression. 
Examples of p53 and pRb cross-talk 
Over the years evidence has accumulated painting a picture of the communication that 
exists between the p53 and pRb pathways.  Proteins known to be implicated in the p53 and pRb 
cross-talk include E2F-1, HDM2, p21, BTG2 and the INK4a locus.  Figure 1.3 is a schematic 
representing known examples of p53 and pRb cross-talk.  Briefly, through mechanisms of 
alternate splicing, the CDKN2A locus codes for two genes, p16/INK4a and p14/ARF [71].  p14 
binds to HDM2, inhibits p53 polyubiquitination its subsequent degradation by the proteasomes 
[71].  This allows p53 to initiate transcription of downstream target genes including p21, and 
BTG2 [72, 73].  The cyclin-dependent kinase inhibitors p16 and p21 together with BTG2 prevent 
the phosphorylation and inactivation of pRb and stop cell cycle progression [71-73].  Loss of 
pRb bound to E2F-1 due to inactivation of pRb or p16 can trigger p53 dependent apoptosis 
through E2F-1 stabilizing p53 by two methods, 1) activating proteins that phosphorylate or 
acetylate p53 thereby preventing HDM2 binding or by 2) inducing expression of p14 [74-78].   
p53 induces expression of HDM2 which functions in a negative feedback loop to inhibit p53.  
However, pRb can bind to HDM2 and p53 complexes leading to the stabilization of p53 [47, 79].  
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p53 complexed to HDM2 and pRb is unable to bind to DNA and regulate transcription, however 
it can induce apoptosis by directly acting on the mitochondria membrane [47, 79]. 
The previous examples of p53 and pRb cross-talk mostly highlight the use of protein-
protein interactions to determine cell fate.  However, p53 and pRb also cross-talk using 
transcriptional regulatory mechanisms, for example, p21 and BTG-2, both transcribed by p53, 
can inhibit inactivation of pRb, illustrating a pathway by which p53 and pRb coordinate  cell 
cycle arrest.  p53 also binds to the RB1 promoter and initiates transcription of pRb triggering 
pRb induced muscle differentiation [17]. Furthermore, both p53 and pRb bind to the promoter of 
the RNA polymerase III specific transcription factor, TFIIIB and suppress transcription of 
TFIIIB providing another example of how these proteins inhibit cell cycle progression [80].  
However, management of p53 and pRb controlled processes such as apoptosis, cell cycle arrest 
or development may require p53 and pRb to regulate gene expression in an opposing rather than 
cooperative manner.  Expression of an embryonic development gene, Placenta-specific 1 
(PLAC1) is down-regulated by p53 and up-regulated by pRb demonstrating how p53 and pRb 
can play contrasting roles to regulate cellular processes [81].   
Although proteins involved in the p53/pRb cross-talk have been identified, there is still a 
lack of information regarding how p53 and pRb communicate to regulate cell fate.  p53 and pRb 
co-regulated genes were investigated to expanding on the current knowledge of the p53 and pRb 
cross-talk.  We have identified 179 proteins co-regulated by p53 and pRb.  Transcriptional 
regulation of the same genes by p53 and pRb may function as a failsafe mechanism if one 
pathway is inactivated, the other is able to prevent the accumulation of additional mutations that 
results in the development of cancer.  Unraveling the complex interactions between p53 and pRb 
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will contribute to further understanding how p53 and pRb cooperate to prevent tumorigenesis, 
while also providing knowledge that can potentially be used to advance current cancer therapy. 
 
 
  
Figure 1.3: Schematic depicting proteins known to mediate p53 and pRb cross-talk.   
Pathway was constructed using Qiagen’s Ingenuity pathway Analysis (IPA®, QIAGEN 
Redwood City, www.qiagen.com/ingenuity) Pathway Designer tools.  
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SECTION 1.2. PANCREATIC CANCER  
Epidemiology and characterization 
Pancreatic ductal adenocarcinoma, also referred to as pancreatic cancer, accounts for 
2.8% of all new cancer cases and is the 4
th
 leading cause of cancer related death in the United 
States compared to the 8
th
 and 9
th
  cause of mortality for men and women respectively world-
wide [82].  The American Cancer Society estimates that approximately 46,420 individuals will 
be diagnosed with pancreatic cancer and 39,590 will die from this disease in 2014 [83]. The one-
year survival rate for all stages of pancreatic cancer is 20% and the five-year survival rate is 6% 
[83].  The percentage of cases and the five year survival rate are depicted in Table 1.3 for stage 
of cancer at time of diagnosis.  A majority of patients (53%) present with metastatic disease at 
time of diagnosis and have a dismal 5-year survival rate of 2.3%.  Only 9% of pancreatic cancer 
patients present with localized disease but their 5-year survival rate is still low at 25.8%.  Most 
patients newly diagnosed with pancreatic cancer present with highly progressed and/or 
metastatic cancer that is resistant to treatment [84, 85].  This data reflects the great need for 
methods to prevent, and therapeutics to treat advanced pancreatic cancer. 
 
Table 1.3: Percentages of survival and cases based on stage of cancer at time of diagnosis 
 
Stage % of Cases at Diagnosis % Survival 
Localized 9 25.8 
Regional (regional lymph node metastasis) 28 9.9 
Distant (metastasized) 53 2.3 
Unstaged (unknown) 11 4.4 
Information obtained from Howlader N et al.. SEER Cancer Statistics Review, 1975-2011, National Cancer 
Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, 
posted to the SEER web site, April 2014. 
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Pancreatic cancer has a higher rate of incidence in industrialized areas and predominately 
affects individuals later in life with the average age of diagnosis being 71.  Smoking, age, and 
chronic pancreatitis have been established as risk factors; whereas, obesity, diabetes, and family 
history of pancreatic cancer are associated with increased risk [86].  Approximately 5 to 10% of 
pancreatic cancer patients have a family history of pancreatic cancer and less than 20% of those 
are due to germline mutations [86-89].   
Staging 
Pancreatic cancers are commonly referred to pancreatic ductal adenocarcinomas (85%) 
however; pancreatic cancers can be classified as acinar cell carcinoma, pancreatoblastoma, solid 
pseudopapillary neoplasm, serous cystadenoma, and pancreatic endocrine tumors [86].  These 
cancers mostly affect the exocrine portion of the pancreas that consists of acinar and duct cells 
that are responsible for secretion of digestion enzymes [86].  The head of the pancreas is a 
favored location of tumor development and allows rapid infiltration into surrounding tissue [85].  
There are four types of preneoplastic pancreatic lesions known as: pancreatic intraepithelial 
neoplasia (PanINs), mucinous cystic neoplasm, (MCN) and intraductal papillary mucinous 
neoplasm (IPMN) [85, 86].  PanINs are the most common preneoplastic lesion and can exist in 
three stages.  Stage III  PanINs develop into pancreatic cancer (pancreatic ductal 
adenocarcinomas) [86].   
 Pancreatic cancers are staged using the American Joint Committee on Cancer tumor-
node-metastasis (TNM) classification described in Figure 1.4 & Table 1.4  Unknown TNM 
tumor classifications are designated with a X, (TX, NX, or MX).  Tis designates carcinoma in 
situ or preneoplastic lesions.   
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Figure 1.4: Describes the American Joint Committee on Cancer Tumor-Node-Metastasis 
classification system.  Information adapted from the National Institute of Health  
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Table 1.4: Pancreatic Cancer Stages 
Stage Tumor Node Metastasis 
0 Tis N0 M0 
IA T1 N0 M0 
IB T2 N0 M0 
IIA T3 N0 M0 
IIB T1-3 N0 M0 
III T4 N0 or N1 M0 
IV Any T N0 or N1 M1 
Based on the American Joint Committee on cancer tumor-node-metastasis.  Information adapted from the National 
Cancer Institute (2014) 
Diagnosis and Treatment 
Pancreatic cancer is rarely diagnosed during the early stages of carcinogenesis because of 
the lack of noticeable and distinct symptoms [85].  Many of the symptoms such as abdominal 
pain, nausea, and jaundice are unspecific and can be equated with other illnesses.   Several 
imaging technologies including contrast enhanced multi-detector row computed tomography 
(MDCT), ultrasonography (US), endoscopic ultrasonography (EUS), and Magnetic resonance 
imaging (MRI) are used to diagnose pancreatic cancer [90].  Ultrasonograhy is often the first 
imaging modality used once a patient presents with jaundice or abdominal pain [90].  However, 
US is not the most reliable method for staging pancreatic cancer and can miss small pancreatic 
tumors (Tis and T1) [91].  Multi-detector row computed tomography is the most accurate and 
used method for diagnosing and staging pancreatic cancer [85, 90].  Endoscopic ultrasonography 
can be used to rule out pancreatic cancer as a diagnosis therefore eliminating the need to use 
other diagnostic methods and is often chosen to visualize tissue extraction for diagnosis [90, 91].  
Contrast enhanced MRI with magnetic cholangiopancreatography is often a secondary imaging 
tool that can more readily diagnose small pancreatic tumors and rule out other pancreatic 
abnormalities [90, 91].   
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Surgery, chemotherapy, and/or chemoradiation are the therapies used to treat pancreatic 
cancer.  Due to late stage of diagnosis less than 20% of patients are eligible for the only possible 
curative pancreatic resection (tumor staging T1-T3).  The presence of metastasis to the lymph 
nodes, peritoneal cavity, liver, or other sites is a negative prognostic factor [85, 92].  In fact 
patients who undergo surgery have decreased survival if there is presence of lymph node 
metastases.  Treatments used for pancreatic cancer are based on tumor staging (Table 1.5).  
Surgery is the first treatment option for patients with stage I & II pancreatic cancer followed by 
chemoradiation therapy.  Neoadjuvant therapy is controversial, however a recent study found 
that patients who underwent neoadjuvant therapy had increased survival and time to recurrence 
than those who underwent surgery first [93].  The majority of patients diagnosed with pancreatic 
cancer present with stage III or IV pancreatic cancer that is ineligible for surgery.  However, a 
portion of patients (8 to 30%) with stage III cancer undergoing neoadjuvant chemoradiation 
therapy become eligible for pancreatic resection and have survival rates similar to patients who 
first undergo surgery [84].  An analysis of the five-year survival rates for various cancers over a 
span of thirty years found that pancreatic cancer had the least improvement from 2% (1975-
1977) to 6% (2003 to 2009) [83].  The aggressive nature of pancreatic cancer, lack of early 
diagnosis, and therapy resistance of this deadly disease contribute to the lack of advancement in 
enhancing the survival rate [94]. 
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Table 1.5: Pancreatic cancer treatment broken down based on tumor stage.  
Tumor Stage Treatment 
I & II 
Surgery 
Postoperative chemoradiation  
(5-fluorouracil (5-FU) chemo and radiation therapy) 
Postoperative chemotherapy  
(gemcitabine or 5-FU/leucovorin)  
III 
Chemoradiation 
1. Chemoradiation followed by chemotherapy 
2. Chemotherapy followed by chemoradiation  
(patients w/o metastasis) 
Chemotherapy 
(gemcitabine; gemcitabine & erlotinib; gemcitabine and nab-
paclitaxel; or 5-FU, leucovorin, irinotecan, & oxaliplatin 
(FOLFIRINOX) 
IV 
Palliative therapy 
(pain relieving procedures and supportive care) 
Chemotherapy 
(gemcitabine; gemcitabine & erlotinib; or (FOLFIRINOX) 
Information adapted from National Cancer Institute (2014) 
Mutations and altered signaling pathways in pancreatic cancer 
Pancreatic cancer is a heterogeneous disease that contains on average 63 genetic 
mutations affecting a set core of 12 pathways [95].  At least one of four genes listed in Table 1.6 
is commonly mutated in pancreatic cancer and aids in proliferation, survival, migration, 
epithelial mesenchymal transition (EMT), and invasion.  K-Ras mutations are the most common 
genetic alteration and occur early in low grade PanIN 1A lesions.  K-Ras is commonly mutated 
at codon G12 and with less frequency, codons G13 and Q61.  These mutations result in the 
constitutive activation of K-Ras [96].  Expression of mutant K-Ras (G12D) in mice induces 
PanIns that develop into pancreatic cancer [97].  K-Ras mutations promote pancreatic cancer 
proliferation, survival, invasion, migration and metastasis  and exerts its cancer promotion via 
modulation of the Raf/Mek/Erk, PI3K/AKT, and Ral-A and Ral-B pathways [96].  K-Ras/PI3K 
signaling is critical for the initiation, progression, and maintenance of pancreatic cancer in mice 
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[98].  Activation of the Raf/ERK MAPK pathway using mice with conditional knock-in 
BrafV
600e
 in the pancreas induced PanIns that later developed into pancreatic cancer [99].  K-Ras 
activates the Ral guanine nucleotide exchange factor (RalGEFs) leading to the subsequent 
activation of Ral-B and Ral-A that are linked to pancreatic cancer growth (Ral-A) and metastasis 
(Ral-B) [100].    
Inactivating mutations in CDKN2A (affecting predominantly INK4a/p16 and to a lesser 
extent, ARF/p14), p53, and Smad4 occur in moderate or advanced PanIns suggesting they are 
late events [101].  CDKN2A is the most targeted tumor suppressor gene for mutations in 
pancreatic cancer and, as highlighted in section 1.1, it codes for the p16/INK41 and p14ARF 
proteins. However, most of the mutations decrease p16 expression, thereby negating its ability to 
inhibit proliferation and induce cell cycle arrest through preventing the phosphorylation and 
inhibition of pRb.  The importance of p16 inactivation in pancreatic cancer can be seen in 
genetically modified mice.  The conditional concomitant mutation knock-in of mutant K-Ras
G12D
 
and knock-out of CDKN2A
flox/flox 
in the pancreas of mice induces more aggressive and metastatic 
pancreatic cancers than K-Ras
G12D
 (only) mice models [102].  Mutations in p53 occur at a high 
frequency and aid in suppression of apoptosis and cell cycle arrest, while also increasing 
metastasis, proliferation and genomic instability [103].  Similar to p16 knock-out mice, knock-in 
mutations of mutant p53
R172H 
and K-Ras
G12D 
 in the pancreas of mice decreases the time for 
tumor development and subsequent metastasis compared to mice with only mutant K-Ras
G12D 
 
[104].  Smad4 is activated by transforming growth factor-β (TGF-β) and mediates some of its 
downstream signaling [86, 101].  TGF-β has both tumor promoting and suppressing mechanisms.  
Mutations affecting Smad4 expression results in the loss of TGF-β mediated cell cycle arrest and 
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cell motility[105].  Loss of Smad4 decreases migration and increases chemoresistance, and 
expression of EGFR and VEGF promoting pancreatic cancer progression [105-107].    
Other genetic alterations result in the overexpression of the epithelial growth factor 
receptor (EGFR), AKT2, and RhoC in pancreatic cancers [108-110].  AKT2 is overexpressed in 
10% of pancreatic cancers and promotes growth and invasion that was inhibited by the use of 
antisense AKT RNA [109].  RhoC is overexpressed in pancreatic cancers with the highest 
expression seen in tumors from patients who had the presence of metastasis [108]. EGFR and its 
fellow family member HER2/erbB2 are overexpressed in 85% or 10% respectively, of pancreatic 
cancers.  EGFR activates a variety of pathways (see following section) that are responsible for 
proliferation, EMT, migration and survival. 
 
Table 1.6: Common genetic mutations in pancreatic cancer and incidence 
Gene Effect of mutation 
% Pancreatic 
Cancers with 
mutation 
Source 
K-Ras 
↑ proliferation; ↓ apoptosis;  
↑ migration; ↑ metastasis & evasion of 
immune response 
>  90 [96] 
CDKN2A 
(p16/INK4a) 
↓ cell cycle control; ↑ proliferation; 85 [51, 101] 
p53 
↓ apoptosis; ↓ cell cycle arrest;  
↑ metastasis; ↑ proliferation;  
↑ genomic instability 
50 to 70 [86, 103, 111] 
SMAD4/DPC4 
↑ epithelial mesenchymal transition 
(EMT); ↑ invasion; ↓cell cycle arrest; 
50 
[86, 101, 105, 
112] 
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Epidermal Growth Factor (EGF) Signaling  
There are four receptors in the EGF family designated as EGFR/erbB1/HER1, 
erbB2/HER2, erbB2/HER3, and erbB4/HER4.  EGFR/erbB1 is overexpressed in pancreatic 
cancer and promotes metastasis, proliferation, angiogenesis, and survival [110, 113, 114].  
Knockdown of EGFR inhibits the epithelial mesenchymal transition in pancreatic cancer and 
EGFR is needed for K-Ras induced pancreatic tumorigenesis [115, 116].  EGFR activity is 
stimulated by the binding of its ligands (epidermal growth factor (EGF), transforming growth 
factor-α (TGF-α), and amphiregulin), which initiate receptor hetero- or homo- dimerization and 
autophosphorylation [110, 113, 114].  As a result of this receptor modification adapter proteins 
are recruited, leading to the activation of PI3K/AKT, Ras/MAPK, and phospholipase Cγ (PLC-γ) 
pathways [110, 113, 114].  Figure 1.5 depicts four downstream pathways stimulated by EGFR 
signaling and the biological effects mediated by these pathways such as metastasis, migration, 
invasion, proliferation and chemoresistance [110, 113, 114, 117-122].  Ras pathway can also 
activate Rho GTPases and PI3K demonstrating cross-talk between these signaling pathways 
[123].   
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Metastasis 
Metastasis accounts for 90% of cancer related deaths and involves a series of steps that 
can be targeted for cancer therapy [124]. Table 1.7, describes the various steps, processes, and 
molecular signals involved for a cancer cell to metastasize.  Briefly, a tumor cell needs to 
disassociate from the tumor and surrounding environment.  Detachment is facilitated by the 
epithelial mesenchymal transition (EMT) in which cells adopt a mesenchymal phenotype [106, 
125].  EMT results in a change in cell morphology,  acquisition of motility and increased 
secretion of proteases [126].  A hallmark of EMT is the loss of E-cadherin and an increase in the 
expression of the mesenchymal markers N-cadherin, vimentin, fibronection, and αvβ6 integrin 
Figure 1.5: Summary of EGFR signaling and downstream effects upon cancer 
progression.  Pathway was constructed using Qiagen’s Ingenuity pathway Analysis (IPA®, 
QIAGEN Redwood City, www.qiagen.com/ingenuity) Pathway Designer tools. Adapted from 
Robert Roskoski Jr. (2014) 
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[106, 125].  N-cadherin forms weaker cell-cell interactions than E-cadherin allowing the 
dissociation of the cancer cells [106, 125].  Growth factors [EGF, TGF-β, tumor necrosis factor-
α (TNF-α), hepatocyte growth factor (HGF), and insulin-like growth factor-1 (IGF-1)] , secreted 
by stromal cells in the tumor microenvironment, act on the tumor cells to initiate EMT [125].  
After acquisition of a mesenchymal phenotype cancer cells can disassociate, migrate and 
invade through surrounding tissues and, intravasate into the lymph or blood system [124].  
Intravasation is a complex process mediated by multiple mechanisms including cell migration 
and invasion.  Proteases are secreted, breaking down the extracellular matrix, creating a path for 
cells to migrate [127].  Once in the lymphatic or blood system, cells need to survive stresses that 
can induce apoptosis such as shear force, lack of adherence, and hypoxia [128].  Once the cell 
has migrated to a distant site, it extravasates out of the lymphatic or blood system.  The migrated 
cell will divide to form a secondary tumor of up to 2 mm in diameter before initiating 
angiogenesis and other processes it needs to colonize the distant location [124, 129].  
Angiogenesis provides the micro-metastasis with the nutrients it needs to further grow beyond 2 
mm of diameter.  Angiogenesis is promoted by the secretion of vascular endothelial growth 
factor (VEGF), platelet derived growth factor, (PDGF), chemokines, and cytokines by the tumor 
and stromal cells [129, 130].    
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Table 1.7 : Steps, processes and molecular signals involved in the metastasis of cancer cells  
Steps of metastasis Process Molecular signals involved 
Disassociation 
EMT: cells obtain phenotype of 
mesenchymal cells that aids in 
metastasis. (↓ E-cadherin, ↑ N-
cadherin, ↑ vimentin, ↑ fibronectin, ↑ 
αvβ6 integrin) 
EGF, TGF-β, tumor necrosis 
factor-α (TNF-α), hepatocyte 
growth factor (HGF), and  
insulin-like growth factor-1 
(IGF-1) 
Intravasation 
& 
Extravasation 
Cancer cells migrate and invade 
surrounding tissue and intravasate into 
lymph or blood vessels and 
extravasate into a new site.  
Intravasation and extravasation 
involve the ability of cancer cells to 
migrate and invade surrounding tissue 
and vessels. 
Migration mediated by activation 
of Rho GTPases: RhoA, Cdc-42, 
Rac-1 (also associated with 
EMT). 
Invasion mediated by secretion 
of proteases that break down 
ECM: Matrix Metalloproteinases 
(MMP), urokinase plasminogen 
activator (uPA), and 
plasminogen. 
Survival 
Cells need to avoid cell death evoked 
by loss of cellular attachments and 
survive in vasculature 
Activation of survival signals 
(Ras, AKT, & ERK) inhibition of 
apoptotic suppressors (p53, Bim) 
and upregulation of apoptosis 
inhibitors (BCL-2, BCL-XL) 
Angiogenesis 
Generation of blood vessels to supply 
metastasized cell(s) with nutrients 
needed to grow 
Secretion of Vascular endothelial 
growth factor (VEGF), Platelet 
derived growth factor PDGF, 
chemokines, and cytokines. 
Sources: [106, 124, 125, 127-129, 131] 
  
24 
 
SECTION 1.3. RGS16: EXPRESSION, REGULATION, AND FUNCTION 
Background 
The regulator of G protein coupled receptor (GPCR) signaling (RGS) family is comprised 
of 37 RGS proteins that regulate GPCR signaling [132].  GPCRs are the largest family of 
receptors, encoded by more than 2% of the genome [133].  GPCRs are overexpressed in cancer 
and promote proliferation, migration, metastasis, and angiogenesis [133].  GPCRs mediate 
cancer progression through activation and downstream signaling of small G proteins [133]. In 
their inactive state small G proteins consist of a heterotrimeric subunit complex (Gαβγ). 
Stimulation of GPCRs by ligand binding initiates the exchange of GDP to GTP on Gα by 
guanine nucleotide exchange factors (GEFs).  Now in its active state, Gα dissociates from the 
Gβγ subunits and both Gα and Gβγ activate downstream signaling events.  GPCR signaling is 
terminated by the hydrolysis of GTP to GDP on the Gα subunit.  In the stimulated state the 
GTPase activity in G is lower than what is needed to mediate GPCR signals.  RGS proteins 
function as GTP accelerating proteins (GAPs) by binding to Gα and enhancing the hydrolysis of 
GTP to GDP [132, 134].  All RGS proteins contain a ~120 amino acid conserved region called 
the RGS box that is responsible for accelerating GTPase activity of Gα proteins [132, 134]. 
RGS proteins are divided into 8 subfamilies based on homology and function.  The R4 
subfamily contains the highest number of members and consists of the smallest (molecular 
weight) RGS proteins.  The R4 proteins contain one RGS box domain and a small number of 
amino acids on its N- and C- terminals.  With the exception of RGS2 (Gαq only) R4 members 
modulate Gαi and Gαq proteins [132, 134].  The other subfamilies contain domains that assist in 
the stability, localization, and protein-protein interactions (reviewed [132, 134]). The induction 
of p53 levels through DNA damage was used to identify RGS16, an R4 family member, as a 
target gene in several cancer cell lines [135].  We have identified RGS16 as a p53 and pRb cross-
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talk candidate using RNA expression profiling (Chapter 2) and expression of RGS16 inhibited 
the migration and invasion activity in several pancreatic cancer cell lines (Chapter 3).  In this 
next section we will explore the expression, regulation, and function of RGS16.   
RGS16 Expression 
RGS16 expression is seen in a wide variety of normal and cancerous tissues as shown in 
Table 1.  RNA tissue array analysis found RGS16 mRNA to be highly expressed in the kidney, 
brain, and lung; moderately expressed in the pancreas, colon, and small intestines, and ovaries; 
and weakly expressed in the skeletal muscle, liver, and heart [135].  Animal studies have also 
found wide spread expression of this G protein regulator corresponding to expression patterns 
seen in human tissue (Table 1.8).  Recently aberrant expression of RGS16 has been found in 
colon (higher), breast (lower), metastatic pancreatic (lower), Burkitt’s lymphomas and pediatric 
high hyperdiploid acute lymphoblastic leukemias (higher) (Table 1.8).  Although RGS16 has 
been found to be aberrantly expressed in several cancer types, there are few reported studies 
focused on the function of RGS16 in cancer progression.      
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Table 1.8: Expression of RGS16 in normal and cancer tissue 
Tissue with expression of RGS16 Species Sources 
Normal tissues 
Expressed in: kidney, brain, lung, pancreas, colon, small 
intestine, ovary, skeletal muscles, liver, and heart by RNA 
tissue array. 
Human [135] 
Expressed in immune system: T-lymphocytes, auto immune B-
cells,  
Mouse [136-138] 
Expressed in Liver: periportal hepatocytes Mouse [139] 
Expressed in progenitor cells: progenitor pancreatic cells during 
development and expression initiated in type I and II diabetes 
models and megakaryocytes 
Mouse (pancreas) 
Human 
(megakaryocytes)  
[140, 141] 
Expressed in brain: superchiasmatic nucleus (SCN) and 
hypothalmus 
Mouse [142] 
Expressed highly in retina Mouse [143] 
Expressed in the heart myocardial myocytes Rat [144, 145] 
Cancer 
Central neurocytomas: upregulated Human [146] 
Burkitt’s lymphomas and pediatric high hyperdiploid acute 
lymphoblastic leukemias: upregulated 
Human [147] 
Colorectal cancers: upregulated Human [148] 
Metastatic pancreatic cancer: downregulated Human [149] 
Breast cancers with chromosomal breakpoints, promoter 
methylation, and allelic imbalances: downregulated 
Human [150] 
 
RGS16 Regulation 
RGS16 expression is modulated by GPCR signaling pathways and other stimuli 
In the previous section, expression of RGS16 was shown to be widely expressed in 
several tissue types.  But what regulates RGS16 expression?  This section will highlight 
pathways and stimuli that induce expression of RGS16 and post-translational modifications that 
modulate its activity.  RGS16 is upregulated by a variety of compounds including doxorubicin, 
retinoic acid, fetal bovine serum (FBS) and several ligands and signaling mediators of GPCRs 
(Table 1.9).  The binding of Lysophosphatidic acid (LPA), Endothelin-1 (ET-1), and 
Sphingosine 1-phosphate (S1P) to their respective GPCRs increases transcription and expression 
of RGS16.  Upregulation of RGS16 by ET-1 and SP-1 is dependent on RhoA and Rac-1 
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signaling respectively [145].  The transcription regulator Yin Yang inhibits transcription of 
RGS16 by induced by FBS, ET-1, and S1P [145].   
Upregulation of RGS16 by PKC is hypothesized to induce increase expression of tumor 
necrosis factor- α (TNF-α) in an ERK dependent manner.  TNF-α then signals through its 
receptor and upregulates RGS16.   It is hypothesized that upregulation of RGS16 regulates the 
GPCRs responsible for T-cell response during inflammation [151].  Doxorubicin, retinoic acid, 
or histone deacetylase inhibitor (Vorinostat) plus lysine-specific demethylase1 (LSD1) 
knockdown induce expression of RGS16 in cancer cells.  Doxorubicine increases expression of 
RGS16 through a p53 dependent mechanism, demonstrating for the first time that RGS16 is a 
transcriptional target for p53 [135]. 
Post translational modification regulate RGS16 activity and localization 
RGS16 transcription is up-regulated by a variety of stimuli; however other mechanisms 
such as post-translational modification and proteasomal degradation regulate RGS16 activity and 
protein half-life.  Palmitoylation, the addition of palmitic acid to a cysteine residue in the N-
terminal domain of RGS16, is integral to the localization and activity of RGS16.  Loss of the N-
terminal region inhibits RGS16 localization to the membrane and as a consequence the Gα 
GTPase activity [152, 153].  RGS16 contains two palmitoylation sites at cysteines 2 and 12 of 
the N-terminus.  Mutational studies inhibiting palmitoylation at either site impaired RGS16 GAP 
activity and prevented RGS16 localization to lipid rafts [154, 155].  Localization of RGS16 to 
lipid rafts promotes the palmitoylation of cysteine 98 in the RGS box by a protein acyltransferase 
resulting in the acceleration of RGS16 GAP activity demonstrating the necessity of 
palmitoylation for RGS16 function [155, 156].   
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RGS16 activity is also regulated by phosphorylation.  Prevention of EGFR induced 
phosphorylation of Tyr168 in RGS16 diminished its GTPase activity by 30% [157].  
Furthermore phosphorylation of RGS16 by Src inhibited RGS16 degradation [158].  However 
phosphorylation of RGS16 can also impair its function in regulating GPCRs.  Phosphorylation of 
mouse RGS16 on Ser 58 and Ser194 subsequent to GPCR stimulation prevented its ability to 
accelerate hydrolysis of GTP [159]. 
RGS16 contains a destabilizing N-terminal residue called N-degron which targets RGS16 
for degradation by the N-end rule pathway [160].  The N-end rule was developed to calculate a 
protein’s half-life based upon its N-terminal amino acid sequence [161].  Recognition of the N-
degron by the E3 ubiquitin ligases N-recognins marks RGS16 for degradation by the 
proteasomes [160, 161]. Degradation of RGS16 by the N-end rule pathway demonstrates another 
layer of RGS16 regulation. 
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Table 1.9: Regulation of RGS16 transcription 
Protein / Stimulus Effect on RGS16 Sources 
Doxorubicin/p53 activation Increases transcription [135] 
Retinoic acid 
Increases expression 
(Neuroblastoma cell lines) 
[162] 
Concomitant treatment HDAC 
(Vorinostat) inhibitor and LSD1 
(lysine-specific demethylase1) 
knockdown 
Increased transcription 
(Triple negative breast cancer cells) 
[163] 
Carbachol 
Increases transcription  
(Mouse fibroblast cells) 
[135] 
Fasting 
Increases RGS16 transcription (in mouse 
liver) 
[139] 
IL-17 
Increases transcription 
(Mice autoimmune B cells) 
[138] 
Lysophosphatidic acid (LPA) 
Increases RGS16 transcription 
(MCF-7 breast cancer cells) 
[164] 
Endotoxin (LPS) 
Increases transcription 
(Rat myocardial myocytes) 
[144, 165] 
FBS 
Increases transcription 
(Rat myocardial myocytes) 
[135, 145] 
Sphingosine 1-phosphate (S1P) 
Increases transcription 
(Rat myocardial myocytes) 
[145] 
Endothelin-1 (ET-1) 
Increases transcription 
(Rat myocardial myocytes) 
[145] 
Yin Yang 
Inhibits transcription induced by FBS, S1P, 
and ET-1 
(Rat myocardial myocytes) 
[145] 
Runx2 
inhibits transcription 
(mouse calvariae progenitors) 
[166] 
 
RGS16 Function 
Pathways regulated by RGS16  
There are 16 known Gα proteins that mediate GPCR signaling.  The Gα proteins are 
broken down into four subfamilies based on function designated as Gαi/o, Gαq, Gα12/13 and Gαs 
[167].  RGS16 regulates GPCR signaling mediated by Gαi/o and Gαq/11 proteins by accelerating 
GTPase activity [134].  Gαi/o proteins are so named because they inhibit adenyl cyclase 
activation preventing generation of cAMP [167].  These proteins activate phospholipase Cβ 
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(PLCβ) which hydrolyzes PIP2 (phosphoinositide 4,5-bisphospate) to DAG (diacyl glycerol) and 
IP3 (inositol 1,4,5 triphosphate) [167].  DAG and IP3 activation results in activation of PKC-ε 
(protein kinase C-ε) and mobilization of Ca2+ respectively [167].  However, the Gβγ complex 
also mediates downstream signaling that is deactivated by the hydrolysis of GTP on Gα by 
RGS16 [135]. An example of this is the loss of MAPK activation induced by Gβγ of M1 and M2 
muscarinic receptors due to RGS16 GAP activity [135].  
RGS16, as seen in Table 1.9, is regulated by mitogenic signals and analogous to other 
RGS proteins, functions in a negative feedback loop to inhibit GPCRs that induce their 
expression.  Examples of this negative regulatory process can be seen for the GPCRs of LPA and 
ET-1 ligands.  Binding of LPA to its receptor (LPA1) increases expression of RGS16 which then 
inhibits activation of RhoA and serum response element dependent transcription induced by LPA 
[164].  ET-1 was previously shown to induce expression of RGS16, however this increased 
expression inhibits activation of PLCβ by ET-1 [145, 165].  Table 1.10 contains on overview of 
RGS16 targets and effects on cell signaling.   
Table 1.10: Effect of RGS16 on downstream events 
Target of RGS16 Effect Sources 
LPA 
↓ RhoA activation &  
↓ transcription of Serum response element 
[164] 
ET-1 ↓ activation of PLCβ [165] 
Platelet Activating Factor ↓ activation of p38 MAPK [168] 
GPR39 
↓ of survival & ↓ pigment epithelium-derived 
growth factor (PEDF) 
[169] 
Muscarinic receptor ↓ activation of ERK/MAPK [135] 
Chemokines 
(CxCR4, CCR10, CCR3, 
CCR5, and CCR4) 
↓ migration in megakaryocytes, B cells,  
and T-lymphocytes 
[136, 137, 141, 
170] 
EGF/EGFR 
↓ proliferation &  
↓ activation of PI3K/AKT pathway 
[171] 
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Non-canonical functions of RGS16 
RGS proteins also have non-canonical functions, ergo, regulation of cell signaling 
independent of the RGS box (Reviewed in [172]).  Two examples of RGS16 functioning in a 
non-canonical fashion are the regulation of LPA induced activation of RhoA and inhibition of 
EGF/EGFR phosphorylation and activation of PI3K.  LPA, as previously mentioned, stimulates 
expression of RGS16, which with a negative feedback loop inhibits LPA induced activation of 
RhoA.  LPA is a GPCR that mediates its signaling through Gα12/13, which is not a target for 
RGS16 regulation.   
RGS16 regulates LPA signaling events by binding to Gα13 independently of its RGS box 
and sequestering this subunit to the lipid rafts.  The exile of Gα13 by RGS16 inhibits Gα13 
mediated activation of RhoA and serum response elements [164].   
RGS16 can also inhibit EGF/EGFR signaling.  Knockdown of RGS16 in breast cancer 
cells increased proliferation induced by EGF or FBS and increased expression of RGS16 
inhibited EGF and FBS induced proliferation [171].  RGS16 binds to the p85α subunit of PI3K 
preventing recruitment of PI3K to adapter proteins attached to EGFR thereby inhibiting PI3K 
mediated phosphorylation and activation of AKT [171].  GPCRs can activate tyrosine kinase 
receptors such as EGFR and together these two proteins  induce MAPK activation [173].   
Regulation of EGFR signaling by RGS16 is another mechanism by which RGS16 inhibits 
mitogenic signals initiated by GPCRs.   
RGS16 and cell migration 
Several studies have shown a role for RGS16 in inhibiting cell migration.  Trafficking or 
migration of T lymphocytes, B cells, and megakaryocytes induced by chemokine GPCRs are 
inhibited by RGS16 [136, 137, 141, 170].  RGS16 inhibits migration of megakaryocytes and 
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activation of MAPK and AKT by the SDF-1/CxCR4 chemokine pathway [141].  Expression of 
RGS16 in the lymphocytes of a transgenic mice inhibited CxCR4, CCR3, and CCR5 allergen 
induced migration to the lung parenchyma [137].  Conversely, in RGS16 knockout mice there 
are decreases in T helper type 2 and 17 cell trafficking through regulation of CCR4 and CCR10 
chemokine pathways [136].  These studies also show the importance of RGS16 in immune 
response and trafficking.  Several studies have used knockout mice to delineate the function of 
RGS16, but it should be noted that there is no observable phenotype for mice lacking RGS16 
[174].   
RGS16 and Cancer 
RGS16 is aberrantly expressed in some cancer types (Table 1.8).  However, the role of 
RGS16 in cancer progression remains unclear.  RGS16 is upregulated in colon, central 
neurocytomas, Burkitt’s lymphomas, and pediatric high hyperdiploid acute lymphoblastic 
leukemia (Table 1.8).  Upregulation of RGS16 is due to mitogenic signals.  The question remains 
whether RGS16 is a reporter for GPCR signaling or does it indeed have a cancer promoting 
function in these cancer types?  Studies investigating the function of RGS16 in these cancer 
types will determine if it promotes cancer progression or if post-translational modifications can 
affect its function.  Furthermore post-translational modifications can affect the function of 
RGS16 and should also be investigated in these cancer types.  
Recent research suggests RGS16 may specifically have tumor suppressor function in 
breast and pancreatic cancer.  Figure 1.6 depicts the signaling pathways that RGS16 can regulate 
demonstrating its potential as a tumor suppressor.  As previously mentioned RGS16 inhibited 
EGF and FBS induced cell proliferation by blocking the PI3K/AKT pathway.  RGS16 knockout 
breast cancer cells are more resistant to tyrosine kinase inhibitor treatments [171].  Loss of 
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RGS16 occurs in metastatic pancreatic cancer and is associated with decreased patient survival 
suggesting RGS16 may inhibit the metastatic process [149].  We have found in our in vitro 
studies that RGS16 is co-regulated by p53 and pRb and inhibits pancreatic cancer cell migration 
and invasion (Chapters 2 & 3 and [175]).  Furthermore, increased expression of RGS16 is 
induced by retinoic acid and the down regulation of RGS16 with another retinoic regulated 
protein (DUSP6) disrupted retinoid inhibition of neuroblastoma growth [162].  Combined 
treatment of triple negative breast cancer cells with a HDAC inhibitor and knockdown of LSD1 
induced RGS16 expression that was vital for HDAC induced cytoxicity, downregulation of NF-
κB, and expression of E-cadherin, ING1, and CDKN1C, all of which have tumor suppressor 
function [163].  
Several of the GPCRs regulated by RGS16 (Table 1.10) have been implicated in 
promoting angiogenesis, proliferation, and metastasis including M1 and M2 muscarinic 
receptors, Platelet-activating factor (PAF),  LPA, CxCR4, and ET-1 [133, 176, 177].  These 
pathways are prime targets for future research regarding the role of RGS16 in cancer and will aid 
in identifying possible tumor suppressive functions of RGS16.   
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Figure 1.6: Known RGS16 regulation targets and downstream events that promote 
cancer progression. These pathways can be activated by a variety of signals including 
through EGFR which can also be regulated by RGS16.  CxCR4 is a prototypical 
representation of a GPCR that is involved in promoting cancer and is regulated by RGS16.  
Pathway was constructed using Qiagen’s Ingenuity pathway Analysis (IPA®, QIAGEN 
Redwood City, www.qiagen.com/ingenuity) Pathway Designer tools.  
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CHAPTER 2.  
EXPRESSION PROFILING ANALYSIS OF WI38 NORMAL LUNG 
FIBROBLASTS FOLLOWING CO-EXPRESSION OF p53 AND pRb
1
 
SUMMARY 
Mutations in p53 or RB1 (Retinoblastoma) genes, their upstream regulators, or 
downstream effectors have been found in almost all human malignancies.  Evidence suggests 
that p53 and pRb cooperate to suppress tumorigenesis, but does not elucidate the extent to which 
p53 and pRb cross-communicate to regulate cellular functions.  RNA expression profiling was 
performed on normal human lung fibroblast WI38 cells following overexpression of p53 and/or 
pRb, to identify genes co-regulated and involved in mediating p53 and pRb tumor suppressor 
processes.  The goals of the analyses were to investigate the cross-talk between p53 and Rb 
proteins and to find downstream effectors regulated by these two tumor suppressor genes. This 
knowledge might be used in the development of novel anti-cancer treatments.  Microarray 
analyses performed on WI38 cells overexpressing p53, pRb, or both p53 and pRb identified 294-
p53, 650-Rb, and 514-p53/Rb differentially regulated transcripts compared to vector control.  By 
examining the intersecting genes, we generated lists of p53 and pRb cross-talk candidates. 
Several of the cross-talk candidates are known to be regulated by p53 and/or pRb.  Five 
differentially expressed transcripts were chosen for validation by quantitative Real-Time PCR 
(qRT-PCR) in WI38 cells and in the p53 negative and RB1 mutated SAOS-2 cells.  Ingenuity 
Pathway Analysis (IPA) identified an enrichment of transcripts involved in cellular movement, 
development, cellular growth and proliferation among others in the WI38 cells overexpressing 
                                                 
1
 A portion of this work has been submitted and accepted for publication in the journal Genes 
and Cancer (see Appendix for draft) or [175].. 
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p53 and pRb. To our knowledge, this is the first time microarray analyses have been used to 
identify putative p53 and pRb cross-talk candidate genes.   The identity of these genes can be 
used in future studies on specific cancer types to better understand how p53 and pRb regulate 
cellular functions to prevent tumorigenesis.  Deeper knowledge of the p53 and pRb cross-talk 
pathway may aid in identifying new molecular targets, developing better therapies for cancer, 
and providing more information on the coordination of tumor suppressor mechanisms by p53 
and pRb. 
INTRODUCTION 
The p53 and pRb tumor suppressors are two signaling molecules that are frequently 
altered during cancer progression. Mutations that disrupt the p53 and pRb function can occur in 
the gene sequences or in their upstream regulators and/or downstream effectors [178].  Both 
tumor suppressor genes are inactivated in a variety of malignancies including osteosarcoma, 
small cell lung, breast, and bladder carcinomas [1, 4, 45, 46].  Furthermore, alterations in 
expression or activity of proteins involved in p53 and pRb signaling pathways have been 
identified in retinoblastoma and cancers of the pancreas, colon, and head and neck among others 
[49, 51, 52, 111].  The large number of cancers that have defects in the p53 and pRb pathways 
demonstrates the importance of these signaling modules in preventing cancer development and 
progression.  
Both p53 and pRb regulate processes vital for the suppression of cancer progression, such 
as cell cycle arrest, apoptosis, senescence, and differentiation [4, 73, 179].  Existing data 
suggests that p53 and pRb cooperate to prevent tumor progression.  Examples of this cooperative 
interaction have been shown in various studies using human primary cancer samples and mouse 
models.  Patients who have mutations in both p53 and RB1 genes have increased tumor 
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recurrence and decreased survival compared to patients with a mutation in either p53 or RB1 [45, 
47, 180].  Studies conducted in primary tumor samples and established cell lines found that 
inactivation of both p53 and pRb signaling pathways promotes processes that support cancer 
progression such as chromosome instability, chemoresistance, and the Epithelial Mesenchymal 
Transition (EMT) [60, 62, 181]. Mice that are p53-/-  and also heterozygous for RB1 developed 
more tumors than mice with single mutations; i.e. heterozygous p53 or RB1 null or p53 null with 
w.t. RB1 [4].  In another study, mice with conditional inactivation of both p53 and RB1 in 
prostate epithelium developed highly metastatic tumors and had decreased survival time 
compared to mice with single inactivation of either p53 or RB1 [5]. The accumulated evidence 
suggests p53 and RB1 gene products have cooperative or synergistic effects for cancer 
suppression. 
Considering the network of communication that exists within a cell, the rate of mutation 
of p53 and RB1, and the cellular processes these two proteins regulate, a natural hypothesis is 
that these two genes and respective gene products cross-communicate in order to determine 
cellular fate and prevent carcinogenesis. Over the years, data have accumulated that paints a 
picture of the communication that exists between the p53 and pRb pathways. The cell cycle 
stimulating transcription factor E2F protein provides a prime example of the link between the 
p53 and pRb pathways.  In its hypophosphorylated form pRb binds to E2F family members 
(E2F1, E2F2, or E2F3) and acts as a transcriptional repressor to inhibit the transcription of genes 
needed for the continuation of the cell cycle [18-20]. Cyclin-dependent kinases-4 and -6 
phosphorylate pRb resulting in the release of E2F from pRb binding thus allowing this factor to 
stimulate the transcription of genes encoding cell cycle stimulatory proteins [19, 21]. An 
increased amount of unbound E2F due to loss of RB1 or alteration in the pRb pathway can 
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trigger a p53-dependent apoptotic response [74, 78].  The interaction between E2F1 and p53 to 
initiate apoptosis demonstrates a protective mechanism employed by the cell to prevent cancer 
development when pRb regulation is lost.  E2F1 is not the only protein known to be involved in 
the convergent signaling between the p53 and pRb pathways; other proteins known to be 
implicated in p53 and pRb cross-talk are Hdm2, p21, and the INK4a locus (reviewed in [3, 47, 
182]).  Although several proteins that are involved in the p53 and pRb pathways have been 
identified, the full extent in which these two tumor suppressors interact along their pathways to 
regulate cellular fate is still unknown. Current data and analyses have only begun to elucidate the 
proteins involved between p53 and pRb mediated cancer suppression. The focus of this study 
was to identify signaling molecules involved in the p53 and pRb cross-talk pathway and to 
provide leads to the nature of downstream effector molecules responsible for inducing p53 and 
pRb mediated cancer suppression. Identification of p53 and pRb downstream effectors will 
provide new targets for future anti-cancer therapies. 
Materials and Methods 
Cell culture and virus transductions  
The human lung fibroblast WI38 cell line and the osteosarcoma cell line SAOS-2 (p53 
null and truncated RB1) were purchased from the American Type Culture Collection (Manassas, 
VA, USA).  WI38 cells were grown in Hyclone MEM/EBSS (ThermoFisher Scientific, 
Waltham, MA) media supplemented with 10% research grade fetal bovine serum (FBS) 
(ThermoFisher Scientific, Waltham, MA)  and 1% Penicillin Streptomycin (Corning, Corning, 
NY) and SAOS-2 cells were grown in Hyclone High Glucose DMEM  (ThermoFisher Scientific, 
Waltham, MA) supplemented with 10% FBS and 1% Penicillin Streptomycin.  Cells were 
cultured at 37°C in a humidified 5% CO2 incubator.   
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Ad.CMV (adenovirus with CMV promoter) and Ad.CMV.p53 (Adenovirus containing 
wild-type p53 gene under control of CMV promoter) viral vectors were generated using the 
AdEasy system (Carlsbad, CA). The Ad.CMV.pRb (Adenovirus containing RB1 gene cDNA 
under control of CMV promoter) vector was provided by Dr. Juan Fueyo (M.D. Anderson 
Cancer Center, The University of Texas).  Viruses were amplified and tittered as previously 
described [183-185].   
Microarray expression profiling  
For expression profiling, WI38 cells were transduced with each of the following vectors 
or vector combination:  (1) adenovirus vector with no insert (Adenoviral CMV-vector ctrl), (2) 
Ad.CMV.p53, (3) Ad.CMV.pRb, and (4) both Ad.CMV.p53 and Ad.CMV.pRb.  Vectors were 
added at a multiplicity of infection (MOI) of 50 to confluent WI38 cells (500,000 cells / 100mm 
plate) in MEM/EBSS media supplemented with 2% heat-inactivated FBS.  Culture media were 
replaced with 10% FBS and 1% Penicillin/Streptomycin supplemented MEM/EBSS medium 16 
hours after vector addition; cells were collected after 48 hours.  Four biological replicates were 
performed for each of the four expression studies.  Immunoblots were used to verify increased 
expression of p53 and/or pRb in the WI38 samples prior to microarray analysis. 
Total RNA was isolated from transduced WI38 cells using TRIzol reagent (Invitrogen, 
Carlsbad, CA) according the manufacturer’s protocol.  Using a universal reference design, two 
RNAs (transduced WI38 cells + Agilent (Santa Clara, CA) human universal reference RNA) 
were hybridized to Agilent 44K whole human genome expression arrays. Total RNAs were 
labeled with either cyanine (Cy)-3-CTP and Cy5-CTP (Perkin Elmer, Waltham, MA) using 
Agilent QuickAmp cRNA labeling kits. Following purification, Cy3- and Cy5-labeled cRNAs 
40 
 
were combined and hybridized for 17 hours at 65ºC in an Agilent hybridization oven. 
Microarrays were then washed and scanned using Agilent DNA Microarray Scanner. 
Statistical Analysis of Expression Profiling Data 
Lowess-normalized feature intensities were extracted from the scanned image using 
Feature Extraction (Agilent). These data were exported as tab-delimited files (one file per 
sample) to Microsoft Excel® for filtering.  For each feature, data were removed if both channels 
reported values not well-above background according to default Feature Extraction Criteria.  For 
each comparison, log base-2 ratios of each sample to universal reference RNA were collated into 
a single table.  Features for which fewer than 50% of all samples had a present value were 
removed from further analysis.   
The resulting tables were imported into Multiple Experiment Viewer (MEV) v4.3.  Log 
base 2 ratios were compared between each of three sample sets (p53 overexpressed samples.  
RB1 overexpressed samples and p53 and RB1 overexpressed samples) and the adenovirus vector 
control samples by Significance Analysis of Microarrays [186].  We used a conservative 
threshold whereby only genes for which MEV reported a false discovery rate of 0% were 
considered significantly differentially expressed. 
Data extracted using Feature Extraction was uploaded to the NCBI’s Gene Expression 
Omnibus (GEO) public database and is available via access number GSE59660.   
Ingenuity Pathway Analysis 
 The functional analyses were generated through the use of QIAGEN’s Ingenuity 
Pathway Analysis (IPA®, QIAGEN Redwood City, www.qiagen.com/ingenuity). The accession 
number and fold change of differentially expressed mRNA identified by RNA expression 
profiling were uploaded into Ingenuity Pathway Analysis (IPA) software for functional analysis.  
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The gene transcripts identified in the microarray were categorized based on their molecular and 
cellular function in order to identify pathways that are being altered or enriched by p53 and pRb 
signaling, however, information regarding disease and physiological system development were 
also reported (Doc. SI2 or Doc. SI3).  Benjamini-Hochberg multiple correction p-values were 
computed for the null hypotheses that genes with altered mRNA levels are independent of 
molecular and cellular functions, and functions with a corrected p-value less than 0.05 were 
considered statistically significant.  Pathways examining known relationships between the cross-
talk candidates and p53, pRb, and E2F1-3 were generated using IPA Knowledge Base and 
Pathway designer tools (grow and connect).     
Quantitative Real-time PCR analysis 
Total RNA was isolated from cells using TRIzol reagent (Invitrogen, Carlsbad, CA) 
according to the manufacturer’s protocol.  Total RNA (2ug) was reverse transcribed into cDNA 
using the High Capacity cDNA Reverse Transcription kit from Applied Biosystems (Foster City, 
CA) according to the manufacturer’s protocol.   Real-Time PCR was performed using the 
Applied Biosystems TaqMan Gene Expression Assays in the ABI 7000 detection system (Foster 
City, CA). TaqMan probes were purchased from Applied Biosystems (Foster City, CA) IL-6 
(HS00197982_m1), BCL2L11 (BCL2L11) (HS00197982_m1), RGS16 (HS00892674_m1), 
BTG2 (HS00198887), STAT4 (HS00231372_ml) and GAPDH (HS02758991). The relative fold 
change for each marker was calculated using the 2
-ΔΔCT
 analysis according to Livak et.al and 
statistical significance was determined using a one way ANOVA with a Dunnett’s post-hoc test, 
using Prism V6.0c (GraphPad Software, Inc., La Jolla, CA) [187].    
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Western blot analysis 
WI38 or Saos-2 cells were lysed in whole cell lysis buffer containing 50mM Tris-HCl 
(pH7.4), 5mM EDTA 250mM NaCl, 50mM NaF, 0.1mM Na3VO4, 0.1% Triton X-100 and 
protease inhibitors (Pierce Protease inhibitor Tablets 88661; Thermo Scientific, Rockford, IL).  
Protein extracts (50ug, measured using Bradford protein assay) were loaded onto 8% 
polyacrylamide gels and proteins were separated using sodium dodecyl sulphate-polyacrylamide 
gel electrophoresis (SDS-PAGE).  Blots were blocked 1 hour in 5% dry non-fat milk diluted in 
Tris-buffered saline solution containing 0.1% Tween-20 pH 7.6  (TBS-T). Membranes were 
probed overnight at 4°C with mouse anti-p53 (SC-DO1, 1: 1000) or mouse anti-pRb (SC-IF8, 
1:500) antibodies from Santa Cruz Biotechnology (Dallas, TX).  Following primary antibody 
incubation the membranes were washed using TBS-T (three times; 5 minutes) and probed with 
Horseradish peroxidase (HRP)-conjugated goat anti-mouse (1:5000) secondary antibodies 
(Rockland, Gilbertsville, PA) for 1 hour at room-temperature.  Primary and Secondary antibodies 
were diluted in TBS-T.  Blots were washed 5 minutes in TBS-T three times and Amersham ECL 
prime western blotting detection reagent was added in order visualize the protein bands (RPN 
2232, GE Life Sciences, Pittsburgh, PA).  Western blot images were captured using 
FOTODYNE FOTO/Analyst FX (Hartland, WI) imaging camera.   Membranes were normalized 
using mouse anti-actin (1:1000).  
RESULTS 
Identification of p53 and pRb cross-talk candidates in WI38 cells following exogenous 
expression of p53 and/or pRb.   
Studies have shown that p53 and pRb cooperate to prevent tumorigenesis.  Currently, the 
molecules that function in the p53 and pRb cross-talk pathway to regulate cellular fate are not 
43 
 
known thus expression profiling by microarray was performed to find genes co-regulated by p53 
and pRb. Normal human lung WI38 fibroblast cells were transduced with adenoviral vectors 
expressing the p53 and/or RB1 genes under the control of a cytomegalovirus (CMV) promoter. 
The WI38 cell line was used because it is from non-cancerous tissue and lacks mutations or viral 
transformations that could disrupt the p53 and pRb pathways. Four experimental conditions were 
used in which WI38 cells were transduced with adenovirus vector control (cond. 1, Adenoviral 
CMV-vector control, Ad.CMV.p53 (cond. 2), Ad.CMV.pRb (cond. 3), or both Ad.CMV.p53 and 
Ad.CMV.pRb (cond. 4).  RNA and protein from WI38 cells was collected 48 hours after 
adenoviral infection. Immunoblots verified increased expression of p53 (fold change compared 
to Ad.CMV control = 2.80, 1.54, and 2.77) and/or hypophosphorylated (active form) pRb 
(hypophosphorylated/total pRb fold change compared to Ad.CMV control = 0.94, 5.48, 5.02) in 
the WI38 cells treated with adenoviruses containing p53, pRb, or both p53 and pRb respectively 
(Figure 2.1A).  Fold change values for p53 and hypophosphorylated pRb coincided with 
previously reported results in experiments that activated endogenous p53 and pRb [30, 31].  
Microarray data from the adenovirus vector control (empty vector with CMV promoter) was 
used as a reference to determine genes that were differentially expressed as a consequence of 
p53, pRb, and p53 + pRb expression. Analysis of the microarray data identified 294-p53, 650-
pRb, and 514-p53 + pRb differentially expressed genes (Figure 2.1B). Of the differentially 
expressed genes, 294/294 genes were upregulated in cells with p53 expression, 427/650 genes 
were upregulated in cells with pRb expression, and 319/514 genes were up-regulated in cells 
with p53 + pRb coexpression (Figure 2.1B). Consistent with protein measurements, increased 
expression of p53 and/or RB1 mRNAs were also found in the appropriate groups (data not 
shown).   
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A Venn diagram shows the number of differentially expressed genes shared between the 
experimental groups (Figure 2.1B). By looking at the common genes between the three 
experimental groups, we were able to generate two lists of genes that may be involved in the p53 
and pRb cross-talk pathway. The first list of cross-talk candidates (designated as the p53 and pRb 
common gene set) consisted of 39 genes found to be commonly up-regulated in cells expressing 
either p53 or pRb. The second list of possible cross-talk members (designated as the p53 and 
pRb interaction gene set) contained 140 genes that were found to be differentially expressed only 
when p53 and pRb were overexpressed together (see Addendum for Chapter 2 for p53 and pRb 
interaction gene set).  Thirty-two of the 39 common gene set cross-talk candidates were found to 
be up-regulated in the interaction gene set, while the remaining 7 were commonly up-regulated 
in cells that overexpress either p53 or pRb (Table 2.1).  By focusing on the common and 
interaction gene sets, we were able to remove transcripts that were up- or down-regulated by 
only p53 or pRb and focus on candidates that may be involved in the p53 and pRb cross-talk 
pathway.   
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  Figure 2.1: Identification of differentially expressed transcripts in WI38 cells 
overexpressing p53 and/or pRb.  WI38 cells were transduced with adenoviruses carrying the 
transgenes p53, or RB1/p105; a MOI of 50 was used in each case.  A) Western blot analysis 
was used to test for p53 and pRb expression prior to microarray analysis.  B) Fold change of 
protein expressions compared to CMV control.  C) A Venn diagram shows the differentially 
expressed transcripts and intersects identified during the microarray analysis.  The numbers in 
red denote transcripts that were up-regulated due to p53, pRb, or p53 and pRb expression. 
. 
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Table 2.1: Fold change of p53 and pRb common gene set cross-talk candidates 
 
Gene Symbol Name FC-p53 FC-Rb FC-p53+Rb 
LOC387763 hypothetical LOC387763 30.62 159.25 297.07 
A_24_p775812 Unknown 15.65 199.36 252.80 
RGS16 Regulator of G-protein signaling 16 18.84 30.82 149.75 
AREG Amphiregulin 8.15 46.41 81.91 
CCL3 Chemokine (c-c motif ligand 3) 3.78 8.18 56.12 
TNFSF15 Tumor necrosis factor (ligand) superfamily, member 15 10.68 69.61 53.34 
IL-1B Interleukin-1 beta 4.82 22.53 43.79 
OLFM2 Olfactomedin 2 10.60 37.76 27.31 
NR4A1 Nuclear receptor subfamily 4 group A member 1 11.56 20.73 27.08 
POSTN Periostin 2.91 21.051 25.66 
D4S234e D4S234e (NSG1; neuron specific gene family member 1) 21.20 7.86 22.06 
IL-6 Interleukin-6 6.04 12.37 21.99 
DMN Desmuslin 4.57 27.42 21.25 
EPPK1 Epiplakin 32.06 8.27 20.04 
IQSEC3 IQ motif and Sec7 domain 3 7.29 20.37 19.95 
PLAC2 Placenta specific 2 21.60 4.63 19.00 
L3MBTL2 Lethal(3)malignant brain tumor-like protein 2 18.33 11.82 16.00 
LHX6 LIM homeobox 6 10.11 7.11 15.15 
AKR1B10 Aldo-keto reductase family 1 member B10 11.61 13.92 13.30 
RRAD Ras associated with diabetes 5.98 7.80 12.61 
c10orf58 chromosome 10 open reading frame 58 4.86 9.20 11.74 
BCL2L11 Bcl2-like 11 (apoptosis facilitator) 9.58 6.50 11.34 
COL7A1 Collagen, type VII, alpha 1 5.97 10.65 10.94 
JUP Junction plakoglobin 7.60 16.61 9.92 
VCAN Versican proteoglycan 5.61 9.17 9.73 
CRISPLD2 Cystein-rich secretory protein 11 10.11 5.38 9.55 
STOX2 Storkhead-box 2 14.48 8.70 9.33 
BTG-2 B-cell translocation gene 2 3.85 5.07 7.46 
P2RY2 purinergic receptor P2Y, G-protein coupled, 2 2.38 19.53 6.91 
TSKU Tsukusi,small leucine rich proteoglycan 5.28 5.42 5.97 
C4B Complement component 4B 3.38 7.64 2.22 
RTN4R Reticulon 4 receptor 8.01 6.19 N/A 
STAT4 Signal transducer and activator of transcription 4 5.98 7.80 N/A 
AK124344 cDNA FLJ42353 fis, clone UTERU2007520 5.21 7.13 N/A 
KLHL20 Kelch like 20 4.88 4.46 N/A 
NOTCH3 Notch homolog 3 4.68 3.96 N/A 
KSR1 Kinase suppressor of RAS 3.86 4.08 N/A 
GDF15 Growth/differentiation factor 15 3.24 3.40 N/A 
LOC654346 similar to galectin 9 short isoform (LOC654346) 2.81 4.77 N/A 
FC = Fold change 
N/A= Fold change not available.  Gene was not found to be significantly differentially expressed in WI38 cells overexpressing p53 and 
pRb. 
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qRT-PCR validation of microarray data in WI38 and SAOS-2 cells 
 The ultimate goal in performing the microarray analysis was to determine molecules 
involved in the p53 and pRb cross-talk pathway in order to identify and study downstream 
effector molecules that can be expressed to induce a p53 and/or pRb tumor suppressive function.  
Because of our interest in identifying downstream effector molecules, we chose five mRNA 
transcripts (IL-6, BTG-2, STAT4, RGS16, BCL2L11) from the set of 39 commonly up-regulated 
transcripts by p53 and pRb for validation via qRT-PCR.  IL-6, BTG-2, STAT4, RGS16, and 
BCL211 were chosen for validation because of vaying function, known regulation by p53 and 
pRb, and fold change values of the expression profiling assay.  WI38 cells were plated and 
transduced with adenoviral expression vectors via the same methods used for the microarray 
analysis.  Relative fold change was calculated for IL-6, BTG-2, STAT4, RGS16, and BCL2L11 
in WI38 cells expressing p53 and/or pRb as shown in Figure 2.2. Statistically significant up-
regulation of all transcripts tested except BCL2L11 was found in WI38 cells expressing p53 and 
pRb confirming the microarray results. Expression of p53 and pRb in WI38 cells increased 
mRNA expression for some of the transcripts (for example, RGS16 and BTG-2) to a greater 
extent than single expression of either p53 or pRb. This suggests p53 and pRb are working 
together resulting in an additive (i.e. BTG-2) or synergistic (i.e. RGS16) effect on mRNA 
expression for some of the transcripts.  
To further support the RNA expression profiling results, we repeated the expression of 
p53 and pRb in a p53 null, RB1 mutant osteosarcoma cell line (SAOS-2) and performed qRT-
PCR analysis of IL-6, BTG-2, STAT4, RGS16, and BCL2L11. The expression of all five 
transcripts including IL-6 and BCL2L11 were found to be significantly increased by one-way 
ANOVA compared to vector control in SAOS-2 cells expressing p53 and/or pRb (Figure 2.3). 
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Dunnett’s test for multiple comparison found BCL2L11 expression to be significantly increased  
in cells expressing p53, pRb, and both p53 and pRb and IL-6 was found to be significantly 
increased in cells expressing pRb and p53+pRb. Expression of IL-6 was not found to be 
statistically significant in SAOS-2 cells expressing p53 due to variation between replicates (fold 
change= 2.86).  All five transcripts were found to be up-regulated when p53 and/or pRb were 
expressed in the microarray analysis and qRT-PCR analysis showed similar results in WI38 and 
SAOS-2 cells.   
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Figure 2.2: Validation of microarray data using qRT-PCR in WI38 cells.   
Five transcripts RGS16, BCL2L11, BTG2, IL-6 and STAT4 from the p53 and pRb intersect were 
chosen for validation by qRT-PCR in WI38 cells overexpressing p53, pRb, or both p53 and pRb.  
The vector control (Ad.CMV) was used to calculate the fold change for each transcript.  One-way 
ANOVA with Dunnett’s test for multiple comparison were used to test for statistical significance * 
p-value < 0.05, ** p-value < 0.01, *** p-value < 0.001, and **** p-value < 0.0001.   
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Figure 2.3: Validation of microarray data using qRT-PCR in SAOS-2 cells.  
Five transcripts RGS16, BCL2L11, BTG2, IL-6 and STAT4 from the p53 and pRb intersect 
were chosen for validation by qRT-PCR in SAOS-2 cells overexpressing p53, pRb, or both p53 
and pRb.  The vector control (Ad.CMV) was used to calculate the fold change for each 
transcript.  One-way ANOVA with Dunnett’s test for multiple comparison were used to test for 
statistical significance * p-value < 0.05, ** p-value < 0.01, *** p-value < 0.001, and **** p-
value < 0.0001.   
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Ingenuity Pathway Analysis of differentially expressed transcripts in WI38 cells following 
overexpression of p53 and/or pRb. 
The web-based Ingenuity Pathway Analysis software (IPA) was used to perform 
functional analysis on the WI38 expression profiles. Differentially expressed mRNA transcripts 
with known functions are eligible for IPA analysis.  Eligible transcripts for each overexpression 
were as follows: p53: 263/294, pRb: 533/650, and p53 + pRb: 441/514). These gene sets were 
loaded into IPA for global functional analysis to predict biological functions that may be 
activated or inhibited due to p53 and pRb signaling. Lists of the significant molecular and 
cellular functions found to be statistically overrepresented by p-value (Benjamini-Hochberg 
correction after Fisher’s exact test) due to overexpression of p53, pRb, and both p53 and pRb 
based on IPA annotations are shown in Figures 2.4-2.6.  Cellular development was the top 
overrepresented molecular and cellular function in WI38 cells overexpressing p53 followed by 
cellular movement and cell-to-cell signaling and interaction (Figure 2.4).  Transcripts associated 
with cell cycle regulation functions such as cell cycle, cellular assembly and organization, and 
DNA replication, recombination, and repair were enriched in WI38 cells overexpressing pRb 
(Figure 2.5). WI38 cells overexpressing both p53 and pRb showed enrichment in transcripts 
associated with cellular growth and proliferation, cell cycle, cell death and survival, and 
development (Figure 2.6). Similar cell and molecular functions were found to be overrepresented 
in WI38 cells overexpressing p53, pRb, and p53 + pRb. Transcripts involved in cellular 
development, cellular growth and proliferation, cell death and survival, and cellular movement 
were found to be differentially expressed in all three experimentally conditions with differences 
in order of significance between groups. Genes involved in DNA replication, recombination and 
repair biological functions were not found to be significantly differentially expressed in WI38 
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cells overexpressing p53 but were significantly enriched in cells overexpressing pRb and p53 + 
pRb. There was also enrichment in genes involved in cell cycle regulation in all three 
experimental conditions, however, in WI38 cells overexpressing p53, cell cycle was the twelfth 
significant biological pathway. The differences in biological functions found to be enriched by 
IPA highlights the various pathways regulated by p53 or pRb.     
Because of my interest in discovering p53/pRb cross-talk mechanisms, IPA functional 
analysis was also performed on IPA-eligible genes from both cross-talk candidate gene subsets 
(p53 and pRb common (36/39) and interaction (104/140) gene sets combined and separately) 
identified by RNA expression profiling.  IPA functional analysis on all cross-talk candidates 
(combined cross-talk gene subsets) revealed statistically significant enrichment in functions 
involved in cellular growth and proliferation, cellular development, cell death and survival, 
cellular movement, and cell cycle (Figure 4.7). Interestingly, when examining the cross-talk gene 
sets separately; different functions are significantly enriched between groups. Only annotations 
associated with cellular growth and proliferation, cell cycle, and cellular development were 
found to be statistically significant in the interaction gene set (Figure 4.8).  In the common gene 
set, 25 functions were found to be statistically overrepresented including cellular movement, 
cellular development, cellular growth and proliferation, cell cycle, and lipid metabolism (Figure 
4.9).   
Each category of cell and molecular functions is broken down into subcategories.  
Analysis of these sub categories in combination with examination of the top annotations 
associated with disease in IPA, revealed an enrichment of transcripts involved in immune 
response (not a category for cell and molecular function) in cells expressing p53, pRb, and p53 + 
pRb.  Interestingly, annotations associated with immune response were among the top 
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statistically significant functions in the IPA analysis of p53 and p53 + pRb common gene sets. 
Biological processes associated with inflammation of organ (2.29E-03), development of 
leukocytes (2.29E-03), accumulation of leukocytes (2.75E-03), and movement of lymphocytes 
(1.10E-02) were found to be statistically significant in WI38 cells that overexpress p53 (Data not 
shown).  Generation of T lymphocytes (3.04E-04), inflammation of organ (6.41E-04), TH1 
immune response (5.36E-03), development of TH17 cells (5.70E-03), and mobilization of 
phagocytes (8.25E-03) among others were statistically significant in the p53 and pRb common 
gene set (data not shown).  Annotations associated with immune response were also statistically 
enriched in the other gene sets (WI38 overexpressing pRb, p53 + pRb, collective cross-talk 
candidates).  These data demonstrate an increase in proteins associated with immune response. 
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Figure 2.4: Cell and molecular functions statistically overrepresented in WI38 cells 
overexpressing p53.   
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Figure 2.5: Cell and molecular functions statistically overrepresented in WI38 cells 
overexpressing pRb.   
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Figure 2.6: Cell and molecular functions statistically overrepresented in WI38 cells 
overexpressing p53 + pRb.   
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Figure 2.7: Cell and molecular functions statistically overrepresented in collective p53 
and pRb common and interaction cross-talk candidates.   
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Figure 2.8: Cell and molecular functions statistically overrepresented in the 
interaction gene set p53 and pRb cross-talk candidates  
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Figure 2.9: Cell and molecular functions statistically overrepresented in the common 
gene set p53 and pRb cross-talk candidates.   
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IPA pathway generation of known interactions between p53, pRb, E2F family members 
(E2F1-3), and cross-talk candidates identified by RNA expression profiling 
By using RNA expression profiling, we were able to identify transcripts that may be co-
regulated by p53 and pRb and involved in regulating tumor progression.  In order to gain more 
understanding of p53 and pRb cross-talk, pathways were generated examining known direct and 
indirect relationships between the cross-talk candidates and p53, pRb, and E2F1-3 using IPA’s 
Ingenuity Knowledge Base (Ingenuity Systems).  The p53 and Rb common and interaction cross-
talk candidate gene sets were loaded into IPA and pathways were generated using the Ingenuity 
Knowledge Base and IPA pathway tools (“Grow, Connect, and Pathway Designer”) to examine 
upstream and downstream relationships between p53, pRb, E2F1-3 (E2F family members 
regulated by pRb) and the differentially expressed cross-talk gene sets (Figure 2.10-2.12). A 
pathway comprised of known interactions between all of the cross talk candidates (designated as 
the collective p53 and pRb cross-talk candidate pathway) made using the p53 and pRb common 
and interaction gene sets is depicted in Figure 2.12.  Separate pathways for each cross-talk gene 
set, designated as p53 and pRb common gene set and interaction gene set pathways, respectively, 
were also generated (Figures 2.10-2.11).  Pathway generation by IPA identified the common 
gene set candidates RGS16, D4s234e/NSG1, BTG-2, GDF-15, VCAN, AKR1B10 and AREG 
and the interaction gene set candidates: F11R, TNFRSF10C, CERS6, HDM2, SESN1, RBM38 
and PMAIPI/NOXA as targets of p53 transcriptional activation (Figures 2.10-2.12).  The 
interaction gene set cross-talk candidates BUB1, CDT1, and MCM3 are targets for 
transcriptional repression by p53, whereas, VRK1, MCM3, and CDT1 are known to be down-
regulated by pRb (Figure 2.11-2.12).  Interactions between E2F and the cross-talk candidates 
were assessed because of regulation of E2F gene expression by pRb.  IPA identified FGFR3, 
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MCM3, and KRT14 interaction gene set candidates as transcriptional targets of E2F1-3 family 
members (Figures 2.11-2.12).  Interestingly, IPA’s database identified only 17 out of 39 of the 
p53 and pRb common and 26 out of 140 of the interaction cross-talk candidates as having known 
up- or down-stream relationships with p53, pRb, or E2F1. The low number of cross-talk 
signaling molecules known to have a direct and indirect relationship with p53 and pRb highlights 
the need for more research to understand the functions of these tumor suppressors. 
Known interactions between the p53 and pRb cross-talk candidates are also depicted.  
Connections can be seen between cross-talk members that are centrally located in the IPA 
pathway.  In the common gene set pathway, IL-1β, IL-6, BCL2L11, STAT4, BTG-2, and 
NR4A1 all have multiple connections (4 or more) with p53, pRb, E2Fs, or other cross-talk 
candidates (Figure 2.10).  Centrally located signaling molecules or nodes are also present in the 
p53 and pRb interaction pathway and consist of HDM2, BMP-2, and IL-12A (Figure 2.11). 
Furthermore, the same cross-talk candidates (IL-1β, IL-6, BCL2L11, STAT4, BTG-2, NR4A1, 
HDM2, BMP-2, and IL-12A) appear to function as signaling nodes in the collective cross-talk 
pathway signifying their possible role in mediating p53 and pRb functions.   
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Figure 2.10: Known interaction network of common gene set cross-talk candidates 
with p53, pRb, and E2F1-3.   IPA Ingenuity Knowledge base pathway tools and pathway 
designer were used to generate a pathway showing known direct (solid lines) and indirect 
(dashed lines) relationships between the p53 and pRb common gene set and p53, pRb, and 
E2F1-3.  Each shape represents a different type of signaling molecule.  Color intensity is 
associated with the degree in which the transcripts were up- (red) or down-regulated 
(green).   
 
63 
 
 
 
  
Figure 2.11: Known interaction network of p53 and pRb interaction gene set cross-talk 
candidates with p53, pRb, and E2F1-3.    IPA Ingenuity Knowledge base pathway tools and 
pathway designer were used to generate a pathway showing known direct (solid lines) and 
indirect (dashed lines) relationships between the p53 and pRb interaction gene set cross-talk 
candidates and p53, pRb, and E2F1-3.  Each shape represents a different type of signaling 
molecule.  Color intensity is associated with the degree in which the transcripts were up- (red) 
or down-regulated (green).   
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Figure 2.12: Known interaction network of colectiveollective p53 and pRb cross-
talk candidates with p53, pRb, and E2F1-3.  IPA Ingenuity Knowledge base 
pathway tools and pathway designer were used to generate a pathway showing known 
direct (solid lines) and indirect (dashed lines) relationships between all of the p53 and 
pRb cross-talk candidates and p53, pRb, and E2F1-3.  Each shape represents a different 
type of signaling molecule.  Color intensity is associated with the degree in which the 
transcripts were up- (red) or down-regulated (green).    
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DISCUSSION 
Significance of investigating p53 and pRb cross-talk  
Historically, investigations of p53 and pRb regulated transcription have focused on 
identifying the individual downstream targets of p53 and pRb. However, cell fate is not 
determined solely by one signaling pathway but by many pathways that communicate through a 
network of signaling molecules.  Cross-communication between pathways allows the integration 
of the exogenous and endogenous signals in a cell to aid in the determination of cell fate.  Co-
expression of p53 and pRb in cancer cells with compromised p53 and pRb activity inhibited p53 
mediated apoptosis and promoted cell cycle arrest suggesting that p53 and pRb cross-talk to 
regulate cellular fate [188, 189].  Furthermore, data from previous studies suggests p53 and pRb 
may also cooperate to inhibit cancer progression. Patients diagnosed with breast cancer and 
treated with adjuvant chemotherapy had a better prognosis to adjuvant chemotherapy if they had 
functional p53 and pRb [61].  
To our knowledge this is the first study that examined altered gene expression when p53 
and pRb are overexpressed together or separately with the purpose of finding genes co-regulated 
by both tumor suppressor genes.  How p53 and pRb cross-communicate to regulate cellular 
functions or cooperate to inhibit cancer progression still remains largely unknown.  The p53 and 
pRb pathways are commonly altered during tumorigenesis. The study of genes dually regulated 
by p53 and pRb will provide a valuable insight into the collaborative cancer preventative 
properties of these two tumor suppressor proteins.   
Transcriptional regulation may be one method used by p53 and pRb to coordinate cellular 
functions.  For example, the cyclin kinase inhibitor p21 is a down-stream target gene of p53 that 
inhibits phosphorylation and inactivation of pRb [25]. Transactivation of p21 demonstrates a 
mechanism by which p53 can coordinate with pRb to initiate cell cycle arrest.  During 
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myogenesis, p53 increases the expression of Rb (mRNA and protein), which later leads to pRb 
and MyoD initiation of muscle differentiation [17]. This provides an example by which p53 
directly enhances pRb expression leading to muscle differentiation. However, this one example 
is likely an indicator of large number of interactions that regulate complex cellular programs.   
Change in RNA expression profiles of WI38 cells overexpressing both p53 and pRb 
compared to expression of p53 or pRb alone and identification of cross-talk candidates. 
In this study, we identified genes that may be regulated by p53 and pRb and compiled 
two lists of p53 and pRb cross-talk candidates by overexpressing p53 and/or pRb in WI38 cells.  
Although p53 has transcriptional repression activity, our microarray analysis did not detect any 
down-regulated transcripts in the WI38 cells overexpressing p53 [190, 191].  The deficit of p53 
down-regulated transcripts in our microarray analysis compared to previous work, could be due 
to our method of p53 activation, cell type, or p53 levels, which have previously been found to 
induce a distinct p53 response with a small set of overlapping genes [192, 193]. Our expression 
profiling analyses were conducted in normal lung fibroblasts cells instead of cancer epithelial 
cells.  Lack of p53 down-regulated genes in the p53 overexpressing WI38 cells could also be 
attributed to the ability of p53 and pRb to alter each other’s transcriptional activation or 
repression functions. Previous studies that discovered p53 down-regulated targets using 
expression profiling were done in cancer cells with mutated or null p53 and wild-type RB1 such 
as PC-3, HCT116, and H1299 cells [190, 194].   
There were 319 upregulated transcripts when p53 and pRb were expressed together 
compared to 427 and 295 in the WI38 cells expressing pRb and p53 respectively. The change in 
upregulated genes suggests p53 and pRb can alter one another’s ability to regulate gene 
expression.  Management of p53 and pRb processes may require these transcription factors to 
67 
 
regulate gene expression in an opposing manner. Expression of an embryonic development gene, 
Placenta-specific 1 (PLAC1), has recently been found to be down-regulated by p53 and up-
regulated by pRb demonstrating how p53 and pRb can play contrasting roles to regulate cellular 
processes [81].   
pRb is most associated with transcriptional repression of E2F target genes. However, 
binding of E2F by pRb is not needed to promote transcription, suppress tumor growth and induce 
cellular differentiation or senescence [22, 23].  In fact, pRb acts as a co-activator for several 
transcription factors including Sp-1, RUNX-2, MyoD, and several nuclear receptors (including 
NR4A1) resulting in cellular differentiation [22, 39].  We found more upregulated transcripts in 
WI38 cells overexpressing pRb demonstrating its function as a transcription co-activator. There 
is still a lack of information regarding pRb regulation, therefore, this study could contribute to 
identifying genes up-regulated by pRb and understanding the function of pRb as a transcriptional 
co-activator.  
Candidates for the p53 and pRb cross-talk pathway were chosen based on whether (1) the 
transcripts were differentially expressed in both WI38-p53 overexpressing cells and WI-38-pRb-
overexpressing cells (the common gene set), or (2) only in WI38 cells that simultaneously 
overexpress p53 and pRb (interaction gene set). By focusing on the p53 and pRb common and 
unique genes, we were able to remove from our analysis genes regulated by p53 or pRb alone.  
RNA expression profiling validation  
Validation of microarray data was performed using qRT-PCR for five (RGS16, 
BCL2L11, BTG-2, IL-6 and STAT4) of the p53 and pRb common gene set cross-talk candidates.  
Up-regulation of all transcripts tested except BCL2L11 was found to be statistically significant 
in WI38 cells overexpressing p53 and pRb confirming the microarray results.  The analysis was 
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performed using a normal cell line in order to avoid any mutations that could be present up- or 
downstream of p53 and pRb that could hinder identification of downstream targets of both genes.  
Although p53 and pRb were expressed using adenoviruses in normal cells, the fold change of 
p53 and hypophosphorylated pRb proteins compared to CMV control were equivalent to or less 
than fold change values in WI38 cells incubated in serum free media to induce quiescence (fold 
change p53 after 24 hours in serum free media = 5.5) or MCF7 cells undergoing confluence 
induced cell growth arrest (fold change hypophosphorylated pRb/total pRb = 6.00) [195, 196]. 
This data suggests the concentration of virus used did not induce protein expression exceeding 
endogenous protein expression of p53 and the active hypophosphorylated form of pRb.  The use 
of a normal cell line with wild-type p53 and RB1 could make it difficult to identify cross-talk 
molecules due to possible interactions between endogenous and exogenous p53 and pRb.  
Expression of RGS16, BCL2L11, BTG-2, IL-6, and STAT4, were measured using qRT-PCR in 
the p53 null and pRb mutated osteosarcoma cell line SAOS-2 to investigate if exogenous and 
endogenous p53 and pRb interactions could influence expression profiles. Expression of all 
transcripts in the p53 and pRb overexpressing SAOS-2 cells was found to be increased with 
differences in magnitude of expression similar to the WI38 microarray data and qRT-PCR 
results.   Differential expression of BCL2L11 was not statistically significant in WI38 cells but 
was in SAOS-2 cells overexpressing p53, pRb, or p53 + pRb. Replication of the qRT-PCR 
analysis in SAOS-2 cells provided additional information that supports the hypothesis that the 
chosen transcripts are involved in the p53 and pRb cross-talk pathway.  Interestingly, in the 
microarray data, STAT4 was found to be differentially expressed in WI38 cells overexpressing 
p53 or pRb but not in cells that overexpressing both genes.  However, qRT-PCR analysis found a 
statistically significant increase in STAT4 expression in WI38 and SAOS-2 cells overexpressing 
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p53 and pRb.  The statistical analyses of expression profiling data or the sensitivity of microarray 
signal detection could account for the failure to observe differential expression of STAT4 in 
WI38 cells overexpressing p53 and pRb.    
IPA functional analysis identified enriched cell and molecular functions in p53 and/or pRb 
overexpressed WI38 cells 
p53, pRb, and p53 + pRb overexpressing cells 
Co-expression of p53 and pRb in bladder and cervical cancer cells with mutations or 
inactivation of both proteins induced cell cycle arrest and inhibited p53 induced apoptosis [188, 
189].  The ability of pRb to inhibit p53-mediated apoptosis suggests co-expression of both genes 
can alter gene regulation and ultimately cellular fate. IPA functional analysis was performed on 
all three experimental groups plus cross-talk candidate gene sets to determine if co-expression of 
p53 and pRb would differentially induce expression of transcripts associated with different 
biological functions compared to cells with overexpression of either p53 or pRb. IPA software 
cross-references genes and expression changes against Ingenuity Knowledge Base to identify 
known connections, diseases, and biological functions associated with a large dataset. The 
biological functional analysis information provided by IPA is broken down into molecular and 
cellular functions and physiological system development and functions.  In the analysis, I was 
interested in the biological functional analysis information pertaining to molecular and cellular 
functions enriched due to overexpression of p53 and/or pRb.  Interestingly, IPA found significant 
enrichment in molecular and cellular functions such as cellular development, cellular movement, 
cell death and survival, and cellular growth and proliferation in WI38 cells overexpressing p53 
and/or pRb with differences in order of significance between groups.  Furthermore, cell cycle 
regulation and DNA replication recombination and repair did not make the top significant 
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molecular cellular functions in cells overexpressing p53 but did in the pRb and p53 + pRb 
groups. Also noteworthy, biological functions overrepresented in cells overexpressing p53 + pRb 
are a cross between the results obtained from the cells overexpressing p53 or pRb suggesting 
activation of both p53 and pRb alters gene expression and cellular fate more than if one tumor 
suppressor was activated. This data supports the hypothesis that p53 and pRb coordinate to 
regulate cellular functions.  
Cross-talk candidate gene sets  
Both cross-talk candidate gene sets are differentially expressed when p53 and pRb are 
overexpressed together suggesting these candidates could interact with one another.  Because of 
the possible interaction between the p53 and pRb common and interaction gene sets, we 
performed IPA analysis collectively on all of the cross-talk candidate gene sets and separately to 
identify enriched cell and molecular functions.  Even though it was the larger gene set, IPA 
analysis of the interaction gene set, using Benjamini-Hochberg multiple testing correction p-
value, yielded only three IPA annotations significantly enriched (cellular growth and 
proliferation, cell cycle, and cellular development) compared to 25 significantly enriched 
biological functions in the common gene set.    Collective IPA analysis of all of the cross-talk 
candidates increased the amount of cell and molecular functions found to be statistically 
significant compared to separate IPA analyses performed on common and interaction gene sets.  
In summary IPA identified a significant enrichment in transcripts responsible for development, 
cell cycle, apoptosis, and immune response in WI38 cells overexpressing p53 and/or pRb and in 
the cross-talk gene sets.  Enrichment in similar biological functions in all three experimental 
conditions and in the cross-talk gene sets supports the hypothesis that p53 and pRb communicate 
to regulate cell outcomes.  This study provides information regarding the p53 and pRb cross-talk 
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that can be used to better understand how p53 and pRb regulate processes that inhibit cancer 
progression and are those vital for organism development. 
 
IPA pathway generation 
 Identification of known interaction of cross-talk candidates with p53, pRb, and 
E2F1-3  
IPA pathway tools were used to construct pathways to aid in identifying known up- and 
down-stream interactions (i.e. expression, regulation, activation, and protein-protein interaction) 
between the cross-talk candidates, p53, pRb, and E2F1-3.  These interactions were chosen 
because of pRb’s known function as a transcriptional repressor of E2F target genes and the 
known involvement of E2F-1 in p53 and pRb cross-talk [18].  From the IPA derived pathways 
we were able to 1) determine which cross-talk candidates have previously been found to be 
regulated by p53 or pRb, and 2) uncover known interactions between the cross-candidates.  
Using IPA software we were able to identify which of the cross-talk candidates were previously 
found to be regulated by p53 or pRb, providing a validation of the microarray results [135, 193, 
197-205].  Only a few of the downregulated p53 and pRb cross-talk candidates have previously 
been found by other studies to be downregulated by p53 (MCM3, BUB1, and CDT1) or pRb 
individually (VRK1, MCM3, and CDT1) [190, 206-209].  There are no down-regulated p53 and 
pRb commonly expressed cross-talk candidates due to lack of p53 down-regulated transcripts in 
the microarray data.  Although several of the p53 and pRb cross-talk candidates have previously 
been found to be regulated by p53, regulation of these transcripts by pRb has not been reported.  
In fact, very few of the p53 and pRb cross-talk candidates have been identified as down-stream 
targets of pRb regulation by the IPA database. This lack in knowledge regarding pRb 
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transcriptional control can be attributed to lack of studies on the ability of the Rb protein to act as 
a transcriptional co-factor.  Furthermore, function and regulation of several of the cross-talk 
candidates in the common and interaction gene sets remains unknown demonstrating the need for 
more research to understand the function of these unknown genes. 
Identification of possible signaling nodes in WI38 cells overexpressing p53 and pRb 
Also of interest, several cross-talk candidates were found to be centrally located in the 
IPA pathways denoting relationships with other cross-talk candidates and the transcription 
factors of interest (p53, pRb, or E2F1-3).  This observation suggests these candidates may 
function as signaling nodes to mediate p53 and pRb downstream effects.  The cross-talk 
candidates IL-1β, IL-6, BCL2L11, IL12A, STAT4, BTG-2, NR4A1, HDM2, and BMP-2 were 
all found to have a number of interactions between other cross-talk candidates or p53, pRb, or 
E2F1-3.  NR4A1, STAT4, and BTG-2 all have transcription regulation activities and are 
involved in controlling processes such as differentiation, immune response, and cell cycle arrest 
[72, 210, 211].  
 Several of the signaling nodes (IL12A, IL-1β, and IL-6) are known to play a role in 
regulation of immune responses and have been linked to cancer [212, 213].  Contrary to the 
expression profiling and qRT-PCR findings, the cytokine IL-6 is transcriptionally repressed by 
p53 and pRb in HeLa cells and is usually associated with aiding cancer progression [214].  
Despite its role in cancer promotion, IL-6 has also been found to inhibit phosphorylation of pRb 
and to aid in cell cycle arrest in growth-sensitive hematopoietic cells [215]. Furthermore, RB1 
negative murine fibroblasts have decreased expression of chemokines and cytokines including 
IL-6 [216].  With these functions in mind, the role of IL-6 in cells overexpressing p53 and/or 
pRb is unclear.  Expression of IL-6 and other immune associated factors could be due to p53 and 
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pRb induced senescence [217]. Senescence induced by these two tumor suppressors causes an 
immune response through secretion of factors collectively referred to as the senescence 
associated secretory phenotype (SASP) [218, 219].  In fact several of the immune regulatory p53 
and pRb cross-talk candidates upregulated in the microarray data (IL-6, IL-1β, CCL3, and 
AREG) are associated with SASP and their expression could be due to the increased levels of 
p53 and pRb. [217].  
CONCLUSIONS 
p53 and pRb are two of the most studied tumor suppressors and function to regulate 
many of the same processes.  Therefore, it is not surprising similar cell and molecular functions 
are enriched in cells overexpressing p53 and pRb.  The different order of significance when both 
genes are overexpressed suggests that the combination of p53 and pRb alters outcome of the cell 
compared to activation of only one tumor suppressor.   
By utilizing microarray expression profiling, p53 and pRb regulated candidates or genes 
involved in coordinating cancer suppression processes and determining cell fate were identified.  
p53 and pRb are not the only pathways involved in cancer suppression and determination of cell 
fate, but they are currently the most targeted for mutations in cancer.  The investigation of p53 
and pRb cross-talk focused on transcriptional regulation as a mechanism for p53 and pRb to 
coordinate cell functions and provides a frame work to study the cooperation between p53 and 
pRb in determining cell fate. Further studies are required to identify new molecular targets that in 
turn could lead to the development of more effective anti-cancer therapies.  
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Addendum for Chapter 2 
 
p53 and pRb Interaction Significant Differentially Expressed Gene Set 
Systematic 
Name 
Gene Name Description 
Average 
Fold 
Change  
AI911302 AI911302 
AI911302 wd14e10.x1 
Soares_NFL_T_GBC_S1 Homo sapiens 
cDNA clone IMAGE:2328138 3', mRNA 
sequence [AI911302] 
86.74 
 
NM_002632 PGF 
Homo sapiens placental growth factor, 
vascular endothelial growth factor-related 
protein (PGF), mRNA [NM_002632] 
46.762 
 
NM_018965 TREM2 CYP4F2 24.856  
A_24_P878366 A_24_P878366 Unknown 21.512  
NM_198173 GRHL3 
Homo sapiens grainyhead-like 3 
(Drosophila) (GRHL3), transcript variant 2, 
mRNA [NM_198173] 
21.126 
 
NM_017565 FAM20A 
Homo sapiens family with sequence 
similarity 20, member A (FAM20A), 
mRNA [NM_017565] 
20.308 
 
THC2668267 THC2668267 
Q3MAK1_ANAVT (Q3MAK1) 
Phosphoglucomutase/phosphomannomutase  
partial (4%) [THC2668267] 
19.498 
 
THC2565393 THC2565393 
Q5VT28_HUMAN (Q5VT28) Family with 
sequence similarity 27, member B (Family 
with sequence similarity 27, member A) 
(Family with sequence similarity 27, 
member C), partial (81%) [THC2565393] 
19.246 
 
A_32_P168727 A_32_P168727 Unknown 17.802  
BC073976 BC073976 
Homo sapiens cDNA clone IMAGE: 
6018774, partial cds. [BC073976] 
17.16 
 
NM_002590 PCDH8 
Homo sapiens protocadherin 8 (PCDH8), 
transcript variant 1, mRNA [NM_002590] 
16.226 
 
CD511705 CD511705 
AGENCOURT_14360862 NIH_MGC_187 
Homo sapiens cDNA clone 
IMAGE:30405414 5', mRNA sequence 
[CD511705] 
16.062 
 
NM_138344 C14orf152 
Homo sapiens chromosome 14 open 
reading frame 152 (C14orf152), mRNA 
[NM_138344] 
15.977 
 
75 
 
NM_001080468 SYCN 
Homo sapiens syncollin (SYCN), mRNA 
[NM_001080468] 
15.905 
 
NM_021571 ICEBERG 
Homo sapiens ICEBERG caspase-1 
inhibitor (ICEBERG), mRNA 
[NM_021571] 
14.305 
 
NM_001082 CYP4F2 
Homo sapiens cytochrome P450, family 4, 
subfamily F, polypeptide 2 (CYP4F2), 
mRNA [NM_001082] 
12.569 
 
NM_000729 CCK 
Homo sapiens cholecystokinin (CCK), 
mRNA [NM_000729] 
12.407 
 
NM_001200 BMP2 
Homo sapiens bone morphogenetic protein 
2 (BMP2), mRNA [NM_001200] 
11.436 
 
NM_133177 PTPRU 
Homo sapiens protein tyrosine phosphatase, 
receptor type, U (PTPRU), transcript 
variant 2, mRNA [NM_133177] 
11.168 
 
THC2642537 THC2642537 
Q2Q5T5_MOUSE (Q2Q5T5) Embryonic 
stem cell-and germ cell-specific protein 
ESGP, complete [THC2642537] 
10.941 
 
NM_023067 FOXL2 
Homo sapiens forkhead box L2 (FOXL2), 
mRNA [NM_023067] 
10.62 
 
NM_003991 EDNRB 
Homo sapiens endothelin receptor type B 
(EDNRB), transcript variant 2, mRNA 
[NM_003991] 
10.585 
 
NM_004428 EFNA1 
Homo sapiens ephrin-A1 (EFNA1), 
transcript variant 1, mRNA [NM_004428] 
10.517 
 
NM_004387 NKX2-5 
Homo sapiens NK2 transcription factor 
related, locus 5 (Drosophila) (NKX2-5), 
mRNA [NM_004387] 
10.47 
 
NM_000526 KRT14 
Homo sapiens keratin 14 (epidermolysis 
bullosa simplex, Dowling-Meara, Koebner) 
(KRT14), mRNA [NM_000526] 
10.436 
 
NM_003841 TNFRSF10C 
Homo sapiens tumor necrosis factor 
receptor superfamily, member 10c, decoy 
without an intracellular domain 
(TNFRSF10C), mRNA [NM_003841] 
10.17 
 
NM_000142 FGFR3 
Homo sapiens fibroblast growth factor 
receptor 3 (achondroplasia, thanatophoric 
dwarfism) (FGFR3), transcript variant 1, 
mRNA [NM_000142] 
10.133 
 
NM_152404 UGT3A1 
Homo sapiens UDP glycosyltransferase 3 
family, polypeptide A1 (UGT3A1), mRNA 
[NM_152404] 
10.083 
 
76 
 
NM_152670 C2orf51 
Homo sapiens chromosome 2 open reading 
frame 51 (C2orf51), mRNA [NM_152670] 
9.5914 
 
NM_005268 GJB5 
Homo sapiens gap junction protein, beta 5 
(GJB5), mRNA [NM_005268] 
9.5447 
 
NM_000422 KRT17 
Homo sapiens keratin 17 (KRT17), mRNA 
[NM_000422] 
9.5142 
 
NM_033120 NKD2 
Homo sapiens naked cuticle homolog 2 
(Drosophila) (NKD2), mRNA 
[NM_033120] 
8.9252 
 
BC063385 TRAα 
Homo sapiens T cell receptor alpha locus, 
mRNA (cDNA clone MGC:71411 
IMAGE:4853814), complete cds. 
[BC063385] 
8.706 
 
NM_015879 ST8SIA3 
Homo sapiens ST8 alpha-N-acetyl-
neuraminide alpha-2,8-sialyltransferase 3 
(ST8SIA3), mRNA [NM_015879] 
8.6842 
 
NM_005523 HOXA11 
Homo sapiens homeobox A11 (HOXA11), 
mRNA [NM_005523] 
8.521 
 
NM_024989 PGAP1 
Homo sapiens GPI deacylase (PGAP1), 
mRNA [NM_024989] 
8.3487 
 
NM_018558 GABRQ 
Homo sapiens gamma-aminobutyric acid 
(GABA) receptor, theta (GABRQ), mRNA 
[NM_018558] 
8.2783 
 
AK125985 AK125985 
Homo sapiens cDNA FLJ43997 fis, clone 
TESTI4021456. [AK125985] 
8.1169 
 
CB852325 CB852325 
UI-CF-FN0-afp-n-21-0-UI.s1 UI-CF-FN0 
Homo sapiens cDNA clone UI-CF-FN0-
afp-n-21-0-UI 3', mRNA sequence 
[CB852325] 
7.8293 
 
NM_002392 MDM2 
Homo sapiens Mdm2, transformed 3T3 cell 
double minute 2, p53 binding protein 
(mouse) (MDM2), transcript variant 
MDM2, mRNA [NM_002392] 
7.8157 
 
ENST000003775
25 
ENST00000377
525 
Protein FAM27E1. 
[Source:Uniprot/SWISSPROT;Acc:Q5T7N
7] [ENST00000377525] 
7.7762 
 
NM_004755 RPS6KA5 
Homo sapiens ribosomal protein S6 kinase, 
90kDa, polypeptide 5 (RPS6KA5), 
transcript variant 1, mRNA [NM_004755] 
7.7329 
 
NM_015404 DFNB31 
Homo sapiens deafness, autosomal 
recessive 31 (DFNB31), mRNA 
[NM_015404] 
7.657 
 
77 
 
NM_153268 PLCXD2 
Homo sapiens phosphatidylinositol-specific 
phospholipase C, X domain containing 2 
(PLCXD2), mRNA [NM_153268] 
7.6269 
 
AF334945 FKSG43 
Homo sapiens FKSG43 (FKSG43) mRNA, 
complete cds. [AF334945] 
7.4397 
 
NM_005755 EBI3 
Homo sapiens Epstein-Barr virus induced 
gene 3 (EBI3), mRNA [NM_005755] 
7.3997 
 
NM_014759 PHYHIP 
Homo sapiens phytanoyl-CoA 2-
hydroxylase interacting protein (PHYHIP), 
mRNA [NM_014759] 
7.3405 
 
NM_017495 RBM38 
Homo sapiens RNA binding motif protein 
38 (RBM38), transcript variant 1, mRNA 
[NM_017495] 
7.3358 
 
NM_002581 PAPPA 
Homo sapiens pregnancy-associated plasma 
protein A, pappalysin 1 (PAPPA), mRNA 
[NM_002581] 
7.2992 
 
THC2532504 THC2532504 
Q9BX12_HUMAN (Q9BX12) GTP 
binding protein 2 (Fragment), partial (26%) 
[THC2532504] 
7.0938 
 
BC085019 GDF5OS 
Homo sapiens hypothetical LOC554250, 
mRNA (cDNA clone MGC:99835 
IMAGE:6650156), complete cds. 
[BC085019] 
6.7892 
 
AF140675 ADAMTS7 
Homo sapiens zinc metalloprotease 
ADAMTS7 (ADAMTS7) mRNA, complete 
cds. [AF140675] 
6.4441 
 
NM_004097 EMX1 
Homo sapiens empty spiracles homeobox 1 
(EMX1), transcript variant 1, mRNA 
[NM_004097] 
6.4091 
 
NM_033393 KIAA1727 
Homo sapiens KIAA1727 protein 
(KIAA1727), mRNA [NM_033393] 
6.2283 
 
NM_014872 ZBTB5 
Homo sapiens zinc finger and BTB domain 
containing 5 (ZBTB5), mRNA 
[NM_014872] 
6.0517 
 
ENST000003270
26 
ENST00000327
026 
coiled-coil domain containing 57 
[Source:RefSeq_peptide;Acc:NP_932348] 
[ENST00000327026] 
6.0306 
 
NM_017434 DUOX1 
Homo sapiens dual oxidase 1 (DUOX1), 
transcript variant 1, mRNA [NM_017434] 
5.9386 
 
NM_007021 C10orf10 
Homo sapiens chromosome 10 open 
reading frame 10 (C10orf10), mRNA 
[NM_007021] 
5.8409 
 
NM_144503 F11R 
Homo sapiens F11 receptor (F11R), 
transcript variant 4, mRNA [NM_144503] 
5.7322 
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NM_182608 ANKRD33 
Homo sapiens ankyrin repeat domain 33 
(ANKRD33), mRNA [NM_182608] 
5.7262 
 
NM_152361 EID2B 
Homo sapiens EP300 interacting inhibitor 
of differentiation 2B (EID2B), mRNA 
[NM_152361] 
5.7078 
 
NM_021176 G6PC2 
Homo sapiens glucose-6-phosphatase, 
catalytic, 2 (G6PC2), transcript variant 1, 
mRNA [NM_021176] 
5.7053 
 
NM_018897 DNAH7 
Homo sapiens dynein, axonemal, heavy 
chain 7 (DNAH7), mRNA [NM_018897] 
5.6555 
 
NM_014454 SESN1 
Homo sapiens sestrin 1 (SESN1), mRNA 
[NM_014454] 
5.5047 
 
NM_080647 TBX1 
Homo sapiens T-box 1 (TBX1), transcript 
variant C, mRNA [NM_080647] 
5.4698 
 
NM_203463 LASS6 
Homo sapiens LAG1 homolog, ceramide 
synthase 6 (S. cerevisiae) (LASS6), mRNA 
[NM_203463] 
5.4147 
 
BU602485 BU602485 
AGENCOURT_10015118 NIH_MGC_142 
Homo sapiens cDNA clone 
IMAGE:6496567 5', mRNA sequence 
[BU602485] 
5.2332 
 
NM_148959 HUS1B 
Homo sapiens HUS1 checkpoint homolog b 
(S. pombe) (HUS1B), mRNA 
[NM_148959] 
5.2101 
 
NM_006290 TNFAIP3 
Homo sapiens tumor necrosis factor, alpha-
induced protein 3 (TNFAIP3), mRNA 
[NM_006290] 
5.1853 
 
NM_203286 PVRL1 
Homo sapiens poliovirus receptor-related 1 
(herpesvirus entry mediator C; nectin) 
(PVRL1), transcript variant 3, mRNA 
[NM_203286] 
5.0026 
 
NM_002283 KRT85 
Homo sapiens keratin 85 (KRT85), mRNA 
[NM_002283] 
4.9741 
 
ENST000002927
29 
USP41 
Ubiquitin carboxyl-terminal hydrolase 41 
(EC 3.1.2.15) (Ubiquitin thioesterase 41) 
(Ubiquitin-specific-processing protease 41) 
(Deubiquitinating enzyme 41) (Fragment). 
[Source:Uniprot/SPTREMBL;Acc:Q3LFD5
] [ENST00000292729] 
4.8886 
 
BP871540 BP871540 
BP871540 Sugano cDNA library, 
embryonal kidney Homo sapiens cDNA 
clone HKR00303, mRNA sequence 
[BP871540] 
4.6823 
 
A_24_P767699 A_24_P767699 Unknown 4.5259  
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NM_004443 EPHB3 
Homo sapiens EPH receptor B3 (EPHB3), 
mRNA [NM_004443] 
4.03 
 
NM_021127 PMAIP1 
Homo sapiens phorbol-12-myristate-13-
acetate-induced protein 1 (PMAIP1), 
mRNA [NM_021127] 
3.9596 
 
THC2660977 THC2660977 Unknown 3.9263  
NM_017654 SAMD9 
Homo sapiens sterile alpha motif domain 
containing 9 (SAMD9), mRNA 
[NM_017654] 
0.2496 
 
NM_139067 SMARCC2 
Homo sapiens SWI/SNF related, matrix 
associated, actin dependent regulator of 
chromatin, subfamily c, member 2 
(SMARCC2), transcript variant 2, mRNA 
[NM_139067] 
0.232 
 
NM_001280 CIRBP 
Homo sapiens cold inducible RNA binding 
protein (CIRBP), mRNA [NM_001280] 
0.2308 
 
NM_182616 C15orf38 
Homo sapiens chromosome 15 open 
reading frame 38 (C15orf38), mRNA 
[NM_182616] 
0.2277 
 
NM_004627 WRB 
Homo sapiens tryptophan rich basic protein 
(WRB), mRNA [NM_004627] 
0.2273 
 
NM_020422 TMEM159 
Homo sapiens transmembrane protein 159 
(TMEM159), mRNA [NM_020422] 
0.2263 
 
NM_022071 SH2D4A 
Homo sapiens SH2 domain containing 4A 
(SH2D4A), mRNA [NM_022071] 
0.2172 
 
NM_004759 MAPKAPK2 
Homo sapiens mitogen-activated protein 
kinase-activated protein kinase 2 
(MAPKAPK2), transcript variant 1, mRNA 
[NM_004759] 
0.2136 
 
THC2586959 THC2586959 
1PK0_D Chain D, Crystal Structure Of The 
Ef3-Cam Complexed With Pmeapp. {Homo 
sapiens} (exp=-1; wgp=0; cg=0), partial 
(70%) [THC2586959] 
0.212 
 
NM_033219 TRIM14 
Homo sapiens tripartite motif-containing 14 
(TRIM14), transcript variant 2, mRNA 
[NM_033219] 
0.211 
 
NM_003130 SRI 
Homo sapiens sorcin (SRI), transcript 
variant 1, mRNA [NM_003130] 
0.21 
 
NM_007203 
PALM2-
AKAP2 
Homo sapiens PALM2-AKAP2 protein 
(PALM2-AKAP2), transcript variant 1, 
mRNA [NM_007203] 
0.2083 
 
NM_181719 TMCO4 
Homo sapiens transmembrane and coiled-
coil domains 4 (TMCO4), mRNA 
[NM_181719] 
0.2044 
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THC2638360 THC2638360 
Q6STG2_HUMAN (Q6STG2) DNA 
polymerase-transactivated protein 3, partial 
(13%) [THC2638360] 
0.2044 
 
AF256215 ARNTL2 
Homo sapiens cycle-like factor CLIF 
mRNA, complete cds. [AF256215] 
0.2043 
 
NM_030928 CDT1 
Homo sapiens chromatin licensing and 
DNA replication factor 1 (CDT1), mRNA 
[NM_030928] 
0.2038 
 
NM_001008224 UACA 
Homo sapiens uveal autoantigen with 
coiled-coil domains and ankyrin repeats 
(UACA), transcript variant 2, mRNA 
[NM_001008224] 
0.2023 
 
A_24_P927230 A_24_P927230 Unknown 0.2015  
NM_020964 KIAA1632 
Homo sapiens KIAA1632 (KIAA1632), 
mRNA [NM_020964] 
0.1988 
 
NM_024808 C13orf34 
Homo sapiens chromosome 13 open 
reading frame 34 (C13orf34), mRNA 
[NM_024808] 
0.1938 
 
NM_003384 VRK1 
Homo sapiens vaccinia related kinase 1 
(VRK1), mRNA [NM_003384] 
0.1937 
 
NM_002388 MCM3 
Homo sapiens MCM3 minichromosome 
maintenance deficient 3 (S. cerevisiae) 
(MCM3), mRNA [NM_002388] 
0.1906 
 
AB040957 KIAA1524 
Homo sapiens mRNA for KIAA1524 
protein, partial cds. [AB040957] 
0.1875 
 
AK055915 AK055915 
Homo sapiens cDNA FLJ31353 fis, clone 
MESAN2000264. [AK055915] 
0.1793 
 
NM_203284 RBPJ 
Homo sapiens recombination signal binding 
protein for immunoglobulin kappa J region 
(RBPJ), transcript variant 4, mRNA 
[NM_203284] 
0.1661 
 
NM_014857 RABGAP1L 
Homo sapiens RAB GTPase activating 
protein 1-like (RABGAP1L), transcript 
variant 1, mRNA [NM_014857] 
0.1656 
 
NM_004695 SLC16A5 
Homo sapiens solute carrier family 16, 
member 5 (monocarboxylic acid transporter 
6) (SLC16A5), mRNA [NM_004695] 
0.1612 
 
NM_004494 HDGF 
Homo sapiens hepatoma-derived growth 
factor (high-mobility group protein 1-like) 
(HDGF), mRNA [NM_004494] 
0.1605 
 
NM_198969 AES 
Homo sapiens amino-terminal enhancer of 
split (AES), transcript variant 1, mRNA 
[NM_198969] 
0.1605 
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NM_032294 CAMKK1 
Homo sapiens calcium/calmodulin-
dependent protein kinase kinase 1, alpha 
(CAMKK1), transcript variant 1, mRNA 
[NM_032294] 
0.1596 
 
AK090664 AK090664 
Homo sapiens cDNA FLJ33345 fis, clone 
BRACE2003713. [AK090664] 
0.1593 
 
NM_012140 SLC25A10 
Homo sapiens solute carrier family 25 
(mitochondrial carrier; dicarboxylate 
transporter), member 10 (SLC25A10), 
mRNA [NM_012140] 
0.1588 
 
NM_052853 ADCK2 
Homo sapiens aarF domain containing 
kinase 2 (ADCK2), mRNA [NM_052853] 
0.1581 
 
NM_003243 TGFBR3 
Homo sapiens transforming growth factor, 
beta receptor III (TGFBR3), mRNA 
[NM_003243] 
0.1574 
 
AK021837 AK021837 
Homo sapiens cDNA FLJ11775 fis, clone 
HEMBA1005891. [AK021837] 
0.156 
 
NM_016052 RRP15 
Homo sapiens ribosomal RNA processing 
15 homolog (S. cerevisiae) (RRP15), 
mRNA [NM_016052] 
0.1462 
 
ENST000003076
62 
SYNPO 
Synaptopodin. 
[Source:Uniprot/SWISSPROT;Acc:Q8N3V
7] [ENST00000307662] 
0.144 
 
D14041 RBPJ 
Homo sapiens mRNA for H-2K binding 
factor-2, complete cds. [D14041] 
0.1431 
 
NM_173636 WDR62 
Homo sapiens WD repeat domain 62 
(WDR62), mRNA [NM_173636] 
0.1393 
 
ENST000003592
36 
FLJ20674 
CDNA FLJ20674 fis, clone KAIA4450. 
[Source:Uniprot/SPTREMBL;Acc:Q9NWQ
7] [ENST00000359236] 
0.1383 
 
NM_018199 EXDL2 
Homo sapiens exonuclease 3'-5' domain-
like 2 (EXDL2), mRNA [NM_018199] 
0.1366 
 
THC2607337 THC2607337 Unknown 0.1354  
ENST000003748
51 
C9orf125 
Uncharacterized protein C9orf125. 
[Source:Uniprot/SWISSPROT;Acc:Q9BRR
3] [ENST00000374851] 
0.1276 
 
NM_175709 CBX7 
Homo sapiens chromobox homolog 7 
(CBX7), mRNA [NM_175709] 
0.1259 
 
NM_000916 OXTR 
Homo sapiens oxytocin receptor (OXTR), 
mRNA [NM_000916] 
0.1242 
 
A_32_P171043 A_32_P171043 Unknown 0.1202  
NM_024827 HDAC11 
Homo sapiens histone deacetylase 11 
(HDAC11), mRNA [NM_024827] 
0.1186 
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A_32_P36709 A_32_P36709 Unknown 0.1158  
NM_024693 ECHDC3 
Homo sapiens enoyl Coenzyme A 
hydratase domain containing 3 (ECHDC3), 
mRNA [NM_024693] 
0.1099 
 
AK125077 AK125077 
Homo sapiens cDNA FLJ43087 fis, clone 
BRTHA3019105. [AK125077] 
0.1041 
 
NM_007331 WHSC1 
Homo sapiens Wolf-Hirschhorn syndrome 
candidate 1 (WHSC1), transcript variant 8, 
mRNA [NM_007331] 
0.103 
 
NM_152913 TMEM130 
Homo sapiens transmembrane protein 130 
(TMEM130), mRNA [NM_152913] 
0.1005 
 
NM_017915 C12orf48 
Homo sapiens chromosome 12 open 
reading frame 48 (C12orf48), mRNA 
[NM_017915] 
0.0998 
 
THC2677783 THC2677783 Unknown 0.0937  
NM_005498 AP1M2 
Homo sapiens adaptor-related protein 
complex 1, mu 2 subunit (AP1M2), mRNA 
[NM_005498] 
0.0867 
 
NM_024490 ATP10A 
Homo sapiens ATPase, Class V, type 10A 
(ATP10A), mRNA [NM_024490] 
0.0818 
 
NM_133468 BMPER 
Homo sapiens BMP binding endothelial 
regulator (BMPER), mRNA [NM_133468] 
0.0763 
 
NM_145251 STYX 
Homo sapiens serine/threonine/tyrosine 
interacting protein (STYX), mRNA 
[NM_145251] 
0.0724 
 
NM_000882 IL12A 
Homo sapiens interleukin 12A (natural 
killer cell stimulatory factor 1, cytotoxic 
lymphocyte maturation factor 1, p35) 
(IL12A), mRNA [NM_000882] 
0.0702 
 
BC047636 BC047636 
Homo sapiens cDNA clone 
IMAGE:4822429. [BC047636] 
0.0677 
 
NM_000891 KCNJ2 
Homo sapiens potassium inwardly-
rectifying channel, subfamily J, member 2 
(KCNJ2), mRNA [NM_000891] 
0.0657 
 
NM_016448 DTL 
Homo sapiens denticleless homolog 
(Drosophila) (DTL), mRNA [NM_016448] 
0.0554 
 
NM_004336 BUB1 
Homo sapiens BUB1 budding uninhibited 
by benzimidazoles 1 homolog (yeast) 
(BUB1), mRNA [NM_004336] 
0.0461 
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CHAPTER 3.  
IDENTIFYING THE ROLE OF RGS16 IN PANCREATIC CANCER CELL 
MIGRATION AND INVASION
2
 
SUMMARY 
Pancreatic cancer is ranked as the fourth highest cause of cancer-related deaths in the United 
States with a five-year survival rate <5%.  Pancreatic cancer is associated with early systemic 
dissemination resulting in the majority of newly diagnosed patients having aggressive non-
localized cancer and non-eligibility for curative treatments.  New therapies are needed to inhibit 
and treat metastatic pancreatic cancer.  A study aimed at identifying markers for pancreatic 
cancer metastasis found that Regulator of G protein Signaling 16 (RGS16) is downregulated in 
patients with lymph node metastases compared to patients with non-lymph node metastasized 
pancreatic cancer.  RGS16 belongs to a large family of proteins that play a role in swiftly 
shutting down G protein-coupled receptor pathways and is implicated in turning off signaling of 
several oncogene pathways that are involved in proliferation, migration, and invasion of cancer 
cells.  Currently, the role of RGS16 in pancreatic cancer is unknown.   
We found that the expression of RGS16 mRNA was downregulated in established pancreatic 
cancer cell lines compared to mRNA extracted from normal human pancreatic tissue.  We 
exogenously expressed RGS16 and/or GFP (control) using adenoviral vectors in established 
pancreatic cancer cell lines (BxPC-3, PANC-1, or AsPC-1) and measured the impact of RGS16 
expression on cell migration, invasion and cell viability. Expression of RGS16 inhibited 
migration and invasion of BxPC-3 and AsPC-1 cells but did not modify PANC-1 cell migration.  
                                                 
2
 A portion of this work has been submitted and accepted for publication in the journal Genes 
and Cancer (see Appendix for draft) or [175]. 
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RGS16 expression did not alter BxPC-3, PANC-1, or AsPC-1 cell growth stimulated by FBS or 
EGF (epidermal growth factor). Experiments investigating the mechanism behind RGS16 
suppression of migration and invasion found no change in the levels of phosphorylated AKT and 
ERK suggesting RGS16 inhibits pancreatic migration and invasion independent of the 
PI3K/AKT and MAPK pathways.   
For the first time we have shown that RGS16 inhibits EGF induced migration and invasion of 
pancreatic cancer cells.  Further studies are needed to elucidate the mechanism(s) used by 
RGS16 to inhibit pancreatic cancer cell migration and invasion.        
INTRODUCTION 
In 2014, the American Cancer Society estimates that approximately 46,420 individuals will 
be diagnosed with pancreatic cancer and 39,590 will die from this disease [83]. The one-year 
survival rate for all stages of pancreatic cancer is 20% and the five-year survival rate is 6% [83].  
An analysis looking at the five-year survival rates of various cancers over a span of thirty years 
found that pancreatic cancer had the least improvement from 2% (1975-1977) to 6% (2003 to 
2009) [83].  The majority of patients newly diagnosed with pancreatic cancer present with highly 
progressed and/or metastatic cancer that is resistant to treatment [84, 85].  Due to the late stage 
of diagnosis and the aggressive nature of this disease, less than 20% of pancreatic cancer patients 
are eligible for the potentially curative surgery [85, 220].  Therefore, there is a great need for 
more effective drugs aimed at treating or preventing metastatic pancreatic cancer.  
The presence of lymph-node metastases is regarded as a negative prognostic factor for 
patients who have undergone pancreatic surgery [85, 92].  In order to find biomarkers for lymph 
node metastasis to aid in patient prognosis, cDNA microarrays were used to analyze gene 
expression in local vs. lymph-node metastasized pancreatic cancer [149].  Microarray analysis 
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revealed decreased expression of Regulator of G-protein signaling 16 (RGS16) in pancreatic 
tumors with lymph-node metastases compared to non-metastasized pancreatic cancer [149].  
Immunohistological analysis revealed only 5.7% (1 out of 17) of the pancreatic tumors with 
lymph-node metastases had expression of the Regulator of G-protein signaling 16 (RGS16) 
compared to 70.6% (12 out of 17) of pancreatic tumors with non-metastasized pancreatic cancer 
[149]. Furthermore, decreased expression of RGS16 was associated with poor pancreatic cancer 
patient survival indicating the potential of RGS16 as a pancreatic cancer prognostic marker 
[149].   
RGS16, a signaling molecule we identified as a p53 and pRb cross-talk candidate belongs to 
a large family of proteins that play a role in swiftly shutting down G protein-coupled receptor 
(GPCR) signaling pathways [134, 135].  RGS16 is a GTPase activating protein (GAP) that 
enhances GTPase activity of the α-subunit of G proteins associated with G-protein coupled 
receptors (GPCR). RGS16 has been implicated in negatively regulating the MAPK, AKT/PI3K, 
RhoA, and SDF-1/CxCR4 oncogene pathways in normal or cancer cell lines [135, 141, 164, 
171].  These oncogene pathways have been implicated in cancer progression processes (such as: 
proliferation, survival, chemoresistance, migration, invasion, and metastasis) in a variety of 
malignancies including pancreatic cancer [221-225].  
Few reports have been published that describe the impact of RGS16 on cancer cell signaling 
and progression.  Among these are: increased expression of RGS16 in pediatric high 
hyperdiploid acute lymphoblastic leukemia (ALL) and colon cancer; however, functional 
analysis has not been performed to identify any oncogenic function of RGS16 in these cancers 
[147-149].   Functional and expression analysis of RGS16 has been performed in breast cancers.  
The RGS16 promoter is located at a site that is vulnerable to allelic imbalances that can result in 
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promoter methylation of RGS16 in 10% of breast cancers with these genomic instabilities [150].  
Liang et al. (2009) found that RGS16 overexpression in breast cancer cell lines decreased EGF 
induced proliferation and AKT activation by binding to the p85-alpha subunit of PI3K 
preventing the phosphorylation of AKT [171]. RGS16 has also been associated with the anti-
proliferative effect of retinoic acid in neuroblastoma cells and the cytotoxity effect of the histone 
deacetylase inhibitor Vorinostat and lysine-specific demethylase 1 knock-down in triple negative 
breast cancers [162, 163].  The current data suggest RGS16 plays a role in cancer signaling, 
however, more research is needed to delineate the function of RGS16 in cancer cells. 
Due to pre-existing data on RGS16 expression and function, we hypothesized that exogenous 
expression of RGS16 would inhibit migration and proliferation of pancreatic cancer cells in 
vitro.  We chose to focus our investigations on EGF induced migration and invasion because 1) 
RGS16 inhibits EGF signaling in breast cancer cells, and 2) the epidermal growth factor receptor 
(EGFR/ERBB-1) is overexpressed in ~85% of pancreatic cancers, and is linked with 
development, invasion, and decreased survival in this deadly disease [110, 115, 226, 227]. 
Currently, RGS16 has not been linked with inhibition of cancer cell metastasis nor has its 
function been investigated to understand the consequences of its downregulation in metastasized 
pancreatic cancer. 
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MATERIALS AND METHODS 
Cell culture and virus transductions 
The pancreatic cancer cell lines BxPC-3, AsPC-1, MIA PaCa-2, and PANC-1 (described in 
Table 4.1) were purchased from the American Type Culture Collection (Manassas, VA, USA).  
BxPC-3, AsPC-1, MIA PaCa-2 and PANC-1 cells were grown in complete media (RPMI 
supplemented with 10% fetal bovine serum (FBS) (PAA Laboratories, Dartmouth, MA) and 1% 
Penicillin Streptomycin (P/S) (Mediatech, Inc. A Corning Subsidiary, Manassas, VA), RPMI 
supplemented with 15% FBS and 1% P/S or DMEM with 10% FBS and 1% P/S respectively). 
All cell lines were cultured at 37°C in a humidified 5% CO2 incubator.   
Ad.GFP (adenovirus containing GFP) and Ad.GFP.RGS16 (Adenovirus containing 
RGS16 and reporter gene GFP) viruses were purchased from Vector Biolabs (Philadelphia, PA).  
Viruses were amplified and tittered as previously described [183-185]. For each type of virus, 
concentration of 50 MOI (multiplicity of infection) were added to pancreatic cancer cells in 
media supplemented with 2% heat-inactivated Hyclone FBS (GE Healthcare Life Sciences, 
Pittsburgh, PA).   
Quantitative Real-time PCR analysis 
Total RNA was isolated from cells using TRIzol reagent (Invitrogen, Carlsbad, CA) 
according to the manufacturer’s protocol.  Total RNA (2ug) was reverse transcribed into cDNA 
using the High Capacity cDNA Reverse Transcription kit from Applied Biosystems (Foster City, 
CA) according to the manufacturer’s protocol.  Real-Time PCR was performed using the 
Applied Biosystems TaqMan Gene Expression Assays in the ABI 7000 detection system. 
TaqMan probes were purchased from Applied Biosystems [RGS16 (HS00892674_m1), and 
GAPDH (HS02758991)]. The relative fold change for each marker was calculated using the 2
-
ΔΔCT
 analysis according to Livak et.al and statistical significance was determined using a one 
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way ANOVA with a Tukey’s post-hoc test using Prism V6.0c (GraphPad Software, Inc., La 
Jolla, CA)  [187].    
Wound Healing Assay 
Pancreatic cancer cells (BxPC-3, AsPC-1 and PANC-1) were placed in a 6 well plate at 
approximately 70% confluency.  The following day, 50 Multiplicity of Infection (MOIs) of 
Ad.GFP (control) or Ad.GFP.RGS16 were added to the cells in media containing 2% heat-
inactivated FBS and incubated for 24 hours.  The media was then changed to complete media 
(10% FBS for BxPC-3 and PANC-1 or 15% for AsPC-1) and cells incubated for 24hrs.  Forty 
eight hours after the addition of the virus the media was changed from complete media to media 
supplemented with 0.5% FBS and 1% P/S and the cells incubated for additional 24-hours.  The 
media was replaced with PBS and three wounds or scratches were made per well using a p200 
pipette.  The cells were washed three times with PBS and incubated for 16-24 hours in complete 
media or media supplemented with 100ng/ml of EGF.  EGF was added to induce cell migration 
at a concentration previously described in [228-230]. Wound widths were measured and images 
taken at 0, 16, or 24 hrs after addition of media supplemented with FBS or EGF at 100x 
magnification using an Olympus DP71 microscope (Center Valley, PA).  Efficacy of virus 
transduction was confirmed using fluorescent microscopy to examine GFP expression prior to 
the start of the experiment.  Percent wound healing was determined using the following equation; 
% wound-healing = ([initial scratch width – final scratch width]/ initial scratch width) X 100.  
Three independent replicates were performed for each cell line.   
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MTT Assay 
BxPC-3, AsPC-1, and PANC-1 cells (5,000) were plated in quadruplicate in a 96 well 
tissue culture dish and incubated for 24 hours at 37 ֯C.  The pancreatic cancer cells were treated as 
described in the wound healing assay section. After the cells were serum starved (media 
supplement with 0.5% FBS and 1% P/S) for 24-hours complete media or media supplemented 
with 100ng/ml of EGF were added to the cells. A 1:10 dilution of MTT (thiazolyl blue 
tetrazolium bromide; MP Biomedicals; Santa Ana, CA) stock solution (5mg/ml diluted in PBS), 
was added to the media of the cells followed by a 2 hour incubation at 37 ֯C. The media was 
removed and DMSO was added to the cells to solubilize the purple formazan crystals. 
Absorbance (560nm) was determined at 0, 24, 48, and 72 hours after addition of supplemented 
media using the SpectraMax M2
e 
Molecular Devices
 
(Sunnyvale, CA).  Cell viability fold change 
was calculated using the average absorbance for each treatment group at 24, 48, or 72 hours 
divided by the initial absorbance at time zero. Percent viability was calculated using the average 
absorbance for each treatment divided by the average absorbance for the cells not treated with 
virus and multiplied by 100.  Statistical significance was assessed using Student’s t-test by Prism 
V6.0c.  The experiment was repeated 3 independent times.   
Invasion Assay 
BD Bio Coat Matrigel coated polycarbonate invasion chambers (Bedford, MA) 
containing membranes with 8um pores were used to assess the ability of RGS16 to inhibit 
pancreatic cancer cell migration and invasion.  BxPC-3 cells were plated into 6-well dish at 70% 
confluency, 24 hours later 50 MOIs of Ad.GFP or Ad.GFP.RGS16 virus were added to the cells 
followed by 24 hour incubation in complete media and 24 hours in low-serum media as 
described in the wound-healing section.  Chambers were re-hydrated in RPMI containing 1% P/S 
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and 0.1 % Bovine serum albumin (BSA, Fisher Scientific, Waltham, MA) for 2 hours at 37°C.  
BxPC-3 and AsPC-1 cells were collected and 25 x 10
4 
cells were added to the top of the 
chambers in RPMI supplemented with 1% P/S and 0.1% BSA.  RPMI supplemented with 
100ng/ml EGF, 1% P/S, 0.1% BSA was added to lower portion and the chambers were incubated 
for 18- (AsPC-1) or 20- (BxPC-3) -hours at 37°C.  Time points were determined by literature 
and previous preliminary experiments to optimize conditions of the assay.  The non-migrating 
cells were removed using a cotton swab and the invaded cells were fixed using 100% methanol 
(MeOH) for 5 minutes and stained using 0.5% crystal violet plus 20% MeOH (10-15 mins).  
Invaded cells were counted using 200x magnification with 12 different views.  Percentage of 
invasion compared to GFP control was calculated for each cell line [(# of invaded cellstreated / # of 
invaded cellcontrol) x 100].  Three replicates were performed for each cell line.    
Western Blot Analysis 
AsPC-1 and BxPC-3 cells were treated to express GFP and/or RGS16 using adenoviruses 
as described in the wound healing assay section.  Cells were collected after 0 min, 15 mins, 1 
hour and 24 hours after addition of EGF.  Cells were lysed in RIPA (Radioimmunoprecipitation 
assay) buffer plus protease inhibitors (Pierce Protease inhibitor Tablets 88661; Thermo 
Scientific, Rockford, IL).  Protein extracts (35-60ug) were loaded onto 10% or 12% 
polyacrylamide gels and proteins were separated using sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis (SDS-PAGE).  Blots probed with mouse anti-panAKT (40D4, 1:2000), rabbit 
anti-phospho-AKT (p-AKT, S473 D9E, 1:2000), rabbit anti-phospho-p44/42 MAPK (p-ERK1/2, 
Thr202, Tyr204, D13.14.4E, 1:2000), rabbit anti-p44/42 MAPK (total-ERK1/2, 137F5, 1:1000) 
antibodies from Cell Signaling Technology (Danvers, MA) were blocked  in 5% BSA in Tris-
buffered saline solution pH 7.6 containing 0.1% Tween-20 (TBS-T).   Blots probed in rabbit 
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anti-E-cadherin (Santa Cruz Technologies, Dallas, TX, 1:1000), rabbit anti-RGS16 (Proteintech, 
Chicago, IL, 1:250-1:500, band detected at 23kDa) mouse anti-GAPDH (Chemicon 
International, Temecula, CA, 1:1000) or mouse anti-vimentin (AF-14b, 1:500)  were blocked an 
hour in 5% dry non-fat milk diluted in TBS-T.  The anti-vimentin (AMF14b), monoclonal 
antibody developed by Fulton, A.B. was obtained from the Developmental Studies Hybridoma 
Bank, created by the NICHD of the NIH and maintained at The University of Iowa, Department 
of Biology, Iowa City, IA 52242. Membranes were probed in primary antibody overnight at 4°C 
on a rocker. Following primary antibody incubation the membranes were washed and probed 
with Horseradish peroxidase (HRP)-conjugated goat anti-mouse (1:5000) or goat anti-rabbit 
(1:10000) secondary antibodies (Rockland, Gilbertsville, PA) for 1 hour at room-temperature.  
Primary and Secondary antibodies were diluted in TBS-T. Amersham ECL prime western 
blotting detection reagent was added to visualize the protein bands (RPN 2232, GE Life 
Sciences, Pittsburgh, PA).  Western blot images were captured using a FOTODYNE 
FOTO/Analyst FX (Hartland, WI) imaging camera.  Densitometry was performed using 
TotalLab Quant software (TotalLab Ltd, UK). 
Phalloidin F-actin staining 
BxPC-3 and AsPC-1 cells were plated into a six well dish at 70% confluency for 
adenovirus treatment and after 24 hours the cells were treated with 50 MOIs of Ad.GFP or 
Ad.RGS16 for 24 hours.  Cells were washed with PBS and plated into a Lab-TekII chamber slide 
system (Thermo Fisher Scientific, Waltham, MA) with a concentration of 50,000 cells/well and 
incubated for 24 hours in complete media.  Cells were then incubated in low serum (0.5% FBS) 
supplemented media for 24 hours.  Media supplemented with EGF (100ng/ml) was added to the 
cells for 15 min (BxPC-3) or 30 min (AsPC-1) to induce cytoskeleton rearrangement. Time 
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points were determined by literature and previous preliminary experiments to optimize 
conditions of the assay.   Cells were fixed in 4% paraformaldehyde in PBS (Fisher Scientific) for 
15 min and permeabilized using 0.1% Triton X-100 in PBS containing 1% BSA at room 
temperature.  Cells were blocked for 30 min in PBS containing 1% BSA at room temperature 
followed by 30 min incubation of a final concentration of 50nM of Acti-stain 555 Fluorescent 
Phalloidin (Cytoskeleton, Inc., Denvir, CO) at room-temperature in a dark humid chamber.  Cells 
were washed 3x in PBS + 1% BSA for 5 minutes and the nuclei were stained with 300nM DAPI 
for 2 min and the cells washed 3x in PBS + 1% BSA for 5 minutes.  F-actin was visualized at 
400x and 1000x using an Olympus DP71 microscope with a mercury fluorescent light source U-
LH100HG (Center Valley, PA).  The staining for phalloidin was performed three independent 
times in the AsPC-1 cells.     
Statistical Analysis 
All data were expressed as the mean ± SEM and represented using Graph Pad Prism 
V6.0c software (GraphPad Software, Inc., La Jolla, CA).  Differences between control and 
treated samples for the MTT (viability fold change), wound healing and invasion assay were 
analyzed by using Student’s t-test (Graph PadPrism V6.0c). Differences for percent viability 
determined by MTT assay was analyzed by two-way ANOVA with Dunnet’s post-hoc test for 
multiple comparisons.  Data from real-time PCR were analyzed by one-way ANOVA followed 
by Tukey post-hoc test. Additional statistical analysis used for qRT-PCR analyses are listed in 
the respective section. Data was considered significant when the p value was less than 0.05. 
Statistical Analysis tests used for qRT-PCR analyses are listed in the respective section. 
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Table 3.1: Characterization of pancreatic cancer cell lines [51, 111, 231, 232] 
 p53 p16 Ras EGFR Differentiation Origin Metastasis 
BxPC-3 mt del wt high moderate primary no 
PANC-1 mt del mt high poor primary yes 
AsPC-1 mt mt mt high poor metastatic (ascites) yes 
MiaPaCa-2 mt del mt low poor primary no 
mt = mutant, del = deleted, wt = wild-type    
RESULTS 
mRNA expression of RGS16 is decreased in pancreatic cancer cell lines. 
We first investigated the relative expression of RGS16 mRNA in the BxPC-3, MiaPaCa-
2, PANC-1, and AsPC-1 pancreatic cancer (pancreatic ductal adenocarcinomas) cell lines in 
order to characterize the endogenous expression of RGS16.  Expression of RGS16 was measured 
by qRT-PCR analysis and the relative RGS16 mRNA fold change was calculated in the four 
pancreatic cancer cell lines compared to total RNA from normal human pancreatic tissue.  
Expression of RGS16 was decreased in all four pancreatic cancer cell lines compared to control 
with BxPC-3 having the highest expression of RGS16 mRNA (Figure 3.1).  Expression of 
RGS16 varied between the four pancreatic cancer cell lines with BxPC-3 and MIA PaCa-2 
having significantly higher expression of RGS16 than PANC-1 and the metastatic derived AsPC-
1 cells.  Higher RGS16 expression was found in the more differentiated and less aggressive cell 
line, while less RGS16 expression correlated with the more aggressive and/or metastatic cell 
lines (Table 3.1).     
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Figure 3.1: Decreased expression of RGS16 mRNA relative to total RNA extracted from 
normal human pancreatic tissue.   Expression of RGS16 was measured using qRT-PCR in 
BxPC-3, MiaPaCa-2, PANC-1, and AsPC-1 cells.  Relative fold change was measured using total 
RNA extracted from normal human pancreatic tissue as the control.  One-way ANOVA with 
Tukey’s test for multiple comparison were used to test for statistical significance between the cell 
lines and control * p-value < 0.05, ** p-value < 0.01, *** p-value < 0.001, and **** p-value < 
0.0001.   
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Expression of RGS16 inhibited migration of BxPC-3 and AsPC-1 pancreatic cancer cells 
but not PANC-1.  
To test the hypothesis that RGS16 inhibits pancreatic cancer cell migration, we 
exogenously expressed RGS16 in BxPC-3, PANC-1, and AsPC-1 cells with an adenoviral vector 
and used wound-healing assays to measure cell migration. We chose BxPC-3, PANC-1, and 
AsPC-1 because these three cell lines are derived from tumors with varying expression of 
RGS16, differentiation status, mutations, presence of metastases, and expression of Epidermal 
Growth Factor Receptor (Table 3.1).  EGF was used to stimulate cell migration therefore; we did 
not use the MiaPaCa-2 cell line because of the lower levels of EGFR (Table 3.1).  We RGS16 
was expressed using Adenoviruses that contain RGS16 plus a GFP reporter (Ad.GFP.RGS16). 
An Adenovirus expressing GFP (Ad.GFP) was used as the vector control.  Expression of RGS16 
protein correlated with GFP expression in cells treated with Ad.GFP.RGS16 (Figure 3.2).  
Fluorescent microscopy was used to determine viral transductions prior to experiment (Figures 
3.3a, 3.4a, and 3.5a).  Overexpression of RGS16 significantly inhibited FBS and EGF induced 
migration of BxPC-3 cells and FBS induced migration of AsPC-1 cells, but had no effect on FBS 
and EGF induced migration of PANC-1 cells (Figures 3.3-3.5).  Interestingly, expression of 
RGS16 in BxPC-3 cells incubated in media supplemented with EGF caused an increase in 
wound width compared to control 16 hours after the start of the experiment.   
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Figure 3.2: Fluorescence of GFP associated with RGS16 protein expression in cells 
treated with Ad.GFP.RGS16.   Cells were plated and received the following treatment: 1) 
untreated cells, 2) Ad.GFP and 3) Ad.GFP.RGS16 treated cells.  Cells were incubated in 
complete and low serum media 24 hours each.  A) Images of GFP fluorescence were taken 
72 hours after treatment and B) protein expression for RGS16 and GAPDH was assessed by 
western blot analysis.  
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Figure 3.3: Expression of RGS16 inhibited migration of BxPC-3 cells.  
BxPC-3 cells were transduced with 50 MOI of Ad.GFP (CTRL) or Ad.GFP.RGS16.  A) 
Virus transduction was verified by fluorescent microscopy. B) Images (100x) and 
measurements of wounds were taken prior and 16 hours after addition of media 
supplemented with FBS (10%) or EGF (100ng/ml).  The dashed lines represent size of 
scratch at time 0.  C) Mean Percentage of wound healing ± SEM of three separate 
experiments (three scratches/well) was determined. Student’s t-test was used to determine 
statistical significance compared to control * p-value < 0.05, ** p-value < 0.01. 
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Figure 3.4: Expression of RGS16 did not inhibit migration of PANC-1 cells.   
Wound healing assays were performed as described in Figure 3.3 A) Fluorescent microscopy 
was used to verify virus transductions: B) Images (100X) were taken and C) percentages of 
wound healing were calculated at 24 hrs after the addition of media supplemented with FBS or 
EGF.   
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Figure 3.5: Expression of RGS16 inhibited migration of AsPC-1 cells.   
Wound healing assays were performed as described in Figure 3.3. A) Fluorescent microscopy was 
used to verify virus transductions: B) Images (100X) were taken and C) percentages of wound 
healing were calculated at 24 hrs after the addition of media supplemented with FBS or EGF, * p-
value < 0.05.   
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Expression of RGS16 inhibited EGF induced invasion of BxPC-3 and AsPC-1 cells.  
Since RGS16 inhibited EGF induced migration of BxPC-3 and AsPC-1 cells, matrigel 
invasion chambers were used to investigate whether RGS16 could also inhibit EGF induced 
invasion of these pancreatic cancer cells.  Media supplemented with EGF was used as the 
chemoattractant to induce migration and invasion of BxPC-3 and AsPC-1 cells expressing GFP 
and or RGS16. Compared to control cells. RGS16 expression significantly inhibited EGF 
induced invasion of the BxPC-3 and AsPC-1 cells by 35.73% and 66% respectively(Figure 3.7).   
 
  
Figure 3.6: Expression of RGS16 inhibited invasion of BxPC-3 and AsPC-1 cells.   
Matrigel invasion chambers were used to measure cell migration and invasion of GFP and/or 
RGS16 expressing BxPC-3 (A & B) and AsPC-1 (C & D) cells using EGF as a 
chemoattractant. Migrated cells were stained with Crystal Violet and counted at 200x 
magnification (A &C). Percent invasion was calculated for each cell line (B & D) * p-value < 
0.05.   
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Expression of RGS16 using adenoviruses did not modify cell viability 
The results from the wound healing assays demonstrated an increase in the wound width 
of BxPC-3 cells treated with Ad.GFP.RGS16 and incubated in media supplemented with EGF.   
This effect could be due to a decrease in the number of viable cells caused by expression of 
RGS16 or by a cytolytic effect of adenoviruses.  MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assays were used to determine if expression of RGS16 or infection 
with the adenoviruses affects the viability of the pancreatic cancer cell lines.  The cells were 
serum starved for 24 hours to remove any pre-existing growth factors. Complete media 
containing FBS (10 or 15%) or EGF (100 ng/ml) was added to induce growth of the pancreatic 
cancer cells. Absorbance was measured at 0, 24, 48, and 72 hours following the addition of FBS 
or EGF.  The fold change of viable cells after 24, 48, and 72 hours compared to initial viable cell 
number was calculated for BxPC-3, AsPC-1, and PANC-1 cells treated with Ad.GFP or 
Ad.GFP.RGS16.  Expression of RGS16 did not alter the number of viable BxPC-3, PANC-1 or 
AsPC-1 cells stimulated with FBS or EGF (Figure 3.7A – 3.7C).  The percentage of viable 
BxPC-3 and AsPC-1 cells treated with Ad.GFP or Ad.RGS16 was not significantly different 
compared to no virus treated controls (NV FBS or NV EGF) for any of the time points (Figure 
3.7D and 3.7E).  There was a significant 20-25% mean drop in cell viability for PANC-1 cells 
treated with Ad.GFP or Ad.GFP.RGS16 48 and 72 hours after the addition of FBS to serum 
starved cells (Figure 3.7F).  However, all migration and invasion experiments were completed at 
a time in which there was no significant change in the percentage of viable cells (experiment 
completion ≤ 24 hours).  The results from the MTT assays suggest that RGS16 expression does 
not have an impact on BxPC-3, PANC-1, and AsPC-1 cell viability and the concentration of 
virus used to transduce RGS16 was tolerated by the pancreatic cancer cells.  
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Figure 3.7: Expression of RGS16 did not alter number of viable cells and concentration 
of Adenoviruses used was tolerated by BxPC-3, PANC-1, and AsPC-1 pancreatic cancer 
cells.   A-C) The fold change of viable cells was calculated by comparing the initial 
absorbance (0HR) compared to absorbance for 24, 48, and 72 hours after the addition of 
complete media or media supplemented with 100ng/ml of EGF (mean fold change of viable 
cells +/- SEM of three separate experiments) Statistical significance was tested using paired 
Student’s t-test.  D-F) Effect of Adenoviruses on number of viable pancreatic cancer cells was 
determined by calculating the % viability by comparing the number of viable cells treated 
with Ad.GFP or Ad.GFP.RGS16 to cells that were not treated with viruses.  Data represents 
mean % of viable cells +/- SEM of three separate experiments. Statistical significance was 
tested using two-way ANOVA with Dunnet’s post-hoc test for multiple comparisons.  
*P<0.05, # P<0.01 (NV =  No virus)  
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Expression of RGS16 did not alter EGF induced expression of p-AKT (phosphorylated 
AKT), p-ERK (phosphorylated ERK). 
Our next step was the investigation of the mechanism(s) employed by RGS16 to regulate 
EGF induced cell migration and invasion.  Activation of EGFR by EGF initiates a signaling 
cascade that is most commonly associated with activation of the PI3K/AKT and mitogen 
activated protein kinase (MAPK) pathways [110, 114].  Phosphorylation and activation of AKT 
or ERK1/2 (MAPK) are both known to phosphorylate downstream signaling molecules and 
transcription factors that are responsible for promoting cell migration and invasion [119, 233-
235].  Protein expression of p-AKT and p-ERK in BxPC-3 and AsPC-1 cells treated with EGF 
were determined in order to delineate if one or both of these pathways is regulated by RGS16. 
Resulting in the inhibition of EGF induced migration and invasion.  There was no change 
detected in the protein levels of p-AKT or p-ERK following 15 minutes of EGF treatment of 
BxPC-3 or AsPC-1 cells expressing RGS16 compared to GFP controls (Figure 3.8).  This data 
suggests RGS16 inhibits migration and invasion of the pancreatic cancer cells independently of 
AKT and ERK activity.   
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 Figure 3.8: RGS16 did not alter expression of phosphorylated AKT (p-AKT) or 
phosphorylated ERK (p-ERK).  Western blot analyses were used to examine levels of 
phosphorylated AKT and ERK in BxPC-3 and AsPC-1 cells expressing GFP and/or RGS16 
treated with or without EGF for 15 min (A). The mean fold change +/- SEM of p-AKT/total AKT 
(t-AKT) and p-ERK/total ERK (t-ERK) was calculated using densitometry analysis (B & C).   
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Investigation of RGS16’s Efect on epithelial mesenchymal transition markers and 
cytoskeleton rearrangement 
Next we examined if expression of RGS16 inhibits cell migration and invasion by 
preventing epithelial mesenchymal transition (EMT) in BxPC-3 and AsPC-1 cells. EGF 
promotes EMT by decreasing the expression of the epithelial cell-cell adhesion molecule E-
cadherin and increasing the expression of mesenchymal phenotype markers such as vimentin, 
fibronectin, and n-cadherin; these mesenchymal proteins allow cell migration and invasion [116, 
126].  Using western blot analysis, we examined the expression of vimentin and E-cadherin 1 
hour and 24 hours following EGF treatment.  Expression of RGS16 up-regulated E-cadherin 
protein levels in BxPC-3 but not in the metastatic AsPC-1 cells (Figure 4.10).  Furthermore, 
vimentin expression did not change in either BxPC-3 or AsPC-1 cells expressing RGS16 
compared to the GFP control (Figure 3.9).   
Rearrangement of the actin cytoskeleton is an integral part of cancer cell migration and 
invasion and it is regulated by members of the Rho GTPase family.  Activation of the 
EGF/EGFR pathway initiates actin cytoskeleton rearrangement through activation of Rho 
GTPases (Cdc42, RhoA, Rac1) that aide in the migration of cancer cells [121, 122, 236].  We 
treated serum starved cells expressing GFP and or RGS16 with EGF for 15- (BxPC-3) or 30- 
(AsPC-1) minutes and stained the F-actin of the cells using phalloidin.  There was no obvious 
difference in the arrangement of the F-actin in BxPC-3 and AsPC-1 cells expressing RGS16 
compared to GFP controls (Figure 3.10).  Both cell lines contain a heterogeneous population 
making it difficult to quantify a difference in the actin organization between cells expressing 
GFP and/or RGS16.   
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Figure 3.9: RGS16 increased expression of E-cadherin in BxPC-3 cells but not AsPC-1 and 
did not alter vimentin expression in either cell line.  Western blots were used to determine E-
cadherin and Vimentin expression in BxPC-3 and AsPC-1 expressing GFP and/or RGS16 (A & 
C) and treat with EGF for 24h.  Mean fold change +/- SEM of EMT markers was calculated 
using densitometry analysis for both EMT markers (B & D).  * p-value < 0.05 
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Figure 3.10: F-actin of BxPC-3 and AsPC-1 cells did not show obvious 
reorganization in cells expressing GFP and/or RGS16.   BxPC-3 and AsPC-1 cells 
expressing GFP and/or RGS16 were treated with EGF for 15(BxPC-3) or 30 (AsPC-1) minutes, 
fixed, and stained using Phalloidin conjugated to rhodamine and Dapi cells were imaged at (A & 
B) 400x or (C) 1000x  
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DISCUSSION 
Pancreatic cancer and RGS16 significance 
A large portion of patients newly diagnosed with pancreatic cancer present with metastatic or 
locally advanced disease resulting in their ineligibility for curative pancreatic surgical resection 
[237].  Early dissemination and aggressiveness of this disease contributes to the dismal survival 
rates of pancreatic cancer [237, 238].  Loss of RGS16 has been identified as a possible marker 
for lymph node metastasis in pancreatic cancer; however, the function of RGS16 is unknown 
[149].  We, for the first time, showed that RGS16 expression inhibits pancreatic cancer cell 
migration and invasion suggesting that loss of RGS16 could be important in the metastatic 
process.   
New treatments are needed to prevent or treat advanced or metastatic cancer. However, in 
order to develop new treatments we need a better understanding of the molecular changes that 
occur in pancreatic cancer.  We identified RGS16 as a p53 and pRb cross-talk candidate (Chapter 
2). RGS16 has been of interest to further our studies for two reasons: 1) RGS16 regulates 
GPCRs, which are common targets for deregulation in cancer and 2) RGS16 has been linked to 
regulating the MAPK/RAS, PI3K/AKT, RhoA, and SDF-1/CxCR4 oncogene pathways [133, 
135, 141, 164, 171].  Investigations have found that oncogene pathways can feed into one 
another and bypass or overcome the inhibitory effects of monoclonal antibodies or other targeted 
inhibitors. For example, in melanoma, increased production of VEGF or increased expression or 
activation of the platelet-derived growth factor receptor-β or insulin-like growth factor-1 receptor 
is associated with resistance to BRAF inhibitors, demonstrating mechanisms cancer cells use to 
overcome single target modalities [239].  Therefore investigation of RGS16, a protein known to 
modulate several oncogene pathways will aid in understanding mechanisms by which cells alter 
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multiple signaling pathways to prevent carcinogenesis.  This information could then be used for 
future drug development.   
RGS16 and cell migration and invasion 
RGS16 has been linked with inhibition of cell migration in canonical (through regulation 
of GPCR signaling) and non-canonical pathways in normal cells. RGS16 inhibits 
megakaryocytes and T lymphocyte migration by regulating the activation of the GPCR CxCR4 
and decreasing T helper type 2 and 17 cell trafficking through regulation of CCR4 and CCR10 
chemokine pathways representing the canonical form of RGS signaling [136, 137, 141]. The 
activation of RhoA, a small GTPase involved in reorganizing actin cytoskeleton and mediating  
EGF induced pancreatic cell invasion is inhibited in MCF-7 cells by RGS16 preventing the 
relocation of Gα13 to the plasma membrane thus blocking Gα13 mediated activation of RhoA  
[164, 240].  The regulation of RhoA activation by RGS16 is an example of a non-canonical, non- 
GPCR-mediated mechanism.  There are no published reports demonstrating inhibition or 
activation of cell invasion by RGS16.  However, another member of the R4 subfamily of RGS 
proteins, RGS4, suppresses breast cancer migration and invasion in vitro and in vivo by 
regulating PAR-1, CxCR4 signaling, and RAC-1 lamellipodia formation [241].   
Ours is the first report demonstrating a role of RGS16 in inhibiting EGF induced cell 
migration and invasion.  The GPCR CxCR4 is aberrantly expressed in malignant and cancer 
stem cells and contributes to pancreatic cancer progression by aiding in gemcitabine resistance, 
cell migration, and invasion [173, 222, 242, 243].  Although our studies focused on EGF induced 
cell migration and invasion, RGS16 may be able to inhibit other pathways that mediate cell 
migration and invasion such as CxCR4.   
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EGF and pancreatic cancer signaling 
RGS16 and EGF induced activation of the PI3K and AKT pathways 
Pancreatic carcinomas have overexpression or amplification of the tyrosine kinase 
receptors EGFR/erbB1 (~85%) or HER2/erbB2 (2%) [110, 244].  Activation of EGFR by its 
ligands EGF or TGFα induces or enhances activation of a variety of signaling pathways 
including PI3K/AKT, MAPK, SRC, PLC, and the small Rho GTPases (Rac1,RhoA, RhoC, and 
Cdc42) [114, 121, 122].  These pathways are involved in activating processes that enhance cell 
proliferation, migration, invasion, EMT, and metastasis in pancreatic cancer [119, 126, 233].  For 
example, both AKT and ERK can aid in cell migration and invasion through regulating 
production of matrix metalloproteinase 9 [233, 245]. Mutations downstream of EGFR resulting 
in AKT2 amplification or constitutive activation of K-Ras (MAPK pathway) also occur in 
pancreatic cancer, making EGFR and its downstream components popular targets for pancreatic 
cancer treatments [96, 109].  We investigated whether RGS16 can inhibit EGF induced 
migration and invasion via regulation of AKT and ERK (MAPK). A study conducted using 
breast cancer cells found that RGS16 knockdown resulted in an increase rate of EGF induced 
proliferation in these cells due to increase in p-AKT [171], suggesting that RGS16 may regulate 
proliferation by preventing the phosphorylation and activation of AKT.  In our studies, RGS16 
had no effect on the number of viable pancreatic cancer cells and did not decrease the protein 
levels of p-AKT compared to control.  Our conflicting results could be due to two possibilities, 
1) RGS16 targets different signaling pathways in pancreatic cancer compared to breast cancer or 
2) mutations in pancreatic cancer (for example K-Ras or AKT2) overcome the inhibitory effect 
of RGS16 on pancreatic cancer viability or activation of AKT.   
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RGS16 can inhibit MAPK activation via regulation of G proteins associated with GPCRs 
[135].  However, other RGS molecules are known to directly interact and regulate localization 
and activity of members in the MAPK cascade.  We examined the expression of phosphorylated 
ERK and found no change in BxPC-3 and AsPC-1 cells expressing RGS16 relative to the GFP 
controls.  Our data suggests RGS16 inhibits EGF induced migration and invasion independently 
of the PI3K/AKT and MAPK pathways.   
RGS16 and EGF induced activation of EMT and F-actin rearrangement 
Cancer cells can adapt a mesenchymal phenotype aiding in their dissociation and migration 
to a distant site [126].  EGF can induce EMT in a variety of cancer cells by decreasing 
expression or localization of E-cadherin and increasing the expression of EMT markers such as 
N-cadherin, vimentin, and fibronectin [116, 246].  Knockdown of EGFR in the pancreatic cancer 
cell line PANC-1 inhibited EMT and decreased cell migration and invasion [116]. RGS16 may 
play a role in regulating E-cadherin.  Triple negative breast cancer cells that were knocked-down 
for lysine-specific demethylase1 (LSD1) and treated with the histone deacetylase inhibitor 
(SAHA) had increased expression of RGS16 that was vital for growth suppression and increased 
expression of E-cadherin [163].  Our studies showed increased expression of E-cadherin in 
BxPC-3 cells expressing RGS16 compared to GFP control.  We did not see a change in the 
expression of E-cadherin in the metastatic cell line AsPC-1.  This could be due to the differences 
in the status of K-Ras in AsPC-1 (mutant) vs. BxPC-3 (wild-type) cells.  Studies in prostate 
cancer cells overexpressing K-Ras found that increased hypermethylation of E-cadherin 
promoter mediated by K-Ras prevented E-cadherin expression [247].  Promoter methylation or 
other processes regulated by mutated K-Ras could be responsible for prevention of E-cadherin 
expression in AsPC-1.  Our data suggests RGS16 may have a role in regulating E-cadherin 
112 
 
expression, however, further studies are needed to determine if increased expression of E-
cadherin aids in the inhibition of BxPC-3 cell migration and invasion.  We did not find a change 
in vimentin expression.  However in addition to the amount of this protein, phosphorylation of 
vimentin regulates its organization, localization, and function [248, 249].  We did not examine 
the localization or phosphorylation status of vimentin following RGS16 expression, and this is 
something to consider for future studies. 
EGF can also lead to the activation of RhoA, Rac1 and other Rho GTPases that are also 
associated with EMT and initiate rearrangement of filamentous actin (F-actin) [121, 122].  Rac1, 
RhoA and Cdc42 are activated by oncogenic Ras and activation of these proteins is vital for Ras 
transformation and/or cell motility [250, 251]. Activation of Rac1, RhoA, and Cdc42 results in 
reorganization of the actin cytoskeleton causing lamellipodia, stress fiber, or filopodia formation 
respectively that aids in different aspects of cell migration [126, 131].  Activation of Rho 
GTPases contributes to cell motility, invasion, and metastasis [131].  RhoA and RhoC have both 
been shown to be important signaling molecules required for migration, invasion, and metastasis 
of pancreatic cancer.  Quantitative in vivo fluorescence lifetime imaging of mice with p53  and 
K-Ras mutant pancreatic cancer found increased RhoA activity in certain subcellular locations 
that are important for invasion [252]. Fukumoto and colleagues found that the Rho GTPase 
RhoC is overexpressed in human pancreatic cancer and is associated with metastases and 
decreased survival [108].  Inhibition of EGF induced activation of RhoA alone or in combination 
with inhibition of RhoB and RhoC by p190 RhoGap (converts active RhoGTP to inactive 
RhoGTP) in pancreatic cancer cells repressed EGF induced invasion and metastasis [240, 253].   
RGS16 can inhibit activation of RhoA by binding and preventing the small G protein, Gα13 
from mediating the activation of RhoA in MCF-7 cells [164].  Although commonly associated 
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with GPCR signaling, Gα13 was identified as a mediator of growth factor induced migration and 
was found to bind and aid in the localization of active Rac1 to sites of lamellipodia formation 
[254].  The significance of Gα13 binding to Rac1 following growth factor stimulation in unclear, 
but this interaction may aid in the deactivation of Rac1 resulting in the turnover of actin to be 
used for formation of stress fibers or lamellipodia in the cytoskeleton [254].  Rac1 and RhoA 
work in an antagonistic fashion and prolonged activation of Rac1 may inhibit RhoA induced 
formation of stress fibers needed for cell motility [255, 256].   
Although only RGS16 has been directly linked to regulation of RhoA, based on literature 
reports other Rho GTPases could be targets for RGS16 regulation.  We examined F-actin 
organization in BxPC-3 and AsPC-1 cells expressing GFP and/or RGs16 in order to 1) determine 
if there is a change in cytoskeleton, and 2) narrow down possible targets for future study.  We 
were unable to detect any significant change between cells treated with Ad.GFP or 
Ad.GFP.RGS16.  This was due in part to the heterogeneity of the cell population making it 
difficult to quantify differences between control and RGS16 expressing cells.  Also any changes 
to the organization of the cytoskeleton could be subtle and not detectable using phalloidin 
staining.  Measurement of Rho GTPases’ activation state will be required to test the hypothesis 
that RGS16 is regulating cytoskeleton rearrangement through modulation of RhoA, RhoC, Rac1, 
or Cdc42.   
FUTURE STUDIES AND CONCLUSIONS 
RGS16 is downregulated in metastatic pancreatic cancer and for the first time we have 
delineated a function of RGS16 in inhibiting EGF induced pancreatic cancer cell migration and 
invasion in vitro.  Phosphorylation is an important mechanism that regulates RGS16 GTPase, 
accelerating its activity and stability [157-159].  Tyrosine 168 is located in the RGS box and its 
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phosphorylation by EGF/EGFR enhances the GTPase activity of RGS16.  In contrast, 
phosphorylation by Src slowed degradation of RGS16 [157, 158].  Our data suggests the 
enhancement of RGS16 activity by EGF/EGFR functions in a negative feedback loop to inhibit 
pancreatic cancer migration and invasion.  Our study focused on examining migration and 
invasion mediated by the EGF/EGFR pathway.  However, a single RGS protein can interact and 
regulate signaling of multiple pathways ([134, 172]).  Future studies are needed to determine if 
RGS16 can inhibit cell migration and invasion through other pathways such as the SDF-
1/CxCR4 pathway.  The mechanism behind RGS16 inhibition of migration and invasion still 
remains unclear, however, our studies show it is independent of the PI3K/Akt and MAPK 
pathways.  More experiments are needed to determine the mechanism governing RGS16 
inhibition of EGF induced migration and invasion.  Examination of E-cadherin activity in BxPC-
3 cells and activation of Rho GTPases in cells expressing RGS16 will help narrow down possible 
mechanisms.  Our study did not directly investigate whether RGS16 inhibits invasion by 
preventing the secretion of factors (such as matrix metalloproteinases) involved in the 
breakdown of the extracellular matrix and basement membrane required for the infiltration  of 
cancer cell into the vasculature.  However, this is the first report to our knowledge demonstrating 
a relationship between an RGS protein and invasion.  Further studies examining the expression 
and activity of matrix metalloproteinases (MMPs) could determine whether RGS16 may inhibit 
invasion by decreasing the amount, activity or secretion of MMPs. 
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CHAPTER 4.   
DISCUSSION 
Conclusions 
The objectives of our research were twofold: first to identify p53 and pRb cross-talk 
candidates by examining p53 and pRb co-regulated genes; and second to characterize the 
function of a p53 and pRb cross-talk candidate genes in cancer development.  As described in 
Chapter 1, p53 and pRb are vital for cancer suppression and studies suggest p53 and pRb cross-
talk to regulate cellular fate and prevent cancer progression.  By utilizing microarray expression 
profiling, we have identified 179 p53 and pRb regulated cross-talk candidates that may be 
involved in coordinating cancer suppression processes and determining cell fate (Chapter 2).  
Ingenuity Pathway Analysis (IPA) identified molecular and cellular functions that could be 
modulated by the cross-talk candidate genes and in cells exogenously expressing p53, pRb, and 
both p53 and pRb (Chapter 2).  This IPA analysis will be useful for generating future hypotheses 
aimed at identifying mechanisms employed by p53 and pRb to regulate cellular processes.  We 
chose to further study RGS16 a common gene set cross-talk candidate because of its known 
regulation of several oncogene pathways that are depicted in Figure 1.4 and its ability to regulate 
GPCR pathways that are commonly deregulated in cancer.  Loss of RGS16 in metastatic 
pancreatic cancer suggests it functions to inhibit processes that aid in metastasis.  Our results 
support our hypothesis that RGS16 inhibits pancreatic cancer cell migration and invasion in vitro 
and suggests that loss of RGS16 may provide to pancreatic cancer a metastatic advantage.   
Although it is known that RGS16 is regulated by p53, we are the first to report the regulation 
of RGS16 by pRb and its ability to inhibit EGF induced migration and invasion with no impact 
on cell viability (Chapter 2 & 3). The findings from our study suggest RGS16 is regulated by p53 
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and pRb and functions to inhibit pancreatic cancer cell migration and invasion, however this 
effect was cell line dependent.  Although not commonly associated with p53 and pRb signaling, 
regulation of cellular migration and invasion by both tumor suppressors has become evident over 
the course of the past several years.  p53 regulates cell polarization and migration of cells 
predominately by inhibiting Rho signaling [257] and also inhibits cancer cell invasion by 
suppressing the activity or expression of matrix metalloproteinases (MMPs) [258-261].  pRb’s 
role in cell migration has recently come to light.  pRb has been implicated as an important factor 
in regulating neuronal cell migration and was recently found to inhibit CD44 induced collective 
cell migration of breast cancer cells [68, 262].  pRb is linked to regulating invasion through its 
ability to bind and inhibit E2F induced transcriptional activation of the matrix metalloproteinases 
(MMPs) 9, 14, and 15 [67].  Knock-down of E2F1 and E2F3 inhibited migration and invasion of 
non-small cell lung cancer cells [67].  RGS16 may be another mechanism employed to regulate 
cell migration and invasion by p53 and pRb.  However, future studies are needed to verify if 
RGS16 regulation by p53 and pRb mediates suppression of cancer cell migration and invasion.    
While the exact mechanisms employed by RGS16 to regulate pancreatic cancer cell 
migration and invasion remains unknown,, our studies suggests RGS16 regulation is independent 
of the PI3K/AKT, and MAPK pathways and increases RGS16 in Ras wild-type cells.  Critique of 
the data and future directions will be explored below in the following sections outlining the next 
steps that can be taken to understand the role of RGS16 in pancreatic cancer.   
Critique and Data analysis 
Expression profiling analysis was used to identify p53 and pRb cross-talk candidates using 
normal lung fibroblast cells (WI38) expressing p53, pRb, or p53 + pRb.  Our studies focused on 
transcriptional regulation as a cross-talk mechanism employed by p53 and pRb.  However, 
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downstream protein-protein interactions are another mechanism of communication and were not 
investigated in our study.  To avoid mutations that can alter p53 and pRb signaling pathways, 
normal WI38 cells were used to study p53 and pRb cross-talk.  Our experimental design used an 
exogenous system to express p53 and pRb in cells that already express both tumor suppressors.  
This method does raise the concern that the total expression of p53 and pRb (exogenous + 
endogenous) exceeds normal activation levels of these tumor suppressors inducing irregular 
responses in the WI38 cells.  This is a valid concern, however using western blot and 
densitometry analysis (Figure 2.1), we found that the fold change in p53 and 
hypophosphorylated pRb (active form) to total pRb was equivalent to those seen endogenously 
in cells undergoing quiescence or cell cycle arrest respectively [195, 196].  Pathways that tightly 
control p53 and pRb expression and activity (highlighted in Chapter 1) are present in WI38 cells 
and regulate the expression of these two proteins. 
p53 and pRb activity is tightly controlled, so in order to study their transcriptional regulation 
functions, we had to induce their expression and/or activity.  We used adenoviruses to induce 
expression of p53 and pRb overcoming regulatory pathways and activating p53 and pRb 
transcriptional responses.  There are alternate methods that could have been used to induce p53 
and pRb transcriptional activity and will be briefly discussed.  p53 and pRb can both be activated 
by a variety of compounds or stimuli that induce DNA damage such as doxorubicin, cisplatin, or 
UV [263-265] . However, it is hard to isolate activation of just p53 and/or pRb using chemicals 
or other stimuli that induce DNA damage.  Mouse embryonic fibroblasts (MEF) negative for p53 
or pRb were also considered for studying p53 and pRb cross-talk.  However, we were unable to 
find p53
-/-
 and pRb
-/-
 MEFs.  Furthermore both p53 and pRb induce cell cycle arrest and initiate 
DNA repair.  Loss of both p53 and pRb would make the cells vulnerable to mutations that could 
118 
 
alter the p53 and pRb signaling pathways hindering identification of valid cross-talk candidate 
genes.  siRNA knockdown of p53 and/or pRb could have also been employed.  Levels of p53 are 
kept at low levels in normal cells by MDM2, and depending on the stage of the cell cycle pRb 
could be in its inactive form.  Additional stimuli to siRNA treated samples may have been 
required to initiate p53 and pRb transcriptional activity to compare changes in gene expression 
between controls and siRNA treated cells.  We chose to use adenoviruses to express p53 and pRb 
because it offered a simple method to induce one or both of these tumor suppressor genes 
without initiating other cellular pathways.   
We identified 179 cross-talk candidate genes that were broken down into two gene sets; the 
common (39) and interaction (140) cross-talk candidates (Figure 2.1).  Our interest in the 
common set cross-talk candidate RGS16 was first peaked when qRT-PCR analysis revealed p53 
and pRb combined expression in WI38 cells synergistically increased RGS16 mRNA.  Analysis 
of the literature demonstrated that RGS16 not only regulated GPCR receptor signaling but is also 
associated with regulating oncogene pathways that are altered in cancer signaling. RGS16 has 
been shown to regulate pathways that are associated with cell migration and invasion.  However, 
no studies have investigated whether RGS16 can inhibit migration and invasion.  Primary 
pancreatic tumors from patients with lymph node metastasis had decreased expression of RGS16 
that was associated with decreased survival.  Since a majority of pancreatic cancer patients 
present with metastases at time of diagnosis, we used pancreatic cancer as a model to study 
RGS16 migration and invasion.    
When we began the migration and invasion studies, we chose to use adenoviruses to express 
RGS16 because of the decreased expression of RGS16 in clinical data.  Western blot analysis 
later showed a faint endogenous band in the BxPC-3 cells (highest expression of RGS16 mRNA) 
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(chapter 3) further supporting our decision to express RGS16.  However, repeating the migration 
and invasion studies using RGS16 siRNA would complement our data and further support our 
hypothesis, however due to low basal levels of RGS16, it would be difficult to detect RGS16 
knockdown.    
We saw decreased EGF induced migration of BxPC-3 and AsPC-1 but not in the PANC-1 
cells.  The difference in behavior between cell lines could be due to alternate mutations that are 
preventing inhibition of PANC-1 cell migration by RGS16.  However, this does not mean that 
RGS16 could still not inhibit migration of these cells.  We examined the ability of RGS16 to 
inhibit EGF induced migration and invasion; however, RGS proteins canonically regulate GPCR 
signaling [134].  The RGS16 targeted GPCR CxCR4 is expressed in pancreatic cancer and 
promotes migration and invasion of the PANC-1 cells [141, 222, 242].   
We explored the mechanism behind RGS16 suppression of migration and invasion.  
EGF/EGFR activates a variety of pathways that can contribute to cell migration and invasion 
including PI3K/AKT, Ras/MAPK, and Rho GTPases.  We did not see a change in expression of 
phosphorylated AKT or ERK suggesting RGS16 does not modulate EGF induced migration and 
invasion through the PI3K/AKT or MAPK pathways.  Examinations of EMT markers E-cadherin 
and vimentin were inconclusive.  We did find an increase in E-cadherin expression in the K-Ras 
wild-type BxPC-3 cells but there was no change in vimentin for either BxPC-3 or AsPC-1 cells.  
Although there was an increase in E-cadherin expression in BxPC-3 cells by RGS16, we did not 
test the activity of E-cadherin in these cells.  Induced upregulation of RGS16 increased 
expression of E-cadherin in triple negative breast cancer cells [163].  E-cadherin, often referred 
to as the master regulator of EMT, is important for the formation of tight cell-cell contact [125].  
RGS16 may regulate E-cadherin in a Ras wild-type dependent manner.  K-Ras mutations in 
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prostate cancer inhibit E-cadherin expression by promoting methylation of the E-cadherin 
promoter [247].  Future studies are needed to test the hypothesis that K-Ras mutations inhibit 
increased expression of E-cadherin by RGS16. 
Phosphorylation of vimentin regulates its activity and localization.  Our studies only focused 
on mechanisms that regulate vimentin by increasing or decreasing its expression.  Investigation 
of the phosphorylation state and localization of vimentin will determine if RGS16 regulates cell 
migration and invasion by regulating the post-translational modifications of vimentin.  We 
cannot say definitively if RGS16 regulates EMT due to the use of only two EMT markers and 
differences seen between the two cell lines.  Examination of other EMT markers such as 
fibronectin and N-cadherin will provide a more complete picture that will aid in forming more 
conclusive results regarding RGS16 and EMT.   
Activation of Rho GTPases is also associated with EMT and aids in cell migration and 
invasion [126].  Although RGS16 is only directly linked with inhibiting activation of RhoA in 
MCF-7 cells there are other Rho GTPases that are involved in the reorganization of the 
cytoskeleton and that are integral to motility [164].  We used phalloidin to stain and visualize F-
actin in BxPC-3 and AsPC-1 cells.  We were expecting that phalloidin staining would identify 
distinct changes in the organization of F-actin that would pinpoint alterations in signaling to a 
Rho GTPase.  We could not distinguish changes quantitatively in the F-actin that forms 
lamellipodia, filopodia, or stress fibers; this is likekly due in part to the heterogenous population 
of cells.  Furthermore phalloidin staining is not a very good quantitative assay and changes in F-
actin may be subtle in these cells.  Activation kits examining RhoA, RhoC Rac1, Cdc42 would 
provide more quantifiable assays that would help determine whether RGS16 causes changes to 
expression of activated Rho GTPases.   
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Our mechanistic investigations concentrated on pathways that are predominately known to 
mediate cell migration.  However, both AKT and ERK (MAPK) can aid cell invasion by 
increasing expression of MMP-9 [233, 245].  Activation of Rho GTPases does stimulates cell 
invasion in vitro and in vivo, however, this is predominately linked with rearrangement of the 
actin cytoskeleton, changes in cell-cell contact, and cell adhesion dynamics that mediate cell 
movement [126].  Remodeling of the extracellular matrix is an important step for invasion and is 
mediated by extracellular proteases such as matrix metalloproteases (MMPs).  The mesenchymal 
phenotype adopted by cancer cells that underwent EMT is associated with an increase in the 
secretion of MMP 2 & 9 [125]. We did not examine the activity or expression of MMPs, but 
since we are found an inhibition of invasion, it is possib inhibits the activity or expression of 
MMPs.  
Future studies 
Our studies have only begun to uncover the function and role of RGS16 in pancreatic cancer 
progression.  There are still several questions that remain unanswered.  These questions will be 
explored along with future studies that can be performed to fill in the gaps.     
How does RGS16 inhibit pancreatic cancer cell migration and invasion in vitro? 
We were unable to identify the mechanism used by RGS16 to inhibit pancreatic cancer cell 
migration and invasion.  However there are several steps that can be taken to further understand 
the function of RGS16 in pancreatic cancer that are outlined in Table 4.1.  All proposed 
experiments are for BxPC-3 and AsPC-1 cells expressing GFP and/or RGS16 and treated with 
EGF following previous protocols as described in Materials and Methods of Chapter 3.   
E-cadherin binds to β-catenin and other proteins to form a complex that connects cell-cell 
adhesion complexes with the F-actin [126, 266].  Loss of E-cadherin liberates β-catenin that can 
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be stabilized by the Wnt signaling pathway in the cytosol leading to the translocation of β-
catenin to the nucleus where it can initiate transcription of factors that promote proliferation, 
migration, and invasion [126]. Examination of β-catenin expression in the nucleus will determine 
if the increased expression of E-cadherin in BxPC-3 translates to increased expression of E-
cadherin at the membrane.    
The second proposed experiment is the investigation of the localization and phosphorylation 
of vimentin.  The post-translational modification of vimentin regulates its organization, 
localization, and function [248, 249].  Although the role of phosphorylated vimentin is not well 
known it appears to aid in cell migration [249, 267]  Phoshorylation of vimentin causes 
disassembly of the intermediate filament resulting in increase of soluble vimentin.  Investigation 
of vimentin localization (still in filamentous fibers) and phosphorylation will show whether 
RGS16 regulates this protein through post-translational modifications.  
The Third experiment will test the hypothesis that mutant K-Ras prevents the upregulation of 
E-cadherin by mediating the promoter methylation of its gene.  A demethylating agent 
(decitabine and azacitidine) will be used in cells with or without adenoviruses expressing GFP 
and/or RGS16.  The hypothesis will be supported if the data shows increased expression of E-
cadherin in cells expressing RGS16 and treated with the demethylating agent.   
The last three proposed experiments focus on examining expression or activation of other 
EMT markers, MMPs, and Rho GTPases.  These proteins can be examined using western blots 
or PCR arrays to obtain a more global view of cellular changes due to RGS16 expression.  
Completion of these experiments will provide data demonstrating whether RGS16 inhibits 
expression of EMT markers, activation of Rho GTPases involved in cytoskeleton rearrangement, 
or activation of MMPs.  
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Table 4.1: Proposed future in vitro studies to examine mechanisms governing RGS16 
inhibition of pancreatic cancer cell migration and invasion. 
 
Experiment Type Method/hypothesized outcome 
1. E-cadherin 
activity 
Examine β-catenin localization in nucleus (western blots or 
immunofluorescence / ↑ E-cadherin activity ↓ localization of β-catenin in 
the nucleus 
 
2. Vimentin 
localization and 
phosphorylation 
Examine localization (immunofluorescence) & phosphorylation (western 
blot using anti-phosphorylated vimentin and/or  extract soluble and 
filamentous proteins followed by western blot using anti-vimentin / 
determine if localization or spread of vimentin changes (for example, 
change in amount of filamentous fibers) and if vimentin is phosphorylated 
(phosphorylated vimentin can break down and become soluble) 
3. Test if RGS16 
induced 
expression of E-
cadherin is 
dependent on 
wild-type K-Ras 
Treat cells with a DNA demethylating agent with or without concomitant 
treatment with adenoviruses expressing GFP and/or RGS16. Measure E-
cadherin expression / determine if K-Ras mutations inhibit up-regulation of 
E-cadherin by methylation and inhibition of E-cadherin promoter. 
4. Examine 
expression of 
other EMT 
markers 
Examine expression of other EMT markers such as N-cadherin, 
fibronectin, αvβ6 integrin, or E-cadherin transcriptional repressors (Snail, 
slug, ZEB1, or twist (by western blot or PCR array) / more conclusively 
show if RGS16 regulates EMT.  
 
5. Activation of 
RhoGTPases 
Rho GTPase activation kits (immunoprecipitation followed by western blot 
analysis) for RhoA, RhoC, Rac1, and Cdc42 / determine if RGS16 inhibits 
activation of select Rho GTPases 
 
6. Matrix 
Metalloproteinase 
(MMPs) activity 
Examine Matrix metalloproteinase activity using fluorometric activation 
kit / determine if and which MMPs are active 
 
Does RGS16 inhibit cell migration and invasion induced by other factors? 
A single RGS protein can interact and regulate signaling of multiple pathways [134, 172].  
While our studies focused on EGF induced migration and invasion, RGS16 may inhibit 
migration and invasion induced by other factors such as CxCR4.  Repeating the migration and 
invasion experiments using other factors to stimulate cell migration and invasion will show if 
RGS16 can regulate multiple mechanism of pancreatic cancer cell migration and invasion.  
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These experiments can be completed by two methods:  the first, is to use single ligands to induce 
activation of certain signaling pathways (for example SDF-1 ligand for CxCR4).  The second 
option is to use fibroblast conditioned media that contains multiple factors providing a partial 
mimic of the microenvironment that cancer cells are exposed to in vivo.  Identification of 
mechanisms will be easier to identify using single ligands to induce migration and invasion.  
However, using fibroblast conditioned media is more representative of the growth factors and 
ligands that a cancer cell is exposed to in the microenvironment.   
Does RGS16 inhibit pancreatic cancer cell metastasis in vivo? 
Pancreatic cancer has a low survival rate that is due in part to the highly metastatic nature of 
this disease.  By understanding the underlying mechanisms of pancreatic cancer progression, we 
will be able to better prevent or treat advanced and metastatic pancreatic cancer.  Although 
RGS16 was found to inhibit pancreatic cancer cell migration and invasion in vitro (Chapter 3) 
this does not guarantee that RGS16 can inhibit pancreatic cancer metastasis.  The process of 
metastasis is dynamic and complex involving multiple interactions between the tumor and the 
surrounding microenvironment that can be better studied using in vivo.  There are several mouse 
models that can be employed to test the hypothesis that RGS16 inhibits pancreatic cancer cell 
metastasis such as genetically engineered mouse (GEM) and mice xenograft models.  There are 
multiple advantages of GEM over xenograft or carcinogen induced pancreatic cancer models: 1) 
GEM models more closely mimic human pancreatic cancer, 2) can be used to study pancreatic 
cancer progression from initiation to metastasis, 3) and allows investigation of any interactions 
between the tumor and immune response [268, 269].  Using GEM models we can induce 
targeted knock-out of RGS16 in the pancreas of mice with knock-in of mutant KRasG12D and 
mutant p53R172H (Pdx1-Cre;LSL-KRas
G12D/+
;LSL-p53
R172H/+
) or mice with knock-in of mutant 
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KRasG12D and knock-out of  Ink4a/ARF (Pdx1-Cre;LSL-KRas
G12D/+
;Ink4a/Arf
lox/lox 
).  Both the 
Pdx1-Cre;LSL-KRas
G12D/+
;LSL-p53
R172H/+ 
 and Pdx1-Cre;LSL-KRas
G12D/+
;Ink4a/Arf
lox/lox
 
models develop pancreatic intraepithelial neoplasias (PANINs) that later progress to pancreatic  
cancer with the presence of metastases [102, 104].  By combining RGS16 knock-out with well 
characterized pancreatic cancer GEM models, we can determine if loss of RGS16 increases 
metastases.   
There are a couple of disadvantages to using GEM models; one, is expense and the second, is 
that the signaling molecules in mice may not have the same mechanisms or effect as in humans.  
Wilkie and colleagues (2010) using RGS16::GFP BAC transgenic mice found that RGS16 is 
expressed in pancreatic progenitor cells during development [140].  However, after birth, 
expression of RGS16::GFP remained in pancreatic cells associated with ducts and veins for 3-4 
weeks but was lost in adult mice.  In an abstract published earlier this year, the authors found 
expression of GFP tagged RGS16 throughout the different stages of tumorigenesis in mice with 
pancreatic cancer induced by knock-in mutant KRas and knock-out p16 and p19 targeted to 
pancreatic acinar cells (p48
CRE
;LSL-KRas
G12D
;CDKN2A
f/f 
) [270].  In our studies, we found that 
the expression of RGS16 mRNA was lower in established pancreatic cancer cells compared to 
normal human pancreatic RNA (Chapter 3).  Immunohistochemical analysis of RGS16 in 
primary samples showed a decrease in RGS16 staining in tumors extracted from patients with 
lymph-node metastases [149].  This data suggests RGS16 expression is present in human 
pancreas tissue and expression is lost during progression of pancreatic cancer contradicting the 
findings of the mice studies.  Human and mouse RGS16 share 85% homology, however, that 
15% difference could be sufficient to elicit different functions of RGS16  in the pancreas of these 
two species [154].  The function of RGS16 in mice with pancreatic cancer has not yet been 
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investigated and experiments using RGS16 knock-out mice will increase our understanding of 
the role of RGS16 in mouse pancreatic cancer.   
A xenograft orthotopic pancreatic tumor mouse model can used to determine if expression of 
RGS16 inhibits pancreatic cancer cell metastasis.  In orthotopic models the pancreatic cancer 
cells are injected directly into the pancreas of an immunodeficient (nude) mouse and up to 65% 
of mice develop metastases [271].  This model can only be used to study the endpoint of 
metastasis (in our case) as opposed to GEM models that can be used to study the different stages 
of tumorigenesis or metastasis.  Using this model, pancreatic cancer cells (AsPC-1) will be 
injected into the pancreas of a nude mouse.  Mice will be treated with adenoviruses expressing 
GFP and/or RGS16 encapsulated in microbubbles for targeted delivery to the tumor site.  
Ultrasound will be used to target the delivery of the bubble to the pancreas of the mouse.  
Metastasis and tumor growth will be measured. Orthotopic models are invasive and rely on 
imaging modalities to measure size of the tumor [272].  However, ultrasound guided tumor 
injection protocols for pancreatic cancer has been developed to limit injury to the mice [273]. 
Use of xenograft mice prevents endogenous investigation of RGS16 function on pancreatic 
cancer development and progression.  However, this model may bypass problems associated 
with RGS16 having different functions in mice vs. humans.  
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Abstract 
Data collected since the discovery of p53 and pRb/RB1 suggests these tumor suppressors 
cooperate to inhibit tumor progression. Patients who have mutations in both p53 and RB1 genes 
have increased tumor reoccurrence and decreased survival compared to patients with only one 
tumor suppressor gene inactivated. It remains unclear how p53 and pRb cooperate toward 
inhibiting tumorigenesis. Using RNA expression profiling we identified 179 p53 and pRb cross-
talk candidates in normal lung fibroblasts (WI38) cells exogenously coexpressing p53 and pRb.  
Regulator of G protein signaling 16 (RGS16) was among the p53 and pRb cross-talk candidates 
and has been implicated in inhibiting activation of several oncogenic pathways associated with 
proliferation, migration, and invasion of cancer cells.   
RGS16 has been found to be downregulated in pancreatic cancer patients with metastases 
compared to patients without metastasis. Expression of RGS16 mRNA was decreased in the 
pancreatic cancer cell lines tested compared to control. Expression of RGS16 inhibited migration 
of the BxPC-3 and AsPC-1 but not PANC-1 cells and inhibited invasion of BxPC-3 and AsPC-1 
cells with no impact on cell viability. We have identified for the first time p53 and pRb cross-talk 
candidates and a role for RGS16 to inhibit pancreatic cancer migration and invasion.  
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Introduction   
The p53 and pRb tumor suppressors are two signaling pathways that are frequently altered 
during cancer progression. Mutations that disrupt the p53 and pRb pathways can occur in the 
gene sequences or in their upstream regulators and/or downstream effectors. Results of studies 
have found that both tumor suppressor genes are inactivated in a variety of malignancies 
including osteosarcoma, small cell lung, breast, and bladder carcinomas [1, 4, 45, 46].  
Furthermore, alterations in expression or activity of proteins involved in p53 and pRb signaling 
pathways have been identified in retinoblastoma and cancers of the pancreas, colon, and head 
and neck among others [49, 51, 52, 111]. The large number of cancers that have defects in the 
p53 and pRb pathways demonstrates the importance of these genes in preventing cancer 
development and progression.  
Existing data suggests that p53 and pRb cooperate to prevent tumor progression.  Examples 
of this cooperative interaction have been shown by various studies using human primary cancer 
samples and mouse models.  Patients who have mutations in both p53 and RB1 genes have 
increased tumor recurrence and decreased survival compared to patients with a mutation in either 
p53 or RB1 [45, 47, 180].  A study conducted in mice found that p53 null mice who were also 
heterozygous for RB1 were susceptible to developing more tumors than mice with single 
mutations; i.e. heterozygous p53 or RB1 null or p53 null mice [4].  In another study, mice with 
conditional inactivation of both p53 and RB1 in prostate epithelium developed highly metastatic 
tumors and had decreased survival time compared to mice with single p53 or RB1 inactivation 
[5]. The accumulated evidence suggests p53 and RB1 gene products have cooperative or 
synergistic effects for cancer suppression. 
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Considering the network of communication that exists within a cell, the rate of mutation of 
p53 and RB1, and the cellular processes these two proteins regulate, a natural hypothesis is that 
these two genes and respective gene products cross-communicate in order to determine cellular 
fate and prevent carcinogenesis. In fact, there are known examples of genes and proteins that are 
involved in the convergent signaling between the p53 and pRb pathways; such as Hdm2, p21, 
E2F-1 and the INK4a locus (reviewed in [3, 47, 74, 182]).  Although several proteins that are 
involved in the p53 and pRb pathways have been identified, the full extent in which these two 
tumor suppressors interact along their pathway to regulate cellular fate is still unknown. To 
identify downstream targets of both p53 and pRb regulation and to elucidate mechanisms of p53 
and pRb cross-talk, we coexpressed p53 and pRb in normal human lung fibroblasts cells (WI38) 
and used RNA expression profiling to identify up- or down-regulated genes.  We identified 
Regulator of G protein Signaling 16 (RGS16) as a p53 and pRb cross-talk candidate.   
RGS16, previously found to be induced by doxorubicin in cells expressing wild-type p53, 
belongs to a large family of proteins that plays a role in swiftly shutting down G protein-coupled 
receptor (GPCR) signaling pathways [134, 135].  RGS16 is a GTPase activating protein (GAP) 
that aids GTPase activity of the α-subunit of G proteins associated with G-protein coupled 
receptors (GPCR). RGS16 has been implicated in negatively regulating the MAPK, AKT/PI3K, 
RhoA, and SDF-1/CXCR4 oncogene pathways in normal or cancer cell lines [135, 141, 164, 
171].  These oncogene pathways have been implicated in cancer progression processes (such as 
proliferation, survival, chemoresistance, migration, invasion, and metastasis in a variety of 
malignancies including pancreatic cancer [221-225]. Recently, evidence has demonstrated a role 
of RGS16 in cancer signaling. RGS16 locus is a site of genomic instability in (50% of 222) 
primary breast tumors  and knockdown of RGS16 in breast cancer cell lines increases Epidermal 
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Growth Factor (EGF) and Fetal Bovine Serum (FBS) initiated proliferation [150, 171]. A 
previous report using tissue microarray analysis revealed decreased expression of Regulator of 
G-protein signaling 16 (RGS16) in pancreatic tumors with lymph-node metastases compared to 
non-metastasized pancreatic cancer and this loss was associated with decreased patient survival 
[149]. Based upon the link of RGS16 regulating several oncogenic pathways and the decreased 
expression of RGS16 in metastasized pancreatic cancer, we chose to further study the function of 
RGS16 in pancreatic cancer in order to identify the role it has in the p53 and pRb signaling 
pathways.  Currently, RGS16 has not been linked with inhibition of cancer cell metastasis nor 
has its function been investigated to understand it’s downregulation in metastasized pancreatic 
cancer.  The majority of patients newly diagnosed with pancreatic cancer present with highly 
progressed and/or metastatic cancer that is resistant to treatment [84, 85].  Due to the late stage 
of diagnosis and the aggressive nature of this disease, less than 20% of pancreatic cancer patients 
are eligible for the potentially curative surgery [85, 220].  Therefore, there is a great need for 
more effective drugs aimed at treating or preventing metastatic pancreatic cancer. Pancreatic 
cancer is associated with p53 mutations and p16 (pRb activator) deletions resulting in the 
crippling of both the p53 and pRb pathways. By investigating the p53 and pRb cross-talk and the 
role of RGS16 in pancreatic cancer cell migration, we have uncovered a novel regulator of 
metastasis processes that could be a future target in developing treatments for metastatic 
pancreatic cancer. 
 
Results 
Identification of p53 and pRb cross-talk candidates in WI38 cells following coexpression of 
p53 and/or pRb.   
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Studies have shown that p53 and pRb cooperate to prevent tumorigenesis.  Currently, the 
molecules that function in the p53 and pRb cross-talk pathway to regulate cellular fate are not 
known thus expression profiling by microarray was performed to find genes co-regulated by p53 
and pRb. Normal human lung WI38 fibroblast cells were transduced with adenoviral vectors 
expressing the p53 and/or RB1 genes under the control of a cytomegalovirus (CMV) promoter. 
The WI38 cell line was used because it is from non-cancerous tissue and lacks mutations or viral 
transformations that could disrupt the p53 and pRb pathways. Four experimental conditions were 
used in which WI38 cells were transduced with adenovirus vector control (cond. 1, Adenoviral 
CMV-vector control, Ad.CMV.p53 (cond. 2), Ad.CMV.pRb (cond. 3), or both Ad.CMV.p53 and 
Ad.CMV.pRb (cond. 4).  RNA and protein from WI38 cells was collected 48 hours after 
adenoviral infection. Immunoblots verified increased expression of p53 (fold change compared 
to Ad.CMV control = 2.80, 1.54, and 2.77) and/or hypophosphorylated (active form) pRb 
(hypophosphorylated/total pRb fold change compared to Ad.CMV control = 0.94, 5.48, 5.02) in 
the WI38 cells treated with adenoviruses containing p53, pRb, or both p53 and pRb respectively 
(Figure 1A and 1B).  Fold change values for p53 and hypophosphorylated pRb coincided with 
previously reported results in experiments that activated endogenous p53 and pRb [195, 196].  
Microarray data from the adenovirus vector control (empty vector with CMV promoter) was 
used as a reference to determine genes that were differentially expressed as a consequence of 
p53, pRb, and p53 + pRb expression. Analysis of the microarray data identified 294-p53, 650-
pRb, and 514-p53 + pRb differentially expressed genes (Figure 1C; see Supplementary 
Document 1) for full list of differentially expressed genes. Of the differentially expressed genes, 
294/294 genes were upregulated in cells with p53 expression, 427/650 genes were upregulated in 
cells with pRb expression, and 319/514 genes were up-regulated in cells with p53 + pRb 
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coexpression (Figure 1C). Consistent with protein measurements, increased expression of p53 
and/or RB1 mRNAs were also found in the appropriate groups (Supplementary Document 1).   
A Venn diagram shows the number of differentially expressed genes shared between the 
experimental groups (Figure 1C). By looking at the common genes between the three 
experimental groups, we were able to generate two lists of genes that may be involved in the p53 
and pRb cross-talk pathway. The first list of cross-talk candidates (designated as the p53 and pRb 
common gene set) consisted of 39 genes found to be commonly up-regulated in cells expressing 
either p53 or pRb. The second list of possible cross-talk members (designated as the p53 and 
pRb interaction gene set) contained 140 genes that were found to be differentially expressed only 
when p53 and pRb were overexpressed together (see Supplementary Document 1).  Thirty-two 
of the 39 common gene set cross-talk candidates were found to be up-regulated in the interaction 
gene set, while the remaining 7 were commonly up-regulated in cells that overexpress either p53 
or pRb (Table 1).  By focusing on the common and interaction gene sets, we were able to remove 
transcripts that were up- or down-regulated by only p53 or pRb and focus on candidates that may 
be involved in the p53 and pRb cross-talk pathway.  
 
qRT-PCR validation of microarray data in WI38 and SAOS-2 cells. 
  Our ultimate goal in performing the microarray analysis was to determine molecules 
involved in the p53 and pRb cross-talk pathway in order to identify and study downstream 
effector molecules that can be expressed to induce a p53 and/or pRb tumor suppressive function.  
Because of our interest in identifying downstream effector molecules, we chose five mRNA 
transcripts (IL-6, BTG-2, STAT4, RGS16, BCL2L11) from the set of 39 commonly up-regulated 
transcripts by p53 and pRb for validation via qRT-PCR.  IL-6, BTG-2, STAT4, RGS16, and 
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BCL2L11 were chosen for validation because of varying function, known regulation by p53 and 
pRb, and fold change values expression profiling assay.  WI38 cells were plated and transduced 
with adenoviral expression vectors via the same methods used for the microarray analysis.  
Relative fold change was calculated for IL-6, BTG-2, STAT4, RGS16, and BCL2L11 in WI38 
cells expressing p53 and/or pRb as shown in Figure 2. Statistically significant up-regulation of 
all transcripts tested except BCL2L11 was found in WI38 cells expressing p53 and pRb 
confirming the microarray results. Expression of p53 and pRb in WI38 cells increased mRNA 
expression for some of the transcripts (for example, RGS16 and BTG-2) to a greater extent than 
single expression of either p53 or pRb. This suggests p53 and pRb are working together resulting 
in an additive (i.e. BTG-2) or synergistic (i.e. RGS16) effect on mRNA expression for some of 
the transcripts.  
 To further support the RNA expression profiling results, we repeated the expression of 
p53 and pRb in a p53 null, RB1 mutant osteosarcoma cell line (SAOS-2) and performed qRT-
PCR analysis of IL-6, BTG-2, STAT4, RGS16, and BCL2L11. The expression of all five 
transcripts including IL-6 and BCL2L11 were found to be significantly increased by one-way 
ANOVA compared to vector control in SAOS-2 cells expressing p53 and/or pRb (Figure 3). 
Dunnett’s test for multiple comparison found BCL2L11 expression to be significantly increased  
in cells expressing p53, pRb, and both p53 and pRb and IL-6 was found to be significantly 
increased in cells expressing pRb and p53+pRb. Expression of IL-6 was not found to be 
statistically significant in SAOS-2 cells expressing p53 due to variation between replicates (fold 
change= 2.86).  All five transcripts were found to be up-regulated when p53 and/or pRb were 
expressed in the microarray analysis and qRT-PCR analysis showed similar results in WI38 and 
SAOS-2 cells.   
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mRNA expression of RGS16 is decreased in pancreatic cancer cell lines. 
RGS16 was identified as a p53 and pRb cross-talk candidate in our expression profiling 
analysis that was validated by qRT-PCR. We chose to study the role of RGS16 in pancreatic 
cancer cell migration due in part to its down-regulation in patients with metastasized pancreatic 
cancer and the high rate of p53 mutations (50-70%) and p16 deletions (85%) affecting both the 
p53 and pRb pathways in this disease  [51, 111, 149].  We first investigated the relative 
expression of RGS16 mRNA in four pancreatic cancer cell lines (BxPC-3, MIA PaCa-2, PANC-
1, and AsPC-1) in order to characterize the endogenous expression of RGS16. Expression of 
RGS16 was measured by qRT-PCR analysis and the relative RGS16 mRNA fold change was 
calculated in the four cell lines compared to total RNA from normal human pancreatic tissue. 
Expression of RGS16 was decreased in all four lines compared to control with BxPC-3 having 
the highest expression of RGS16 mRNA (Figure 4). Expression of RGS16 varied between the 
four lines with BxPC-3 and MIA PaCa-2 having significantly higher expression of RGS16 than 
PANC-1 and the metastatic derived AsPC-1 cells. RGS16 expression corresponded with the 
more differentiated and less aggressive cell lines having higher levels of RGS16 than the more 
aggressive and/or metastatic cell lines (Table 2).     
 
RGS16 inhibited migration of BxPC-3 and AsPC-1 pancreatic cancer cells but not PANC-
1.  
To test the hypothesis that RGS16 inhibits pancreatic cancer cell migration, we exogenously 
expressed RGS16 in BxPC-3, PANC-1, and AsPC-1 cells with an adenoviral vector and used 
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wound healing assays to measure cell migration. We chose BxPC-3, PANC-1, and AsPC-1 
because these three cell lines are derived from tumors with varying expression of RGS16, 
differentiation status, mutations, presence of metastases, and expression of Epidermal Growth 
Factor Receptor (EGRF, Table 2). We expressed RGS16 using adenoviral vector that contains 
RGS16 plus a GFP reporter (Ad.GFP.RGS16) and used a vector expressing only GFP (Ad.GFP) 
as the control. Expression of RGS16 protein correlated with GFP expression in cells treated with 
Ad.GFP.RGS16 (Supplementary Figure 1). Fluorescent microscopy was used to determine viral 
transduction prior to experiment (Figures 5a, 6a, and 7a). EGF was used to stimulate cell 
migration because EGFR is overexpressed in pancreatic cancer and is linked with development, 
invasion, and decreased survival in pancreatic cancer [115, 226, 227].  RGS16 significantly 
inhibited FBS- and EGF-induced migration of BxPC-3 cells and FBS-induced migration of 
AsPC-1 cells, but had no effect on FBS and EGF induced migration of PANC-1 cells (Figures 5-
7).   
Interestingly, expression of RGS16 in BxPC-3 cells incubated in media supplemented with 
EGF caused an increase in wound width compared to control 16 hours after the start of the 
experiment.  However, MTT assay revealed that there was no statistically significant change in 
cell viability of FBS or EGF treated BxPC-3, PANC-1 or AsPC-1 following expression of 
RGS16 compared to control cells expressing GFP (Supplementary Figure 2).   
Expression of RGS16 inhibited EGF induced invasion of BxPC-3 and AsPC-1 cells.  
RGS16 inhibited EGF induced migration of BxPC-3 and AsPC-1 cells, we further 
investigated if RGS16 can inhibit EGF induced invasion of these pancreatic cancer cells using 
matrigel invasion chambers.  Media supplemented with EGF was used as the chemoattractant to 
induce migration and invasion of BxPC-3 and AsPC-1 cells expressing GFP and or RGS16. 
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Expression of RGS16 significantly inhibited EGF induced invasion of the BxPC-3 and AsPC-1 
cells by 35.73% and 66% respectively, compared to control (Ad.GFP) (Figure 8).   
Discussion 
Significance of investigating p53 and pRb cross-talk  
Historically, investigations of p53 and pRb regulated transcription have focused on 
identifying the individual downstream targets of p53 and pRb. However, cell fate is not 
determined solely by one signaling pathway but by many pathways that communicate through a 
network of signaling molecules.  Cross-communication between pathways allows the integration 
of the exogenous and endogenous signals in a cell to aid in the determination of cell fate.  
Previous studies have found that co-expression of p53 and pRb in cancer cells with compromised 
p53 and pRb activity inhibited p53 mediated apoptosis and promoted cell cycle arrest suggesting 
p53 and pRb cross-talk to regulate cellular fate [188, 189].  Furthermore, data from previous 
studies suggests p53 and pRb may also cooperate to inhibit cancer progression. Patients 
diagnosed with breast cancer and treated with adjuvant chemotherapy had a better prognosis to 
adjuvant chemotherapy if they had functional p53 and pRb [61].  
To our knowledge this is the first study that examines altered gene expression when p53 and 
pRb are expressed together or separately with the purpose of finding genes co-regulated by both 
tumor suppressor genes. How p53 and pRb cross-communicate to regulate cellular functions or 
cooperate to inhibit cancer progression still remains largely unknown. The p53 and pRb 
pathways are commonly altered during tumorigenesis. Due to the dynamic properties of cell 
signaling, the study of genes dually regulated by p53 and pRb will provide a valuable insight into 
the collaborative cancer preventative properties of these two tumor suppressor proteins.   
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Transcriptional regulation may be one method used by p53 and pRb to coordinate cellular 
functions.  For example, the cyclin kinase inhibitor p21 is a down-stream target gene of p53 that 
inhibits phosphorylation and inactivation of pRb [25]. Transactivation of p21 demonstrates a 
mechanism by which p53 can coordinate with pRb to initiate cell cycle arrest.  However, this 
only begins our understanding of the complex regulation of cellular programs. 
 
Change in RNA expression profiles of WI38 cells expressing both p53 and pRb compared 
to expression of p53 and pRb alone, identification of cross-talk candidates, and validation 
by qRT-PCR 
In this study, we identified genes that may be regulated by p53 and pRb and compiled two 
lists of p53 and pRb cross-talk candidates by expressing p53 and/or pRb in WI38 cells.  
Although p53 has transcriptional repression activity, our microarray analysis did not detect any 
down-regulated transcripts in the WI38 cells expressing p53 [190, 191].  The deficit of p53 
down-regulated transcripts in our microarray analysis compared to previous studies could be due 
to our method of p53 activation, cell type, or p53 levels, which have previously been found to 
induce a distinct p53 response with a small set of overlapping genes [192, 193]. Our expression 
profiling analyses were conducted in normal lung fibroblasts cells instead of cancer epithelial 
cells. Absence of p53 down-regulated genes in the p53 expressing WI38 cells could also be 
attributed to the ability of p53 and pRb to alter each other’s transcriptional activation or 
repression functions in normal cells that contain intact pathways. Previous studies that 
discovered p53 down-regulated targets using expression profiling were done in cancer cells with 
mutated or null p53 and wild-type RB1 such as PC-3, HCT116, and H1299 cells [190, 194].   
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There were 319 upregulated transcripts when p53 and pRb were expressed together 
compared to 427 and 295 in the WI38 cells expressing pRb and p53 respectively. The change in 
upregulated genes suggests p53 and pRb can alter one another’s ability to regulate gene 
expression.  Management of p53 and pRb processes may require p53 and pRb to regulate gene 
expression in an opposing manner. Expression of an embryonic development gene, Placenta-
specific 1 (PLAC1), has recently been found to be down-regulated by p53 and up-regulated by 
pRb demonstrating how p53 and pRb can play contrasting roles to regulate cellular processes 
[81].   
pRb is most associated with transcriptional repression of E2F target genes preventing 
transcription of genes needed for the continuation of the cell cycle [18-20]. However, binding of 
E2F by pRb is not needed to promote transcription, suppress tumor growth and induce cellular 
differentiation or senescence [22, 23].  In fact, pRb has been found to act as a co-activator for 
several transcription factors including Sp-1, RUNX-2, MyoD, and several nuclear receptors 
(including NR4A1) resulting in cellular differentiation [22, 39].  We found more transcripts that 
were up-regulated in WI38 cells expressing pRb than downregulated demonstrating its function 
as a transcription co-activator. There is still a lot not known about pRb regulation, therefore, this 
study could contribute to the identification of genes up-regulated by pRb and understanding of 
the function of pRb as a transcriptional co-activator.  
Candidates for the p53 and pRb cross-talk pathway were chosen based on whether (1) the 
transcripts were differentially expressed in both WI38-p53 and WI38-pRb-expressing cells (the 
common gene set), or (2) only in WI38 cells that simultaneously expressed p53 and pRb 
(interaction gene set). By focusing on the p53 and pRb common and unique genes, we were able 
to remove from our analysis genes regulated by p53 or pRb alone. Several of the p53 and pRb 
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common gene set  (RGS16, BTG-2, GDF15, VCAN, D4s234e/NSG1, AKR1B10 and AREG) 
and interaction gene set  (F11R, TNFRSF10C, CERS6, HDM2, SESN1, RBM38 and 
PMAIP1/NOXA) cross-talk candidates have been previously found to be up-regulated by p53, 
and this data is in agreement with our microarray results [135, 193, 197-205].  Only a few of the 
downregulated p53 and pRb cross-talk candidates have previously been found by other studies to 
be downregulated by p53 (MCM3, BUB1, and CDT1) or pRb individually (VRK1, MCM3, and 
CDT1) [190, 206-209].  Although several of our p53 and pRb cross-talk candidates have 
previously been found regulated by p53, regulation of these transcripts by pRb is not known.    
Our expression profiling analysis was performed using a normal cell line in order to avoid 
any mutations that could be present up- or downstream of p53 and pRb that could hinder 
identification of downstream targets of both genes.  Although we expressed p53 and pRb using 
adenoviruses in normal cells, the fold change of p53 and hypophosphorylated pRb proteins 
compared to CMV control were equivalent to or less than fold change values in WI38 cells 
incubated in serum free media to induce quiescence (fold change p53 after 24 hours in serum 
free media = 5.5) or MCF7 cells undergoing confluence induced cell growth arrest (fold change 
hypophosphorylated pRb/total pRb = 6.00) [195, 196]. This data suggests the concentration of 
virus used did not exceed endogenous protein expression of p53 and the active 
hypophosphorylated form of pRb.  However, the use of a normal cell line with wild-type p53 and 
RB1 could make it difficult to identify cross-talk molecules due to possible interactions between 
endogenous and exogenous p53 and pRb. To investigate if exogenous and endogenous p53 and 
pRb interactions could influence expression profiles expression of RGS16, BCL2L11, BTG-2, 
IL-6, and STAT4, were measured using qRT-PCR in the p53 null and pRb mutated osteosarcoma 
cell line SAOS-2. Expression of all transcripts in the p53 and pRb expressing SAOS-2 cells were 
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found increased with differences in magnitude of expression as they did in our WI38 microarray 
data and qRT-PCR results. Interestingly, in the microarray data, STAT4 was found to be 
differentially expressed in WI38 cells expressing p53 and pRb but not in cells expressing both 
genes.  However qRT-PCR analysis found a statistically significant increase in STAT4 
expression in WI38 and SAOS-2 cells expressing p53 and pRb.  The statistical analyses of 
expression profiling data or the sensitivity of microarray signal detection could account for the 
failure to observe differential expression of STAT4 in WI38 cells expressing p53 and pRb.    
 
RGS16 significance and signaling in cancer 
RGS16 was of interest to our study for two reasons: 1) RGS16 regulates GPCRs, which are 
common targets for deregulation in cancer and 2) RGS16 has been linked to regulating the 
MAPK/RAS, PI3K/AKT, RhoA, and SDF-1/CxCR4 oncogene pathways [133, 135, 141, 164, 
171].  Investigations have found that oncogene pathways can feed into one another and bypass or 
overcome the inhibitory effects of monoclonal antibodies or other targeted inhibitors. For 
example, in melanoma, increased production of VEGF or increased expression or activation of 
the platelet-derived growth factor receptor β or insulin like growth factor 1 receptor is associated 
with resistance to BRAF inhibitors demonstrating mechanisms cancer cells use to overcome 
single target modalities [239].  Therefore investigation of RGS16, a protein known to modulate 
several oncogene pathways will aid in understanding mechanisms by which cells alter multiple 
signaling pathways to prevent carcinogenesis that could be used for future drug development.  
We chose to study the function of RGS16 in pancreatic cancer because only 5.7% (1 out of 
17) of pancreatic tumors with lymph-node metastases had expression of RGS16 compared to 
70.6% (12 out of 17) of pancreatic tumors with non-metastasized pancreatic cancer [149]. 
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Furthermore, decreased expression of RGS16 was associated with poor pancreatic cancer patient 
survival indicating the potential of RGS16 as a pancreatic cancer prognostic marker [149].  
Few reports have been published that describe the impact of RGS16 on cancer cell signaling 
and progression.  Although increased expression of RGS16 has been found in pediatric high 
hyperdiploid acute lymphoblastic leukemia (ALL) and colon cancer, functional analysis of 
RGS16 has not been performed to identify any oncogenic function in these cancers [147-149]. 
Functional and expression analysis of RGS16 has been performed in breast cancers.  The RGS16 
promoter is located at a site that is vulnerable to allelic imbalances in a subset of breast cancers 
that can result in promoter methylation of RGS16 in 10% of these cancers [150].  Liang et al. 
(2009) found that RGS16 overexpression in breast cancer cell lines decreased EGF induced 
proliferation and AKT activation by binding to the p85-alpha subunit of PI3K preventing the 
phosphorylation of AKT [171]. RGS16 has also been associated in the anti-proliferative effect of 
retinoic acid in neuroblastoma cells and the cytotoxic effect of histone deacetylase inhibitor 
Vorinostat in triple negative breast cancers [162, 163]. The current data suggests RGS16 plays a 
role in cancer signaling, however, more research is needed to delineate the function of RGS16 in 
cancer cells. 
 
RGS16 and cell migration 
RGS16 has been linked with inhibition of cell migration in a canonical (through regulation of 
GPCR signaling) and non-canonical pathways in normal cells. RGS16 inhibits megakaryocytes 
and T lymphocyte migration by regulating the activation of the GPCR CxCR4 and decreases T 
helper type 2 and 17 cell trafficking through regulation of CCR4 and CCR10 chemokine 
pathways representing the canonical form of RGS signaling [136, 137, 141]. The activation of 
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RhoA, a small GTPase involved in reorganizing actin cytoskeleton and a mediator of EGF 
induced invasion of pancreatic cancer cell lines is inhibited in MCF-7 cells by the relocation of 
Gα13 to the plasma membrane by RGS16 preventing Gα13 mediated activation of RhoA  [164, 
240].  The regulation of RhoA activation by RGS16 is an example of a non-canonical 
mechanism used to regulate signaling.  These studies show mechanisms by which RGS16 can 
regulate cell migration.  To date, this is the first report demonstrating RGS16 induced inhibition 
of cancer cell invasion.     
The findings from our study suggest RGS16 is regulated by p53 and pRb and functions to 
inhibit pancreatic cancer cell migration and invasion; however this effect was cell line 
dependent. PANC-1 cell migration induced by FBS or EGF was not inhibited by RGS16, this 
could be due to different mutations in PANC-1 compared to the other cell lines that prevent 
RGS16 inhibition of FBS or EGF induced cell migration.  Although not commonly associated 
with p53 and pRb signaling, regulation of cellular migration and invasion by both tumor 
suppressors has become evident over the course of the past several years.  p53 has been found to 
regulate cell polarization and migration of cells predominately by inhibiting Rho signaling [257].  
p53 also inhibits cancer cell invasion by inhibiting activity or expression of matrix 
metalloproteinases (MMPs) [258-261].  pRb’s role in cell migration has recently come to light.  
pRb has been implicated as an important factor in regulating neuronal cell migration and was 
recently found to inhibit CD44 induced collective cell migration of breast cancer cells [68, 262].  
pRb is linked to regulating invasion through its ability to bind and inhibit E2F induced 
transcriptional activation of the MMPs 9, 14, and 15 [67].  Knock-down of E2F1 and E2F3 
inhibited migration and invasion of non-small cell lung cancer cells [67].  RGS16 may be 
another mechanism employed to regulate cell migration and invasion by p53 and pRb.   
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Future studies and conclusions 
This is the first report of regulation of RGS16 pRb and RGS16-mediated inhibition of EGF- 
induced migration and invasion in normal and cancer cells. This study focused on examining 
migration and invasion mediated by the EGF/EGFR pathway.  However, a single RGS protein 
can interact and regulate signaling of multiple pathways ([134, 172]).  Future studies are needed 
to determine if RGS16 can inhibit cell migration and invasion through other pathways such as 
the SDF-1/CxCR4 pathway which is deregulated in pancreatic cancer ([222]).    
By utilizing microarray expression profiling, we have 1) identified p53 and pRb regulated 
candidates or genes involved in coordinating cancer suppression processes and determining cell 
fate, 2) and identified a possible role for the cross-talk candidate RGS16 in inhibiting pancreatic 
cancer cell migration and invasion.  Our study suggests that the loss of RGS16 promotes 
pancreatic cancer metastasis by removing the inhibitory function of RGS16 on cell migration and 
invasion.  Our study further supports the use of RGS16 as a prognostic marker for predicting 
pancreatic cancer metastasis previously described by Kim et a.l that can be used to asses 
eligibility of patient for surgery [149].  By investigating the p53 and pRb cross-talk and the role 
of RGS16 in pancreatic cancer cell migration, we have uncovered a novel regulator of metastatic 
processes that could be a future target in developing treatments for late stage pancreatic cancer.   
 
Materials and Methods 
Cell culture and virus transductions  
The human lung fibroblast WI38 cell line, osteosarcoma cell line SAOS-2 (p53 null and 
truncated RB1), and the pancreatic cancer cell lines, BxPC-3, AsPC-1, MIA PaCa-2, and PANC-
1 were purchased from the American Type Culture Collection (Manassas, VA, USA).  WI38 
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cells were grown in Hyclone MEM/EBSS (ThermoFisher Scientific, Waltham, MA) media 
supplemented with 10% research grade fetal bovine serum (FBS) (PAA Laboratories, 
Dartmouth, MA) and 1% Penicillin Streptomycin (Corning, Corning, NY) and SAOS-2, MIA 
PaCa-2, and PANC-1 cells were grown in Hyclone High Glucose DMEM  (ThermoFisher 
Scientific, Waltham, MA) supplemented with 10% FBS and 1% Penicillin Streptomycin.  BxPC-
3 and AsPC-1 were cultured in RPMI supplemented with 10% or 15% FBS (respectively) and 
1% Penicillin Streptomycin.  Cells were cultured at 37°C in a humidified 5% CO2 incubator.   
Ad.CMV (adenovirus with CMV promoter) and Ad.CMV.p53 (Adenovirus containing wild-
type p53 gene under control of CMV promoter) viral vectors were generated using the AdEasy 
system (Carlsbad, CA). The Ad.CMV.pRb (Adenovirus containing RB1 gene cDNA under 
control of CMV promoter) vector was provided by Dr. Juan Fueyo (M.D. Anderson Cancer 
Center, The University of Texas).  The Ad.GFP and Ad.GFP.RGS16 viruses were purchased 
from Vector Biolabs (Philadelphia, PA).  Viruses were amplified and tittered as previously 
described [183-185].   
 
Microarray expression profiling  
For expression profiling, WI38 cells were transduced with each of the following vectors or 
vector combination:  (1) adenovirus vector with no insert (Adenoviral CMV-vector ctrl), (2) 
Ad.CMV.p53, (3) Ad.CMV.pRb, and (4) both Ad.CMV.p53 and Ad.CMV.pRb.  Vectors were 
added at a multiplicity of infection (MOI) of 50 to 80% confluent WI38 cells in MEM/EBSS 
supplemented with 2% heat-inactivated FBS.  Culture media were replaced with 10% FBS and 
1% Penicillin/Streptomycin supplemented MEM/EBSS medium 16 hours after vector addition; 
cells were collected after 48 hours.  Four biological replicates were performed for each of the 
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four expression studies.  Immunoblots were used to verify increased expression of p53 and/or 
pRb in the WI38 samples prior to microarray analysis. 
Total RNA was isolated from transduced WI38 cells using TRIzol reagent (Invitrogen, 
Carlsbad, CA) according the manufacturer’s protocol.  Using a universal reference design, two 
RNAs (transduced WI38 cells + Agilent (Santa Clara, CA) human universal reference RNA) 
were hybridized to Agilent 44K whole human genome expression arrays. Total RNAs were 
labeled with either cyanine (Cy)-3-CTP and Cy5-CTP (Perkin Elmer, Waltham, MA) using 
Agilent QuickAmp cRNA labeling kits. Following purification, Cy3- and Cy5-labeled cRNAs 
were combined and hybridized for 17 hours at 65ºC in an Agilent hybridization oven. 
Microarrays were then washed and scanned using Agilent DNA Microarray Scanner. 
 
Statistical Analysis of Expression Profiling Data 
Lowess-normalized feature intensities were extracted from the scanned image using Feature 
Extraction (Agilent). These data were exported as tab-delimited files (one file per sample) to 
Microsoft Excel for filtering.  For each feature, data were removed if both channels reported 
values not well-above background according to default Feature Extraction Criteria.  For each 
comparison, log base-2 ratios of each sample to universal reference RNA were collated into a 
single table.  Features for which fewer than 50% of all samples had a present value were 
removed from further analysis.   
The resulting tables were imported into Multiple Experiment Viewer (MEV) v4.3.  Log base 
2 ratios were compared between each of three sample sets (p53 expressed samples.  RB1 
expressed samples and p53 and RB1 coexpressed samples) and the adenovirus vector control 
samples by Significance Analysis of Microarrays [186].  We used a conservative threshold 
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whereby only genes for which MEV reported a false discovery rate of 0% were considered 
significantly differentially expressed. 
Data extracted using Feature Extraction was uploaded to the NCBI’s Gene Expression 
Omnibus (GEO) public database and is available via access number GSE59660.   
Real-time PCR analysis 
Total RNA was isolated from cells using TRIzol reagent (Invitrogen, Carlsbad, CA) 
according to the manufacturer’s protocol.  Total RNA was reverse transcribed into cDNA using 
the High Capacity cDNA Reverse Transcription kit from Applied Biosystems (Foster City, CA) 
according to the manufacturer’s protocol.   Real-Time PCR was performed using the Applied 
Biosystems TaqMan Gene Expression Assays in the ABI 7000 detection system. TaqMan probes 
were purchased from Applied Biosystems (Foster City, CA) IL-6 (HS00197982_m1), BCL2L11 
(BCL2L11) (HS00197982_m1), RGS16 (HS00892674_m1), BTG2 (HS00198887), STAT4 
(HS00231372_ml) and GAPDH (HS02758991). Human pancreatic total RNA used for 
comparing the expression of RGS16 mRNA was purchased from Agilent Technologies (Cedar 
Creek, TX).  The relative fold change for each marker was calculated using the 2
-ΔΔCT
 analysis 
according to Livak et.al and statistical significance was determined using a one way ANOVA 
with a Dunnett’s or Tukey (pancreatic cancer cell lines) post-hoc test, using Prism V6.0c 
(GraphPad Software, Inc., La Jolla, CA) [187].    
Western blot analysis 
WI38 or Saos-2 cells were lysed in whole cell lysis buffer containing 50mM TRIS (pH7.4), 
5mM EDTA 250mM NACL, 50mM NaF, 0.1mM Na3VO4, 0.1% Triton X-100 and protease 
inhibitors (Pierce Protease inhibitor Tablets 88661; Thermo Scientific, Rockford, IL).  Protein 
extracts (50ug) were loaded onto 8% polyacrylamide gels and proteins were separated using 
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sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).  Blots were blocked 1 
hour in 5% dry non-fat milk diluted in Tris-buffered saline solution containing 0.1% Tween-20 
(TBS-T). Membranes were probed overnight at 4°C with mouse anti-p53 (SC-DO1, 1: 1000) or 
mouse anti-pRb (SC-IF8, 1:500) antibodies from Santa Cruz Biotechnology (Dallas, TX).  
Following primary antibody incubation the membranes were washed and probed with 
Horseradish peroxidase (HRP)-conjugated goat anti-mouse (1:5000) secondary antibodies 
(Rockland, Gilbertsville, PA) for 1 hour at room-temperature.  Primary and Secondary antibodies 
were diluted in TBS-T.  Blots were washed 5 minutes in TBS-T three times and Amersham ECL 
prime western blotting detection reagent was added in order visualize the protein bands (RPN 
2232, GE Life Sciences, Pittsburgh, PA).  Western blot images were captured using 
FOTODYNE FOTO/Analyst FX (Hartland, WI) imaging camera.   Membranes were normalized 
using mouse anti-actin (1:1000). Densitometry was performed using TotalLab Quant software 
(TotalLab Ltd, UK). 
 
Wound healing Assay 
Pancreatic cancer cells (BxPC-3, AsPC-1 and PANC-1) were placed in a 6 well plate at 
approximately 70% confluency.  The following day, 50 Multiplicity of Infection (MOIs) of 
Ad.GFP (control) or Ad.GFP.RGS16 were added to the cells in media containing 2% heat-
inactivated FBS for 24 hours.  The media was changed to complete media (10% FBS for BxPC-3 
and PANC-1 or 15% for AsPC-1) for 24hrs.  48 hours after the addition of the virus the media 
was changed from complete media to media supplemented with 0.5% FBS and 1% P/S for 
24hours.  Three wounds or scratches were made per well using a p200 pipette tip in PBS.  The 
cells were washed three times with PBS and incubated for 16-24 hours in complete media or 
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media supplemented with 100ng/ml of EGF.  FBS or EGF was added to induce cell migration at 
a concentration previously described in [228-230].  Wound widths were measured and images 
taken at 0, 16, or 24 hrs after addition of media supplemented with FBS or EGF at 100x 
magnification using an Olympus DP71 microscope (Center Valley, PA).  Efficacy of virus 
transduction was confirmed using fluorescent microscopy to examine GFP expression prior to 
the start of the experiment.  Percent wound healing was determined using the following equation; 
% wound healing = ([initial scratch width  – final scratch width]/ initial scratch width)*100.  
Three replicates were performed for each cell line.   
 
Invasion Assay 
BD Bio Coat Matrigel Invasion chambers (Bedford, MA) containing membrane with 8um 
pores were used to assess the role of RGS16 to inhibit pancreatic cancer cell migration and 
invasion.  BxPC-3 cells were plated into 6-well dish, 24 hours later 50 MOIs of Ad.GFP or 
Ad.GFP.RGS16 virus were added to the cells followed by 24 hour incubation in complete media 
and 24 hours in low-serum media as described in the wound healing section.  Chambers were re-
hydrated in RPMI containing 1% P/S and 0.1 % BSA for 2 hours at 37°C.  BxPC-3 and AsPC-1 
cells were collected and 25 x 10
4 
cells were added to the top of the chambers in RPMI 
supplemented with 1% P/S and 0.1%BSA.  RPMI supplemented with 100ng/ml EGF, 1% P/S, 
0.1% BSA was added to lower portion and the chambers were incubated for 18 (AsPC-1) or 20 
(BxPC-3) hours at 37 ֯C.  The non-migrating cells were removed using a cotton swab and the 
invaded cells were fixed using 100% methanol (MeOH) for 5 minutes and stained using 0.5% 
crystal violet plus 20% MeOH (10-15 mins).  Invaded cells were counted using 200x 
magnification with 12 different views.  Percentage of invasion compared to GFP control was 
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calculated for each cell line [(# of invaded cellstreated / # of invaded cellcontrol) *100].  Three 
replicates were performed for each cell line.    
 
Statistical Analysis 
Statistical significance for the wound healing and invasion assays was calculated using 
Student’s t-test using Prism V6.0c (GraphPad Software, Inc., La Jolla, CA).  Statistical Analysis 
tests used for expression profiling and qRT-PCR analyses are listed in their respective sections. 
 
Abbreviations 
qRT-PCR: quantitative real-time PCR; pRb: retinoblastoma protein; RB1: retinoblastoma 
gene; CMV: Cytomegalovirus; MOI: multiplicity of infection; RGS16: regulator of G protein 
signaling 16; EGF: epidermal growth factor; EGFR; epidermal growth factor receptor; GPCR: G 
protein coupled receptor. 
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Figure Legends 
Figure 1: Identification of differentially expressed transcripts in WI38 cells 
expressing p53 and/or pRb.  WI38 cells were transduced with adenoviruses carrying the 
transgenes p53, or RB1/p105; a MOI of 50 was used in each case.  A) Western blot analysis was 
used to test for p53 and pRb expression prior to microarray analysis.  B) A Venn diagram shows 
the differentially expressed transcripts and intersects identified during the microarray analysis.  
The numbers in red denote transcripts that were up-regulated due to p53, pRb, or p53 and pRb 
expression. 
Figure 2: Validation of microarray data using qRT-PCR in WI38 cells.  Five 
transcripts RGS16, BCL2L11, BTG2, IL-6 and STAT4 from the p53 and pRb intersect were 
chosen for validation by qRT-PCR in WI38 cells expressing p53, pRb, or both p53 and pRb.  
The vector control (Ad.CMV) was used to calculate the fold change for each transcript.  One-
way ANOVA with Dunnett’s test for multiple comparison were used to test for statistical 
significance * p-value < 0.05, ** p-value < 0.01, *** p-value < 0.001, and **** p-value < 
0.0001.   
Figure 3: Validation of microarray data using qRT-PCR in SAOS-2 cells. Five 
transcripts RGS16, BCL2L11, BTG2, IL-6 and STAT4 from the p53 and pRb intersect were 
chosen for validation by qRT-PCR in SAOS-2 cells expressing p53, pRb, or both p53 and pRb.  
The vector control (Ad.CMV) was used to calculate the fold change for each transcript.  One-
way ANOVA with Dunnett’s test for multiple comparison were used to test for statistical 
significance * p-value < 0.05, ** p-value < 0.01, *** p-value < 0.001, and **** p-value < 
0.0001.   
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Figure 4: Decreased expression of RGS16 mRNA relative to total RNA extracted 
from normal human pancreatic tissue.  Expression of RGS16 was measured using qRT-PCR 
in BxPC-3, MIA PaCa-2, PANC-1, and AsPC-1 cells.  Relative fold change was measured using 
total RNA extracted from normal human pancreatic tissue as the control.  One-way ANOVA 
with Tukey’s test for multiple comparison were used to test for statistical significance between 
the cell lines and control * p-value < 0.05, ** p-value < 0.01, *** p-value < 0.001, and **** p-
value < 0.0001.   
Figure 5: Expression of RGS16 inhibited migration of BxPC-3 cells. BxPC-3 cells 
were transduced with 50 MOI of Ad.GFP (CTRL) or Ad.GFP.RGS16.  A) Virus transduction 
was verified by fluorescent microscopy. B) Images (100x) and measurements of wounds were 
taken prior and 16 hours after addition of media supplemented with FBS (10%) or EGF 
(100ng/ml).  The dashed lines represent size of scratch at time 0.  C) Mean Percentage of wound 
healing ± SEM of three separate experiments (three scratches / well) was determined. Student’s 
t-test was used to determine statistical significance compared to control * p-value < 0.05, ** p-
value < 0.01. 
Figure 6: Expression of RGS16 did not inhibit migration of PANC-1 cells.  Wound 
healing assays were performed as described in Figure 2. A) Fluorescent microscopy was used to 
verify virus transductions: B&C Images (100X) were taken and percentages of wound healing 
were calculated at 24hrs.   
Figure 7: Expression of RGS16 inhibited migration of AsPC-1 cells.  Wound healing 
assays were performed as described in Figure 2. A) Fluorescent microscopy was used to verify 
virus transductions: B&C Images (100X) were taken and percentages of wound healing were 
calculated at 24hrs * p-value < 0.05.   
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Figure 8: Expression of RGS16 inhibited invasion of BxPC-3 and AsPC-1 cells.  
Matrigel invasion chambers were used to measure cell migration and invasion of GFP and/or 
RGS16 expressing BxPC-3 (A & B) and AsPC-1 (C & D) cells using EGF as a chemoattractant. 
Migrated cells were stained with Crystal Violet and counted at 200x magnification (A &C). 
Percent invasion was calculated for each cell line (B & D) * p-value < 0.05.    
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Table 1. Fold Change of p53 and pRb common gene set cross-talk candidates.  
 
Gene Symbol Name FC-p53 FC-Rb FC-p53+Rb 
LOC387763 hypothetical LOC387763 30.62 159.25 297.07 
A_24_p775812 Unknown 15.65 199.36 252.80 
RGS16 Regulator of G-protein signaling 16 18.84 30.82 149.75 
AREG Amphiregulin 8.15 46.41 81.91 
CCL3 Chemokine (c-c motif ligand 3) 3.78 8.18 56.12 
TNFSF15 Tumor necrosis factor (ligand) superfamily, member 15 10.68 69.61 53.34 
IL-1B Interleukin-1 beta 4.82 22.53 43.79 
OLFM2 Olfactomedin 2 10.60 37.76 27.31 
NR4A1 Nuclear receptor subfamily 4 group A member 1 11.56 20.73 27.08 
POSTN Periostin 2.91 21.051 25.66 
D4S234e D4S234e (NSG1; neuron specific gene family member 1) 21.20 7.86 22.06 
IL-6 Interleukin-6 6.04 12.37 21.99 
DMN Desmuslin 4.57 27.42 21.25 
EPPK1 Epiplakin 32.06 8.27 20.04 
IQSEC3 IQ motif and Sec7 domain 3 7.29 20.37 19.95 
PLAC2 Placenta specific 2 21.60 4.63 19.00 
L3MBTL2 Lethal(3)malignant brain tumor-like protein 2 18.33 11.82 16.00 
LHX6 LIM homeobox 6 10.11 7.11 15.15 
AKR1B10 Aldo-keto reductase family 1 member B10 11.61 13.92 13.30 
RRAD Ras associated with diabetes 5.98 7.80 12.61 
c10orf58 chromosome 10 open reading frame 58 4.86 9.20 11.74 
BCL2L11 Bcl2-like 11 (apoptosis facilitator) 9.58 6.50 11.34 
COL7A1 Collagen, type VII, alpha 1 5.97 10.65 10.94 
JUP Junction plakoglobin 7.60 16.61 9.92 
VCAN Versican proteoglycan 5.61 9.17 9.73 
CRISPLD2 Cystein-rich secretory protein 11 10.11 5.38 9.55 
STOX2 Storkhead-box 2 14.48 8.70 9.33 
BTG-2 B-cell translocation gene 2 3.85 5.07 7.46 
P2RY2 purinergic receptor P2Y, G-protein coupled, 2 2.38 19.53 6.91 
TSKU Tsukusi,small leucine rich proteoglycan 5.28 5.42 5.97 
C4B Complement component 4B 3.38 7.64 2.22 
RTN4R Reticulon 4 receptor 8.01 6.19 N/A 
STAT4 Signal transducer and activator of transcription 4 5.98 7.80 N/A 
AK124344 cDNA FLJ42353 fis, clone UTERU2007520 5.21 7.13 N/A 
KLHL20 Kelch like 20 4.88 4.46 N/A 
NOTCH3 Notch homolog 3 4.68 3.96 N/A 
KSR1 Kinase suppressor of RAS 3.86 4.08 N/A 
GDF15 Growth/differentiation factor 15 3.24 3.40 N/A 
LOC654346 similar to galectin 9 short isoform (LOC654346) 2.81 4.77 N/A 
FC = Fold change 
N/A= Fold change not available.  Gene was not found to be significantly differentially expressed in WI38 cells coexpressing p53 and pRb. 
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 p53 p16 Ras EGFR Differentiation Origin Metastasis 
BxPC-3 mt del wt high moderate primary no 
PANC-1 mt del mt high poor primary yes 
AsPC-1 mt mt mt high poor metastatic (ascites) yes 
MiaPaCa-2 mt del mt low poor primary no 
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